Repurposing Drugs for Enhancement of P53 Expression
About 3k among the 1.5M annotated molecules in the ChEMBL DB are prescription drugs. For some of them, there is a record of activity on P53 expression experiments, but for the most that don’t have any, there is a predicted score. The variable AvgPredIdex contains the actual score if it exists, but the predicted one if it doesn’t. It results from a combination of binomial and regression decision trees and random forests outcome. These scores have a -log(molar potency) scale.
Applying the dashboard based selection methods described in the prediction of P53 activity section upon prescription drugs we have created unique drug target pairs with average scores per pair: the already described AvgPredIdex and the chemblActivityScoreC which shows the effect that the molecule average score for each particular target.
The 2 graphs below shows AvgPredIdex vs chemblActivityScoreC . Marked dots are displayed on the right side showing the targets where the drugs have an activity record and the value, in bars of their potency at target compared to the potency enhancing P53 expression.
Most potent drug-target pairs. data from actual values.
Most potent drug-target pairs. data from predicted values.
Most potent drugs for repurposing
| molName | kindOfValue | p53ActivityScoreActual | p53ActiveActual | proteinNameC | organismC | avgPredIndex | AvgPrediction80RFRegression | AvgChemblActivityScoreC | countRatioRpart | countRatioRF | countRatioAvgRpartRF | CountChemblActivityScoreC | drugIndicationC | drugMoAs | eccentricityProtein | closnesscentralityProtein | harmonicclosnesscentralityProtein | betweenesscentralityProtein | modularity_classProtein | pageranksProtein | degreeProtein | weighted degreeProtein | eccentricityMolName | closnesscentralityMolName | harmonicclosnesscentralityMolName | betweenesscentralityMolName | modularity_classMolName | pageranksMolName | degreeMolName | weighted degreeMolName |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DIAZEPAM | actual | 6.7070797 | Y | NotRecorded | Homo sapiens | 8.069026567 | 6.7070797 | 7.542744887 | 0.875 | 0.875 | 0.875 | 24 | ANXIETY, EPILEPSY, PAIN, POST-TRAUMATIC STRESS DISORDER, SEIZURES | GABA-A receptor; anion channel positive allosteric modulator | 7 | 0.259065028 | 0.275501942 | 8450.908168 | 3 | 0.001274989 | 11 | 11 | 7 | 0.262686114 | 0.291234956 | 24208.29753 | 3 | 0.002753017 | 20 | 20 |
| DIAZEPAM | actual | 6.7070797 | Y | NotRecorded | Homo sapiens | 8.485693233 | 6.7070797 | 7.254067598 | 0.875 | 1 | 0.9375 | 24 | ANXIETY, EPILEPSY, PAIN, POST-TRAUMATIC STRESS DISORDER, SEIZURES | GABA-A receptor; anion channel positive allosteric modulator | 7 | 0.259065028 | 0.275501942 | 8450.908168 | 3 | 0.001274989 | 11 | 11 | 7 | 0.262686114 | 0.291234956 | 24208.29753 | 3 | 0.002753017 | 20 | 20 |
| DIAZEPAM | actual | 6.7070797 | Y | GABA-A receptor; anion channel | Bos taurus | 7.473788472 | 6.7070797 | 7.84 | 0.571428571 | 1 | 0.785714286 | 42 | ANXIETY, EPILEPSY, PAIN, POST-TRAUMATIC STRESS DISORDER, SEIZURES | GABA-A receptor; anion channel positive allosteric modulator | 8 | 0.256072275 | 0.273265582 | 8687.902093 | 0 | 0.001208292 | 11 | 11 | 7 | 0.262686114 | 0.291234956 | 24208.29753 | 3 | 0.002753017 | 20 | 20 |
| DIAZEPAM | actual | 6.7070797 | Y | GABA receptor gamma-1 subunit | Rattus norvegicus | 5.569026567 | 5.530309775 | 8.3 | 1 | 0 | 0.5 | 1 | ANXIETY, EPILEPSY, PAIN, POST-TRAUMATIC STRESS DISORDER, SEIZURES | GABA-A receptor; anion channel positive allosteric modulator | 8 | 0.251967356 | 0.266384368 | 411.737579 | 3 | 0.000250849 | 2 | 2 | 7 | 0.262686114 | 0.291234956 | 24208.29753 | 3 | 0.002753017 | 20 | 20 |
| DIAZEPAM | actual | 6.7070797 | Y | GABA receptor alpha-1 subunit | Homo sapiens | 8.9023599 | 6.7070797 | 7.44 | 1 | 1 | 1 | 1 | ANXIETY, EPILEPSY, PAIN, POST-TRAUMATIC STRESS DISORDER, SEIZURES | GABA-A receptor; anion channel positive allosteric modulator | 8 | 0.208062575 | 0.22064915 | 0 | 3 | 0.000200723 | 1 | 1 | 7 | 0.262686114 | 0.291234956 | 24208.29753 | 3 | 0.002753017 | 20 | 20 |
| DIAZEPAM | actual | 6.7070797 | Y | GABA A receptor alpha-3/beta-2/gamma-2 | Homo sapiens | 8.9023599 | 6.7070797 | 7.925 | 1 | 1 | 1 | 6 | ANXIETY, EPILEPSY, PAIN, POST-TRAUMATIC STRESS DISORDER, SEIZURES | GABA-A receptor; anion channel positive allosteric modulator | 8 | 0.208062575 | 0.22064915 | 0 | 3 | 0.000200723 | 1 | 1 | 7 | 0.262686114 | 0.291234956 | 24208.29753 | 3 | 0.002753017 | 20 | 20 |
| CLOZAPINE | predicted | Alpha-1d adrenergic receptor | Homo sapiens | 7.333333333 | 2 | 7.615 | 1 | 1 | 1 | 2 | BIPOLAR DISORDER, PSYCHOSIS, SCHIZOPHRENIA | Dopamine D2 receptor antagonist, Serotonin 2a (5-HT2a) receptor antagonist | 6 | 0.281046814 | 0.304279931 | 2336.531662 | 0 | 0.001223953 | 22 | 22 | 7 | 0.288358906 | 0.319887631 | 9716.580303 | 0 | 0.001473077 | 24 | 24 | ||
| ONDANSETRON | predicted | Serotonin 3 receptor (5HT3) | Mus musculus | 7.572922134 | 2.718766402 | 7.92 | 1 | 1 | 1 | 2 | ALCOHOL DEPENDENCE, BRAIN DISEASE, BREAST CARCINOMA, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, COCAINE DEPENDENCE, DYSPNEA, FISH-EYE DISEASE, IRRITABLE BOWEL SYNDROME, NAUSEA, NAUSEA AND VOMITING, NEOPLASM, OBSESSIVE-COMPULSIVE DISORDER, PAIN, POST OPERATIVE NAUSEA AND VOMITING, RADIATION-INDUCED NAUSEA AND VOMITING, SCHIZOPHRENIA | Serotonin 3a (5-HT3a) receptor antagonist | 8 | 0.202743902 | 0.214232697 | 17.82662574 | 0 | 0.000250467 | 2 | 2 | 7 | 0.228885359 | 0.244340246 | 2435.863369 | 0 | 0.000580921 | 5 | 5 | ||
| RISPERIDONE | predicted | Alpha-1a adrenergic receptor | Rattus norvegicus | 7.296109286 | 4.388327857 | 8.8375 | 1 | 0.75 | 0.875 | 4 | ANOREXIA NERVOSA, ASPERGER SYNDROME, ATTENTION DEFICIT HYPERACTIVITY DISORDER, AUTISM, BIPOLAR DISORDER, COCAINE DEPENDENCE, DIABETES MELLITUS, FISH-EYE DISEASE, INJURY, METAMPHETAMINE DEPENDENCE, MOVEMENT DISORDER, PSYCHOSIS, SCHIZOPHRENIA, UNIPOLAR DEPRESSION | Dopamine D2 receptor antagonist, Serotonin 2a (5-HT2a) receptor antagonist, Serotonin 2c (5-HT2c) receptor antagonist | 6 | 0.277350016 | 0.299575863 | 1543.583178 | 0 | 0.001147715 | 21 | 21 | 7 | 0.259921828 | 0.283919965 | 522.6479682 | 0 | 0.000849914 | 15 | 15 | ||
| RISPERIDONE | predicted | Alpha-2c adrenergic receptor | Homo sapiens | 7.162116914 | 3.986350743 | 8.3425 | 1 | 0.75 | 0.875 | 4 | ANOREXIA NERVOSA, ASPERGER SYNDROME, ATTENTION DEFICIT HYPERACTIVITY DISORDER, AUTISM, BIPOLAR DISORDER, COCAINE DEPENDENCE, DIABETES MELLITUS, FISH-EYE DISEASE, INJURY, METAMPHETAMINE DEPENDENCE, MOVEMENT DISORDER, PSYCHOSIS, SCHIZOPHRENIA, UNIPOLAR DEPRESSION | Dopamine D2 receptor antagonist, Serotonin 2a (5-HT2a) receptor antagonist, Serotonin 2c (5-HT2c) receptor antagonist | 6 | 0.279321486 | 0.302544824 | 2596.316271 | 0 | 0.001323976 | 24 | 24 | 7 | 0.259921828 | 0.283919965 | 522.6479682 | 0 | 0.000849914 | 15 | 15 | ||
| RISPERIDONE | predicted | Alpha-1b adrenergic receptor | Rattus norvegicus | 8.00417952 | 4.01253856 | 8.84 | 1 | 1 | 1 | 2 | ANOREXIA NERVOSA, ASPERGER SYNDROME, ATTENTION DEFICIT HYPERACTIVITY DISORDER, AUTISM, BIPOLAR DISORDER, COCAINE DEPENDENCE, DIABETES MELLITUS, FISH-EYE DISEASE, INJURY, METAMPHETAMINE DEPENDENCE, MOVEMENT DISORDER, PSYCHOSIS, SCHIZOPHRENIA, UNIPOLAR DEPRESSION | Dopamine D2 receptor antagonist, Serotonin 2a (5-HT2a) receptor antagonist, Serotonin 2c (5-HT2c) receptor antagonist | 6 | 0.279773463 | 0.30317139 | 2167.215495 | 0 | 0.0013047 | 24 | 24 | 7 | 0.259921828 | 0.283919965 | 522.6479682 | 0 | 0.000849914 | 15 | 15 | ||
| RISPERIDONE | predicted | Alpha-1d adrenergic receptor | Homo sapiens | 8.090889114 | 4.272667343 | 8.155 | 1 | 1 | 1 | 2 | ANOREXIA NERVOSA, ASPERGER SYNDROME, ATTENTION DEFICIT HYPERACTIVITY DISORDER, AUTISM, BIPOLAR DISORDER, COCAINE DEPENDENCE, DIABETES MELLITUS, FISH-EYE DISEASE, INJURY, METAMPHETAMINE DEPENDENCE, MOVEMENT DISORDER, PSYCHOSIS, SCHIZOPHRENIA, UNIPOLAR DEPRESSION | Dopamine D2 receptor antagonist, Serotonin 2a (5-HT2a) receptor antagonist, Serotonin 2c (5-HT2c) receptor antagonist | 6 | 0.281046814 | 0.304279931 | 2336.531662 | 0 | 0.001223953 | 22 | 22 | 7 | 0.259921828 | 0.283919965 | 522.6479682 | 0 | 0.000849914 | 15 | 15 | ||
| PACLITAXEL | actual | 8.075720714 | Y | Prelamin-A/C | Homo sapiens | 6.025240238 | 8.075720714 | 7.498 | 0 | 1 | 0.5 | 5 | ADENOCARCINOMA, BLADDER CARCINOMA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CERVICAL CARCINOMA, COLORECTAL ADENOCARCINOMA, CORONARY RESTENOSIS, CUTANEOUS MELANOMA, ENDOMETRIAL NEOPLASM, ESOPHAGEAL CARCINOMA, GASTRIC ADENOCARCINOMA, GASTRIC CARCINOMA, GASTROINTESTINAL STROMAL TUMOR, GLIOBLASTOMA MULTIFORME, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HEPATOCELLULAR CARCINOMA, KAPOSI'S SARCOMA, LUNG CARCINOMA, MALE BREAST CARCINOMA, MELANOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, OVARIAN CARCINOMA, PANCREATIC CARCINOMA, PERIPHERAL VASCULAR DISEASE, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, STOMACH NEOPLASM, THYROID CARCINOMA, UPPER AERODIGESTIVE TRACT NEOPLASM, UTERINE NEOPLASM | Tubulin inhibitor | 6 | 0.300591099 | 0.336495084 | 23750.15287 | 4 | 0.003255772 | 46 | 46 | 5 | 0.335207445 | 0.362810873 | 30411.3695 | 4 | 0.002558381 | 33 | 33 |
| PACLITAXEL | actual | 8.075720714 | Y | Integrin alpha-V/beta-3 | Homo sapiens | 9.358573571 | 8.075720714 | 7.47 | 1 | 1 | 1 | 2 | ADENOCARCINOMA, BLADDER CARCINOMA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CERVICAL CARCINOMA, COLORECTAL ADENOCARCINOMA, CORONARY RESTENOSIS, CUTANEOUS MELANOMA, ENDOMETRIAL NEOPLASM, ESOPHAGEAL CARCINOMA, GASTRIC ADENOCARCINOMA, GASTRIC CARCINOMA, GASTROINTESTINAL STROMAL TUMOR, GLIOBLASTOMA MULTIFORME, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HEPATOCELLULAR CARCINOMA, KAPOSI'S SARCOMA, LUNG CARCINOMA, MALE BREAST CARCINOMA, MELANOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, OVARIAN CARCINOMA, PANCREATIC CARCINOMA, PERIPHERAL VASCULAR DISEASE, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, STOMACH NEOPLASM, THYROID CARCINOMA, UPPER AERODIGESTIVE TRACT NEOPLASM, UTERINE NEOPLASM | Tubulin inhibitor | 6 | 0.251089166 | 0.261509543 | 0 | 4 | 0.00014962 | 1 | 1 | 5 | 0.335207445 | 0.362810873 | 30411.3695 | 4 | 0.002558381 | 33 | 33 |
| PACLITAXEL | actual | 8.075720714 | Y | Vitamin D receptor | Homo sapiens | 9.358573571 | 8.075720714 | 7.749579998 | 1 | 1 | 1 | 1 | ADENOCARCINOMA, BLADDER CARCINOMA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CERVICAL CARCINOMA, COLORECTAL ADENOCARCINOMA, CORONARY RESTENOSIS, CUTANEOUS MELANOMA, ENDOMETRIAL NEOPLASM, ESOPHAGEAL CARCINOMA, GASTRIC ADENOCARCINOMA, GASTRIC CARCINOMA, GASTROINTESTINAL STROMAL TUMOR, GLIOBLASTOMA MULTIFORME, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HEPATOCELLULAR CARCINOMA, KAPOSI'S SARCOMA, LUNG CARCINOMA, MALE BREAST CARCINOMA, MELANOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, OVARIAN CARCINOMA, PANCREATIC CARCINOMA, PERIPHERAL VASCULAR DISEASE, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, STOMACH NEOPLASM, THYROID CARCINOMA, UPPER AERODIGESTIVE TRACT NEOPLASM, UTERINE NEOPLASM | Tubulin inhibitor | 6 | 0.279502102 | 0.302332755 | 4501.207978 | 4 | 0.001198924 | 16 | 16 | 5 | 0.335207445 | 0.362810873 | 30411.3695 | 4 | 0.002558381 | 33 | 33 |
| PACLITAXEL | actual | 8.075720714 | Y | Tubulin beta-3 chain | Homo sapiens | 9.358573571 | 8.075720714 | 8.075 | 1 | 1 | 1 | 2 | ADENOCARCINOMA, BLADDER CARCINOMA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CERVICAL CARCINOMA, COLORECTAL ADENOCARCINOMA, CORONARY RESTENOSIS, CUTANEOUS MELANOMA, ENDOMETRIAL NEOPLASM, ESOPHAGEAL CARCINOMA, GASTRIC ADENOCARCINOMA, GASTRIC CARCINOMA, GASTROINTESTINAL STROMAL TUMOR, GLIOBLASTOMA MULTIFORME, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HEPATOCELLULAR CARCINOMA, KAPOSI'S SARCOMA, LUNG CARCINOMA, MALE BREAST CARCINOMA, MELANOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, OVARIAN CARCINOMA, PANCREATIC CARCINOMA, PERIPHERAL VASCULAR DISEASE, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, STOMACH NEOPLASM, THYROID CARCINOMA, UPPER AERODIGESTIVE TRACT NEOPLASM, UTERINE NEOPLASM | Tubulin inhibitor | 6 | 0.251089166 | 0.261509543 | 0 | 4 | 0.00014962 | 1 | 1 | 5 | 0.335207445 | 0.362810873 | 30411.3695 | 4 | 0.002558381 | 33 | 33 |
| PACLITAXEL | actual | 8.075720714 | Y | ATPase family AAA domain-containing protein 5 | Homo sapiens | 7.691906905 | 8.075720714 | 7.636827961 | 0.5 | 1 | 0.75 | 2 | ADENOCARCINOMA, BLADDER CARCINOMA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CERVICAL CARCINOMA, COLORECTAL ADENOCARCINOMA, CORONARY RESTENOSIS, CUTANEOUS MELANOMA, ENDOMETRIAL NEOPLASM, ESOPHAGEAL CARCINOMA, GASTRIC ADENOCARCINOMA, GASTRIC CARCINOMA, GASTROINTESTINAL STROMAL TUMOR, GLIOBLASTOMA MULTIFORME, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HEPATOCELLULAR CARCINOMA, KAPOSI'S SARCOMA, LUNG CARCINOMA, MALE BREAST CARCINOMA, MELANOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, OVARIAN CARCINOMA, PANCREATIC CARCINOMA, PERIPHERAL VASCULAR DISEASE, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, STOMACH NEOPLASM, THYROID CARCINOMA, UPPER AERODIGESTIVE TRACT NEOPLASM, UTERINE NEOPLASM | Tubulin inhibitor | 6 | 0.285690681 | 0.312406015 | 7238.534228 | 4 | 0.001760396 | 26 | 26 | 5 | 0.335207445 | 0.362810873 | 30411.3695 | 4 | 0.002558381 | 33 | 33 |
| PACLITAXEL | actual | 8.075720714 | Y | Androgen Receptor | Homo sapiens | 9.358573571 | 8.075720714 | 7.536137785 | 1 | 1 | 1 | 2 | ADENOCARCINOMA, BLADDER CARCINOMA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CERVICAL CARCINOMA, COLORECTAL ADENOCARCINOMA, CORONARY RESTENOSIS, CUTANEOUS MELANOMA, ENDOMETRIAL NEOPLASM, ESOPHAGEAL CARCINOMA, GASTRIC ADENOCARCINOMA, GASTRIC CARCINOMA, GASTROINTESTINAL STROMAL TUMOR, GLIOBLASTOMA MULTIFORME, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HEPATOCELLULAR CARCINOMA, KAPOSI'S SARCOMA, LUNG CARCINOMA, MALE BREAST CARCINOMA, MELANOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, OVARIAN CARCINOMA, PANCREATIC CARCINOMA, PERIPHERAL VASCULAR DISEASE, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, STOMACH NEOPLASM, THYROID CARCINOMA, UPPER AERODIGESTIVE TRACT NEOPLASM, UTERINE NEOPLASM | Tubulin inhibitor | 6 | 0.380837004 | 0.4451417 | 265199.9673 | 4 | 0.012134483 | 147 | 147 | 5 | 0.335207445 | 0.362810873 | 30411.3695 | 4 | 0.002558381 | 33 | 33 |
| PACLITAXEL | actual | 8.075720714 | Y | Isocitrate dehydrogenase [NADP] cytoplasmic | Homo sapiens | 6.025240238 | 8.075720714 | 7.436402232 | 0 | 1 | 0.5 | 2 | ADENOCARCINOMA, BLADDER CARCINOMA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CERVICAL CARCINOMA, COLORECTAL ADENOCARCINOMA, CORONARY RESTENOSIS, CUTANEOUS MELANOMA, ENDOMETRIAL NEOPLASM, ESOPHAGEAL CARCINOMA, GASTRIC ADENOCARCINOMA, GASTRIC CARCINOMA, GASTROINTESTINAL STROMAL TUMOR, GLIOBLASTOMA MULTIFORME, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HEPATOCELLULAR CARCINOMA, KAPOSI'S SARCOMA, LUNG CARCINOMA, MALE BREAST CARCINOMA, MELANOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, OVARIAN CARCINOMA, PANCREATIC CARCINOMA, PERIPHERAL VASCULAR DISEASE, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, STOMACH NEOPLASM, THYROID CARCINOMA, UPPER AERODIGESTIVE TRACT NEOPLASM, UTERINE NEOPLASM | Tubulin inhibitor | 6 | 0.28196347 | 0.310535955 | 7654.130812 | 4 | 0.002205777 | 32 | 32 | 5 | 0.335207445 | 0.362810873 | 30411.3695 | 4 | 0.002558381 | 33 | 33 |
| PACLITAXEL | actual | 8.075720714 | Y | Retinoid X receptor alpha | Homo sapiens | 9.358573571 | 8.075720714 | 8.301029996 | 1 | 1 | 1 | 1 | ADENOCARCINOMA, BLADDER CARCINOMA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CERVICAL CARCINOMA, COLORECTAL ADENOCARCINOMA, CORONARY RESTENOSIS, CUTANEOUS MELANOMA, ENDOMETRIAL NEOPLASM, ESOPHAGEAL CARCINOMA, GASTRIC ADENOCARCINOMA, GASTRIC CARCINOMA, GASTROINTESTINAL STROMAL TUMOR, GLIOBLASTOMA MULTIFORME, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HEPATOCELLULAR CARCINOMA, KAPOSI'S SARCOMA, LUNG CARCINOMA, MALE BREAST CARCINOMA, MELANOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, OVARIAN CARCINOMA, PANCREATIC CARCINOMA, PERIPHERAL VASCULAR DISEASE, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, STOMACH NEOPLASM, THYROID CARCINOMA, UPPER AERODIGESTIVE TRACT NEOPLASM, UTERINE NEOPLASM | Tubulin inhibitor | 6 | 0.283442623 | 0.309726239 | 6386.98569 | 4 | 0.001646278 | 24 | 24 | 5 | 0.335207445 | 0.362810873 | 30411.3695 | 4 | 0.002558381 | 33 | 33 |
| COLCHICINE | actual | 6.925183559 | Y | Peroxisome proliferator-activated receptor gamma | Homo sapiens | 8.975061186 | 6.678924381 | 7.583431007 | 1 | 1 | 1 | 3 | ACUTE CORONARY SYNDROME, APHTHOUS ULCER, ATRIAL FIBRILLATION, BEHCET'S SYNDROME, CHRONIC HEPATITIS C INFECTION, CHRONIC KIDNEY DISEASE, CORONARY ARTERY DISEASE, DIABETIC NEPHROPATHY, FAMILIAL MEDITERRANEAN FEVER, GOUT, HEPATOCELLULAR CARCINOMA, MYOCARDIAL INFARCTION, OSTEOARTHRITIS, PROSTATE CARCINOMA, VASCULAR DISEASE | Tubulin inhibitor | 6 | 0.2784219 | 0.301436283 | 4650.25214 | 4 | 0.001331689 | 18 | 18 | 5 | 0.337959343 | 0.367052246 | 19703.89417 | 4 | 0.002569298 | 38 | 38 |
| COLCHICINE | actual | 6.925183559 | Y | Geminin | Homo sapiens | 7.30839452 | 6.014160873 | 7.413098603 | 0.5 | 1 | 0.75 | 8 | ACUTE CORONARY SYNDROME, APHTHOUS ULCER, ATRIAL FIBRILLATION, BEHCET'S SYNDROME, CHRONIC HEPATITIS C INFECTION, CHRONIC KIDNEY DISEASE, CORONARY ARTERY DISEASE, DIABETIC NEPHROPATHY, FAMILIAL MEDITERRANEAN FEVER, GOUT, HEPATOCELLULAR CARCINOMA, MYOCARDIAL INFARCTION, OSTEOARTHRITIS, PROSTATE CARCINOMA, VASCULAR DISEASE | Tubulin inhibitor | 6 | 0.358564911 | 0.408916522 | 90556.91834 | 4 | 0.005157074 | 75 | 75 | 5 | 0.337959343 | 0.367052246 | 19703.89417 | 4 | 0.002569298 | 38 | 38 |
| COLCHICINE | actual | 6.925183559 | Y | Androgen Receptor | Homo sapiens | 8.975061186 | 6.750545694 | 7.604088396 | 1 | 1 | 1 | 10 | ACUTE CORONARY SYNDROME, APHTHOUS ULCER, ATRIAL FIBRILLATION, BEHCET'S SYNDROME, CHRONIC HEPATITIS C INFECTION, CHRONIC KIDNEY DISEASE, CORONARY ARTERY DISEASE, DIABETIC NEPHROPATHY, FAMILIAL MEDITERRANEAN FEVER, GOUT, HEPATOCELLULAR CARCINOMA, MYOCARDIAL INFARCTION, OSTEOARTHRITIS, PROSTATE CARCINOMA, VASCULAR DISEASE | Tubulin inhibitor | 6 | 0.380837004 | 0.4451417 | 265199.9673 | 4 | 0.012134483 | 147 | 147 | 5 | 0.337959343 | 0.367052246 | 19703.89417 | 4 | 0.002569298 | 38 | 38 |
| COLCHICINE | actual | 6.925183559 | Y | Retinoid X receptor alpha | Homo sapiens | 8.975061186 | 6.678924381 | 7.525270601 | 1 | 1 | 1 | 4 | ACUTE CORONARY SYNDROME, APHTHOUS ULCER, ATRIAL FIBRILLATION, BEHCET'S SYNDROME, CHRONIC HEPATITIS C INFECTION, CHRONIC KIDNEY DISEASE, CORONARY ARTERY DISEASE, DIABETIC NEPHROPATHY, FAMILIAL MEDITERRANEAN FEVER, GOUT, HEPATOCELLULAR CARCINOMA, MYOCARDIAL INFARCTION, OSTEOARTHRITIS, PROSTATE CARCINOMA, VASCULAR DISEASE | Tubulin inhibitor | 6 | 0.283442623 | 0.309726239 | 6386.98569 | 4 | 0.001646278 | 24 | 24 | 5 | 0.337959343 | 0.367052246 | 19703.89417 | 4 | 0.002569298 | 38 | 38 |
| COLCHICINE | actual | 6.925183559 | Y | Interleukin-8 | Homo sapiens | 8.975061186 | 6.925183559 | 7.300022169 | 1 | 1 | 1 | 2 | ACUTE CORONARY SYNDROME, APHTHOUS ULCER, ATRIAL FIBRILLATION, BEHCET'S SYNDROME, CHRONIC HEPATITIS C INFECTION, CHRONIC KIDNEY DISEASE, CORONARY ARTERY DISEASE, DIABETIC NEPHROPATHY, FAMILIAL MEDITERRANEAN FEVER, GOUT, HEPATOCELLULAR CARCINOMA, MYOCARDIAL INFARCTION, OSTEOARTHRITIS, PROSTATE CARCINOMA, VASCULAR DISEASE | Tubulin inhibitor | 6 | 0.26284585 | 0.278532871 | 271.1286055 | 4 | 0.000465476 | 6 | 6 | 5 | 0.337959343 | 0.367052246 | 19703.89417 | 4 | 0.002569298 | 38 | 38 |
| COLCHICINE | actual | 6.925183559 | Y | Bile acid receptor FXR | Homo sapiens | 8.975061186 | 6.678924381 | 7.466933823 | 1 | 1 | 1 | 3 | ACUTE CORONARY SYNDROME, APHTHOUS ULCER, ATRIAL FIBRILLATION, BEHCET'S SYNDROME, CHRONIC HEPATITIS C INFECTION, CHRONIC KIDNEY DISEASE, CORONARY ARTERY DISEASE, DIABETIC NEPHROPATHY, FAMILIAL MEDITERRANEAN FEVER, GOUT, HEPATOCELLULAR CARCINOMA, MYOCARDIAL INFARCTION, OSTEOARTHRITIS, PROSTATE CARCINOMA, VASCULAR DISEASE | Tubulin inhibitor | 6 | 0.28465591 | 0.310680548 | 11397.40947 | 4 | 0.001729474 | 23 | 23 | 5 | 0.337959343 | 0.367052246 | 19703.89417 | 4 | 0.002569298 | 38 | 38 |
| COLCHICINE | actual | 6.925183559 | Y | Thyroid hormone receptor beta-1 | Homo sapiens | 8.975061186 | 6.391622007 | 8.117874562 | 1 | 1 | 1 | 2 | ACUTE CORONARY SYNDROME, APHTHOUS ULCER, ATRIAL FIBRILLATION, BEHCET'S SYNDROME, CHRONIC HEPATITIS C INFECTION, CHRONIC KIDNEY DISEASE, CORONARY ARTERY DISEASE, DIABETIC NEPHROPATHY, FAMILIAL MEDITERRANEAN FEVER, GOUT, HEPATOCELLULAR CARCINOMA, MYOCARDIAL INFARCTION, OSTEOARTHRITIS, PROSTATE CARCINOMA, VASCULAR DISEASE | Tubulin inhibitor | 6 | 0.278781038 | 0.303865433 | 12097.90951 | 4 | 0.001979349 | 25 | 25 | 5 | 0.337959343 | 0.367052246 | 19703.89417 | 4 | 0.002569298 | 38 | 38 |
| COLCHICINE | actual | 6.925183559 | Y | Chromobox protein homolog 1 | Homo sapiens | 5.641727853 | 3.641727853 | 8.420216403 | 0 | 1 | 0.5 | 1 | ACUTE CORONARY SYNDROME, APHTHOUS ULCER, ATRIAL FIBRILLATION, BEHCET'S SYNDROME, CHRONIC HEPATITIS C INFECTION, CHRONIC KIDNEY DISEASE, CORONARY ARTERY DISEASE, DIABETIC NEPHROPATHY, FAMILIAL MEDITERRANEAN FEVER, GOUT, HEPATOCELLULAR CARCINOMA, MYOCARDIAL INFARCTION, OSTEOARTHRITIS, PROSTATE CARCINOMA, VASCULAR DISEASE | Tubulin inhibitor | 6 | 0.271088115 | 0.289059186 | 909.0440748 | 4 | 0.000549754 | 7 | 7 | 5 | 0.337959343 | 0.367052246 | 19703.89417 | 4 | 0.002569298 | 38 | 38 |
| COLCHICINE | actual | 6.925183559 | Y | 6-phospho-1-fructokinase | Trypanosoma brucei | 5.641727853 | 6.001711642 | 7.42136079 | 0 | 1 | 0.5 | 1 | ACUTE CORONARY SYNDROME, APHTHOUS ULCER, ATRIAL FIBRILLATION, BEHCET'S SYNDROME, CHRONIC HEPATITIS C INFECTION, CHRONIC KIDNEY DISEASE, CORONARY ARTERY DISEASE, DIABETIC NEPHROPATHY, FAMILIAL MEDITERRANEAN FEVER, GOUT, HEPATOCELLULAR CARCINOMA, MYOCARDIAL INFARCTION, OSTEOARTHRITIS, PROSTATE CARCINOMA, VASCULAR DISEASE | Tubulin inhibitor | 6 | 0.27159912 | 0.289695392 | 837.748486 | 4 | 0.000685623 | 10 | 10 | 5 | 0.337959343 | 0.367052246 | 19703.89417 | 4 | 0.002569298 | 38 | 38 |
| COLCHICINE | actual | 6.925183559 | Y | Isocitrate dehydrogenase [NADP] cytoplasmic | Homo sapiens | 5.641727853 | 5.334759702 | 8.13667714 | 0 | 1 | 0.5 | 1 | ACUTE CORONARY SYNDROME, APHTHOUS ULCER, ATRIAL FIBRILLATION, BEHCET'S SYNDROME, CHRONIC HEPATITIS C INFECTION, CHRONIC KIDNEY DISEASE, CORONARY ARTERY DISEASE, DIABETIC NEPHROPATHY, FAMILIAL MEDITERRANEAN FEVER, GOUT, HEPATOCELLULAR CARCINOMA, MYOCARDIAL INFARCTION, OSTEOARTHRITIS, PROSTATE CARCINOMA, VASCULAR DISEASE | Tubulin inhibitor | 6 | 0.28196347 | 0.310535955 | 7654.130812 | 4 | 0.002205777 | 32 | 32 | 5 | 0.337959343 | 0.367052246 | 19703.89417 | 4 | 0.002569298 | 38 | 38 |
| TRIFLUPERIDOL | predicted | Sigma opioid receptor | Homo sapiens | 7.762511039 | 3.287533116 | 9.08 | 1 | 1 | 1 | 1 | PSYCHOSIS | unknown | 7 | 0.27279899 | 0.293620039 | 6238.027271 | 0 | 0.001227309 | 18 | 18 | 8 | 0.214889386 | 0.224586191 | 1761.120237 | 4 | 0.000404239 | 3 | 3 | ||
| TRIFLUPERIDOL | predicted | C-8 sterol isomerase | Saccharomyces cerevisiae S288c | 7.543755487 | 2.631266462 | 9.82 | 1 | 1 | 1 | 1 | PSYCHOSIS | unknown | 8 | 0.242021277 | 0.253033683 | 566.4997069 | 4 | 0.00033213 | 3 | 3 | 8 | 0.214889386 | 0.224586191 | 1761.120237 | 4 | 0.000404239 | 3 | 3 | ||
| TRIFLUPERIDOL | predicted | Sigma opioid receptor | Rattus norvegicus | 7.762511039 | 3.287533116 | 9.1 | 1 | 1 | 1 | 1 | PSYCHOSIS | unknown | 7 | 0.27279899 | 0.293620039 | 6238.027271 | 0 | 0.001227309 | 18 | 18 | 8 | 0.214889386 | 0.224586191 | 1761.120237 | 4 | 0.000404239 | 3 | 3 | ||
| LORAZEPAM | predicted | Androgen Receptor | Homo sapiens | 7.579166617 | 2.73749985 | 8.568636236 | 1 | 1 | 1 | 1 | ALCOHOL DEPENDENCE, ALCOHOL WITHDRAWAL, ALZHEIMERS DISEASE, ANXIETY, ANXIETY DISORDER, DEMENTIA, EPILEPSY, SUDDEN CARDIAC ARREST, UNIPOLAR DEPRESSION | GABA-A receptor; anion channel positive allosteric modulator | 6 | 0.380837004 | 0.4451417 | 265199.9673 | 4 | 0.012134483 | 147 | 147 | 7 | 0.275845565 | 0.297121926 | 0 | 4 | 0.000153855 | 1 | 1 | ||
| SAQUINAVIR | predicted | Human immunodeficiency virus type 1 protease | Human immunodeficiency virus 1 | 8.043297925 | 4.129893776 | 8.815229317 | 1 | 1 | 1 | 53 | HIV INFECTION | Human immunodeficiency virus type 1 protease inhibitor | 7 | 0.251162115 | 0.264344928 | 264.4304311 | 3 | 0.000523817 | 6 | 6 | 7 | 0.285690681 | 0.311173538 | 3834.974901 | 0 | 0.000949357 | 13 | 13 | ||
| ROPINIROLE | predicted | Dopamine D4 receptor | Homo sapiens | 7.333333333 | 2 | 8.11 | 1 | 1 | 1 | 1 | PARKINSON'S DISEASE, RESTLESS LEGS SYNDROME | unknown | 6 | 0.278691167 | 0.299749373 | 1729.437792 | 0 | 0.000998692 | 17 | 17 | 7 | 0.239341085 | 0.256180286 | 14.29153043 | 0 | 0.000280102 | 4 | 4 | ||
| MEROPENEM | predicted | Peroxisome proliferator-activated receptor delta | Homo sapiens | 7.333333333 | 2 | 7.876148359 | 1 | 1 | 1 | 1 | BRONCHIECTASIS, INFECTION, INFECTIOUS MENINGITIS, PNEUMONIA, SEPSIS, TUBERCULOSIS, URINARY TRACT INFECTION | Bacterial penicillin-binding protein inhibitor | 6 | 0.3490109 | 0.395508001 | 85678.01116 | 4 | 0.005261171 | 68 | 68 | 7 | 0.258754864 | 0.275537745 | 0 | 4 | 0.000149455 | 1 | 1 | ||
| BETAMETHASONE | predicted | Androgen Receptor | Homo sapiens | 8.814365248 | 6.443095743 | 8.077803675 | 1 | 1 | 1 | 7 | ABNORMALITY OF GASTROINTESTINAL VASCULATURE, ADENOMA, ALOPECIA AREATA, ATOPIC ECZEMA, DIABETIC RETINOPATHY, EYE INFLAMMATION, GLAUCOMA, NASAL OBSTRUCTION, NEWBORN RESPIRATORY DISTRESS SYNDROME, OBSTRUCTIVE LUNG DISEASE, OSTEOARTHRITIS, PAIN, PREMATURE BIRTH, PSORIASIS, TENOSYNOVITIS | Glucocorticoid receptor agonist | 6 | 0.380837004 | 0.4451417 | 265199.9673 | 4 | 0.012134483 | 147 | 147 | 7 | 0.315856777 | 0.337807431 | 1595.614437 | 4 | 0.000539632 | 7 | 7 | ||
| BETAMETHASONE | predicted | Glucocorticoid receptor | Homo sapiens | 8.869218282 | 6.607654845 | 7.870040765 | 1 | 1 | 1 | 3 | ABNORMALITY OF GASTROINTESTINAL VASCULATURE, ADENOMA, ALOPECIA AREATA, ATOPIC ECZEMA, DIABETIC RETINOPATHY, EYE INFLAMMATION, GLAUCOMA, NASAL OBSTRUCTION, NEWBORN RESPIRATORY DISTRESS SYNDROME, OBSTRUCTIVE LUNG DISEASE, OSTEOARTHRITIS, PAIN, PREMATURE BIRTH, PSORIASIS, TENOSYNOVITIS | Glucocorticoid receptor agonist | 7 | 0.281871536 | 0.309384726 | 8327.825012 | 4 | 0.002151998 | 30 | 30 | 7 | 0.315856777 | 0.337807431 | 1595.614437 | 4 | 0.000539632 | 7 | 7 | ||
| DICLOFENAC | predicted | Cyclooxygenase-1 | Bos taurus | 8.052455857 | 4.15736757 | 8.52 | 1 | 1 | 1 | 1 | ACTINIC KERATOSIS, ANKYLOSING SPONDYLITIS, ARTHRALGIA, BASAL CELL CARCINOMA, CYSTOID MACULAR EDEMA, DIABETIC RETINOPATHY, EYE INFLAMMATION, GLAUCOMA, INFERTILITY, MYALGIA, OSTEOARTHRITIS, OSTEOARTHRITIS, KNEE, PAIN, PANCREATITIS, PULMONARY EMBOLISM, RHEUMATIC DISEASE, RHEUMATOID ARTHRITIS, UNIPOLAR DEPRESSION, URINARY TRACT INFECTION | Cyclooxygenase inhibitor | 7 | 0.275318471 | 0.297229337 | 8980.265883 | 4 | 0.001619472 | 20 | 20 | 7 | 0.261257177 | 0.285779008 | 1772.563387 | 4 | 0.000705816 | 8 | 8 | ||
| DICLOFENAC | predicted | Interleukin-8 | Homo sapiens | 8.054580577 | 4.16374173 | 8.1 | 1 | 1 | 1 | 1 | ACTINIC KERATOSIS, ANKYLOSING SPONDYLITIS, ARTHRALGIA, BASAL CELL CARCINOMA, CYSTOID MACULAR EDEMA, DIABETIC RETINOPATHY, EYE INFLAMMATION, GLAUCOMA, INFERTILITY, MYALGIA, OSTEOARTHRITIS, OSTEOARTHRITIS, KNEE, PAIN, PANCREATITIS, PULMONARY EMBOLISM, RHEUMATIC DISEASE, RHEUMATOID ARTHRITIS, UNIPOLAR DEPRESSION, URINARY TRACT INFECTION | Cyclooxygenase inhibitor | 6 | 0.26284585 | 0.278532871 | 271.1286055 | 4 | 0.000465476 | 6 | 6 | 7 | 0.261257177 | 0.285779008 | 1772.563387 | 4 | 0.000705816 | 8 | 8 | ||
| DARUSENTAN | predicted | Endothelin receptor ET-A | Rattus norvegicus | 7.795838893 | 3.38751668 | 8.22 | 1 | 1 | 1 | 1 | HYPERTENSION | Endothelin receptor ET-A antagonist, Endothelin receptor ET-B antagonist | 8 | 0.202411613 | 0.213192321 | 3455 | 11 | 0.000679054 | 3 | 3 | 9 | 0.16835443 | 0.174367237 | 0 | 11 | 0.000276094 | 1 | 1 | ||
| DARUSENTAN | predicted | Endothelin receptor ET-A | Homo sapiens | 7.791789567 | 3.375368702 | 9.1 | 1 | 1 | 1 | 1 | HYPERTENSION | Endothelin receptor ET-A antagonist, Endothelin receptor ET-B antagonist | 8 | 0.202411613 | 0.213192321 | 3455 | 11 | 0.000679054 | 3 | 3 | 9 | 0.16835443 | 0.174367237 | 0 | 11 | 0.000276094 | 1 | 1 | ||
| CARVEDILOL | predicted | Beta-1 adrenergic receptor | Homo sapiens | 7.758344331 | 3.275032992 | 9.87 | 1 | 1 | 1 | 2 | ALZHEIMERS DISEASE, ANGINA PECTORIS, ATRIAL FIBRILLATION, BREAST CARCINOMA, CANCER, CARDIOVASCULAR DISEASE, CIRRHOSIS OF LIVER, COCAINE DEPENDENCE, CONGESTIVE HEART FAILURE, DIABETES MELLITUS, DILATED CARDIOMYOPATHY, DUCHENNE MUSCULAR DYSTROPHY, EPILEPSY, HEART FAILURE, HEMORRHAGE, HYPERTENSION, MYOCARDIAL INFARCTION, PORTAL HYPERTENSION, POST-TRAUMATIC STRESS DISORDER, PULMONARY HYPERTENSION | Adrenergic receptor alpha-1 antagonist, Adrenergic receptor beta antagonist | 7 | 0.273575949 | 0.294612906 | 2721.280158 | 0 | 0.00109185 | 17 | 17 | 7 | 0.272026432 | 0.303333884 | 3462.261806 | 0 | 0.001533505 | 27 | 27 | ||
| CARVEDILOL | predicted | Beta-2 adrenergic receptor | Homo sapiens | 7.758344331 | 3.275032992 | 9.7 | 1 | 1 | 1 | 2 | ALZHEIMERS DISEASE, ANGINA PECTORIS, ATRIAL FIBRILLATION, BREAST CARCINOMA, CANCER, CARDIOVASCULAR DISEASE, CIRRHOSIS OF LIVER, COCAINE DEPENDENCE, CONGESTIVE HEART FAILURE, DIABETES MELLITUS, DILATED CARDIOMYOPATHY, DUCHENNE MUSCULAR DYSTROPHY, EPILEPSY, HEART FAILURE, HEMORRHAGE, HYPERTENSION, MYOCARDIAL INFARCTION, PORTAL HYPERTENSION, POST-TRAUMATIC STRESS DISORDER, PULMONARY HYPERTENSION | Adrenergic receptor alpha-1 antagonist, Adrenergic receptor beta antagonist | 7 | 0.262287621 | 0.279016222 | 1113.258603 | 0 | 0.000623933 | 9 | 9 | 7 | 0.272026432 | 0.303333884 | 3462.261806 | 0 | 0.001533505 | 27 | 27 | ||
| CARVEDILOL | predicted | Beta-3 adrenergic receptor | Homo sapiens | 7.758344331 | 3.275032992 | 8.445 | 1 | 1 | 1 | 2 | ALZHEIMERS DISEASE, ANGINA PECTORIS, ATRIAL FIBRILLATION, BREAST CARCINOMA, CANCER, CARDIOVASCULAR DISEASE, CIRRHOSIS OF LIVER, COCAINE DEPENDENCE, CONGESTIVE HEART FAILURE, DIABETES MELLITUS, DILATED CARDIOMYOPATHY, DUCHENNE MUSCULAR DYSTROPHY, EPILEPSY, HEART FAILURE, HEMORRHAGE, HYPERTENSION, MYOCARDIAL INFARCTION, PORTAL HYPERTENSION, POST-TRAUMATIC STRESS DISORDER, PULMONARY HYPERTENSION | Adrenergic receptor alpha-1 antagonist, Adrenergic receptor beta antagonist | 6 | 0.274880763 | 0.293888568 | 2259.082106 | 0 | 0.000800035 | 12 | 12 | 7 | 0.272026432 | 0.303333884 | 3462.261806 | 0 | 0.001533505 | 27 | 27 | ||
| CARVEDILOL | predicted | Alpha-1a adrenergic receptor | Rattus norvegicus | 7.742615194 | 3.227845583 | 8.305 | 1 | 1 | 1 | 2 | ALZHEIMERS DISEASE, ANGINA PECTORIS, ATRIAL FIBRILLATION, BREAST CARCINOMA, CANCER, CARDIOVASCULAR DISEASE, CIRRHOSIS OF LIVER, COCAINE DEPENDENCE, CONGESTIVE HEART FAILURE, DIABETES MELLITUS, DILATED CARDIOMYOPATHY, DUCHENNE MUSCULAR DYSTROPHY, EPILEPSY, HEART FAILURE, HEMORRHAGE, HYPERTENSION, MYOCARDIAL INFARCTION, PORTAL HYPERTENSION, POST-TRAUMATIC STRESS DISORDER, PULMONARY HYPERTENSION | Adrenergic receptor alpha-1 antagonist, Adrenergic receptor beta antagonist | 6 | 0.277350016 | 0.299575863 | 1543.583178 | 0 | 0.001147715 | 21 | 21 | 7 | 0.272026432 | 0.303333884 | 3462.261806 | 0 | 0.001533505 | 27 | 27 | ||
| CARVEDILOL | predicted | Serotonin 2b (5-HT2b) receptor | Homo sapiens | 7.997933131 | 3.993799394 | 7.73 | 1 | 1 | 1 | 2 | ALZHEIMERS DISEASE, ANGINA PECTORIS, ATRIAL FIBRILLATION, BREAST CARCINOMA, CANCER, CARDIOVASCULAR DISEASE, CIRRHOSIS OF LIVER, COCAINE DEPENDENCE, CONGESTIVE HEART FAILURE, DIABETES MELLITUS, DILATED CARDIOMYOPATHY, DUCHENNE MUSCULAR DYSTROPHY, EPILEPSY, HEART FAILURE, HEMORRHAGE, HYPERTENSION, MYOCARDIAL INFARCTION, PORTAL HYPERTENSION, POST-TRAUMATIC STRESS DISORDER, PULMONARY HYPERTENSION | Adrenergic receptor alpha-1 antagonist, Adrenergic receptor beta antagonist | 6 | 0.311419308 | 0.348293811 | 18639.72588 | 0 | 0.00222842 | 38 | 38 | 7 | 0.272026432 | 0.303333884 | 3462.261806 | 0 | 0.001533505 | 27 | 27 | ||
| CARVEDILOL | predicted | Alpha-1b adrenergic receptor | Rattus norvegicus | 7.742615194 | 3.227845583 | 8.58 | 1 | 1 | 1 | 2 | ALZHEIMERS DISEASE, ANGINA PECTORIS, ATRIAL FIBRILLATION, BREAST CARCINOMA, CANCER, CARDIOVASCULAR DISEASE, CIRRHOSIS OF LIVER, COCAINE DEPENDENCE, CONGESTIVE HEART FAILURE, DIABETES MELLITUS, DILATED CARDIOMYOPATHY, DUCHENNE MUSCULAR DYSTROPHY, EPILEPSY, HEART FAILURE, HEMORRHAGE, HYPERTENSION, MYOCARDIAL INFARCTION, PORTAL HYPERTENSION, POST-TRAUMATIC STRESS DISORDER, PULMONARY HYPERTENSION | Adrenergic receptor alpha-1 antagonist, Adrenergic receptor beta antagonist | 6 | 0.279773463 | 0.30317139 | 2167.215495 | 0 | 0.0013047 | 24 | 24 | 7 | 0.272026432 | 0.303333884 | 3462.261806 | 0 | 0.001533505 | 27 | 27 | ||
| CARVEDILOL | predicted | Alpha-2c adrenergic receptor | Homo sapiens | 7.997933131 | 3.993799394 | 7.47 | 1 | 1 | 1 | 2 | ALZHEIMERS DISEASE, ANGINA PECTORIS, ATRIAL FIBRILLATION, BREAST CARCINOMA, CANCER, CARDIOVASCULAR DISEASE, CIRRHOSIS OF LIVER, COCAINE DEPENDENCE, CONGESTIVE HEART FAILURE, DIABETES MELLITUS, DILATED CARDIOMYOPATHY, DUCHENNE MUSCULAR DYSTROPHY, EPILEPSY, HEART FAILURE, HEMORRHAGE, HYPERTENSION, MYOCARDIAL INFARCTION, PORTAL HYPERTENSION, POST-TRAUMATIC STRESS DISORDER, PULMONARY HYPERTENSION | Adrenergic receptor alpha-1 antagonist, Adrenergic receptor beta antagonist | 6 | 0.279321486 | 0.302544824 | 2596.316271 | 0 | 0.001323976 | 24 | 24 | 7 | 0.272026432 | 0.303333884 | 3462.261806 | 0 | 0.001533505 | 27 | 27 | ||
| CARVEDILOL | predicted | Alpha-1d adrenergic receptor | Homo sapiens | 7.758344331 | 3.275032992 | 8.895 | 1 | 1 | 1 | 2 | ALZHEIMERS DISEASE, ANGINA PECTORIS, ATRIAL FIBRILLATION, BREAST CARCINOMA, CANCER, CARDIOVASCULAR DISEASE, CIRRHOSIS OF LIVER, COCAINE DEPENDENCE, CONGESTIVE HEART FAILURE, DIABETES MELLITUS, DILATED CARDIOMYOPATHY, DUCHENNE MUSCULAR DYSTROPHY, EPILEPSY, HEART FAILURE, HEMORRHAGE, HYPERTENSION, MYOCARDIAL INFARCTION, PORTAL HYPERTENSION, POST-TRAUMATIC STRESS DISORDER, PULMONARY HYPERTENSION | Adrenergic receptor alpha-1 antagonist, Adrenergic receptor beta antagonist | 6 | 0.281046814 | 0.304279931 | 2336.531662 | 0 | 0.001223953 | 22 | 22 | 7 | 0.272026432 | 0.303333884 | 3462.261806 | 0 | 0.001533505 | 27 | 27 | ||
| GLUCAGON | predicted | Adenylate cyclase | Rattus norvegicus | 8.668552502 | 6.005657506 | 8.186666667 | 1 | 1 | 1 | 24 | COLORECTAL ADENOCARCINOMA, DIABETES MELLITUS, HEART FAILURE, HYPOGLYCEMIA, PRIMARY SHORT BOWEL SYNDROME, TYPE I DIABETES MELLITUS, TYPE II DIABETES MELLITUS | Glucagon receptor agonist | 7 | 0.252482477 | 0.266234267 | 3454 | 0 | 0.000336367 | 2 | 2 | 8 | 0.20165617 | 0.208747143 | 1728 | 0 | 0.000466216 | 2 | 2 | ||
| CLAVULANIC ACID | predicted | Beta-lactamase | Klebsiella oxytoca | 8.438111762 | 5.314335285 | 7.740362689 | 1 | 1 | 1 | 1 | COCAINE DEPENDENCE | unknown | 7 | 0.231026189 | 0.241755488 | 5166 | 10 | 0.000364098 | 2 | 2 | 8 | 0.187934783 | 0.195740037 | 8630.5 | 10 | 0.001547464 | 7 | 7 | ||
| DEXMEDETOMIDINE | predicted | Adrenergic receptor alpha-1 | Rattus norvegicus | 7.750010938 | 3.250032813 | 8.3 | 1 | 1 | 1 | 3 | ACUTE KIDNEY INJURY, AGITATION, ALCOHOL DRINKING, ANXIETY, CANCER, CEREBRAL PALSY, COLORECTAL ADENOCARCINOMA, CONGENITAL HEART DISEASE, CORONARY ARTERY DISEASE, COUGH, DIABETES MELLITUS, DIGESTIVE SYSTEM DISEASE, GASTRIC CARCINOMA, HEART DISEASE, HEMORRHAGE, HYPERTENSION, INJURY, KIDNEY DISEASE, LUNG CARCINOMA, MENTAL OR BEHAVIOURAL DISORDER, NEOPLASM, OBESITY, OBSTRUCTIVE SLEEP APNEA, OTITIS MEDIA, PAIN, PANCREATITIS, PARKINSON'S DISEASE, POST OPERATIVE NAUSEA AND VOMITING, POST-OPERATIVE SIGN OR SYMPTOM, PULMONARY HYPERTENSION, RESPIRATORY FAILURE, SCOLIOSIS, SEPSIS, SEPTIC SHOCK, SUBARACHNOID HEMORRHAGE, TINNITUS, TONSILLITIS | unknown | 6 | 0.274531597 | 0.295989975 | 6061.932359 | 0 | 0.001260283 | 20 | 20 | 7 | 0.226249673 | 0.240451403 | 15.57315816 | 0 | 0.000285048 | 4 | 4 | ||
| DEXMEDETOMIDINE | predicted | Adrenergic receptor alpha-2 | Rattus norvegicus | 7.543755487 | 2.631266462 | 10.82 | 1 | 1 | 1 | 3 | ACUTE KIDNEY INJURY, AGITATION, ALCOHOL DRINKING, ANXIETY, CANCER, CEREBRAL PALSY, COLORECTAL ADENOCARCINOMA, CONGENITAL HEART DISEASE, CORONARY ARTERY DISEASE, COUGH, DIABETES MELLITUS, DIGESTIVE SYSTEM DISEASE, GASTRIC CARCINOMA, HEART DISEASE, HEMORRHAGE, HYPERTENSION, INJURY, KIDNEY DISEASE, LUNG CARCINOMA, MENTAL OR BEHAVIOURAL DISORDER, NEOPLASM, OBESITY, OBSTRUCTIVE SLEEP APNEA, OTITIS MEDIA, PAIN, PANCREATITIS, PARKINSON'S DISEASE, POST OPERATIVE NAUSEA AND VOMITING, POST-OPERATIVE SIGN OR SYMPTOM, PULMONARY HYPERTENSION, RESPIRATORY FAILURE, SCOLIOSIS, SEPSIS, SEPTIC SHOCK, SUBARACHNOID HEMORRHAGE, TINNITUS, TONSILLITIS | unknown | 6 | 0.27159912 | 0.290881049 | 1565.061931 | 0 | 0.000906941 | 15 | 15 | 7 | 0.226249673 | 0.240451403 | 15.57315816 | 0 | 0.000285048 | 4 | 4 | ||
| METHOTREXATE | actual | 6.919470153 | Y | Dihydrofolate reductase | Homo sapiens | 8.973156718 | 6.919470153 | 8.109533831 | 1 | 1 | 1 | 67 | ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, ALOPECIA AREATA, ASTHMA, ATOPIC ECZEMA, CANCER, CARCINOMA, CARDIOVASCULAR DISEASE, CHRONIC CHILDHOOD ARTHRITIS, CORONARY ARTERY DISEASE, CROHN'S DISEASE, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HISTIOCYTOSIS, HYDATIDIFORM MOLE, IMMUNE SYSTEM DISEASE, LYMPHOMA, MALARIA, MYASTHENIA GRAVIS, MYCOSIS FUNGOIDES, MYOCARDIAL INFARCTION, NEOPLASM, OSTEOARTHRITIS, OSTEOSARCOMA, PAIN, POSTERIOR UVEITIS, PSORIASIS, PSORIATIC ARTHRITIS, RETINOPATHY, RHEUMATOID ARTHRITIS, SYSTEMIC SCLERODERMA, ULCERATIVE COLITIS, UPPER AERODIGESTIVE TRACT NEOPLASM, URTICARIA | Dihydrofolate reductase inhibitor | 7 | 0.252482477 | 0.265395632 | 3369.244517 | 4 | 0.000643071 | 6 | 6 | 6 | 0.30841955 | 0.334461153 | 14777.57427 | 4 | 0.001808992 | 23 | 23 |
| METHOTREXATE | actual | 6.919470153 | Y | Dihydrofolate reductase | Mus musculus | 8.973156718 | 6.919470153 | 8.859266745 | 1 | 1 | 1 | 27 | ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, ALOPECIA AREATA, ASTHMA, ATOPIC ECZEMA, CANCER, CARCINOMA, CARDIOVASCULAR DISEASE, CHRONIC CHILDHOOD ARTHRITIS, CORONARY ARTERY DISEASE, CROHN'S DISEASE, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HISTIOCYTOSIS, HYDATIDIFORM MOLE, IMMUNE SYSTEM DISEASE, LYMPHOMA, MALARIA, MYASTHENIA GRAVIS, MYCOSIS FUNGOIDES, MYOCARDIAL INFARCTION, NEOPLASM, OSTEOARTHRITIS, OSTEOSARCOMA, PAIN, POSTERIOR UVEITIS, PSORIASIS, PSORIATIC ARTHRITIS, RETINOPATHY, RHEUMATOID ARTHRITIS, SYSTEMIC SCLERODERMA, ULCERATIVE COLITIS, UPPER AERODIGESTIVE TRACT NEOPLASM, URTICARIA | Dihydrofolate reductase inhibitor | 7 | 0.252482477 | 0.265395632 | 3369.244517 | 4 | 0.000643071 | 6 | 6 | 6 | 0.30841955 | 0.334461153 | 14777.57427 | 4 | 0.001808992 | 23 | 23 |
| METHOTREXATE | actual | 6.919470153 | Y | Dihydrofolate reductase | Rattus norvegicus | 8.973156718 | 6.919470153 | 8.721666667 | 1 | 1 | 1 | 12 | ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, ALOPECIA AREATA, ASTHMA, ATOPIC ECZEMA, CANCER, CARCINOMA, CARDIOVASCULAR DISEASE, CHRONIC CHILDHOOD ARTHRITIS, CORONARY ARTERY DISEASE, CROHN'S DISEASE, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HISTIOCYTOSIS, HYDATIDIFORM MOLE, IMMUNE SYSTEM DISEASE, LYMPHOMA, MALARIA, MYASTHENIA GRAVIS, MYCOSIS FUNGOIDES, MYOCARDIAL INFARCTION, NEOPLASM, OSTEOARTHRITIS, OSTEOSARCOMA, PAIN, POSTERIOR UVEITIS, PSORIASIS, PSORIATIC ARTHRITIS, RETINOPATHY, RHEUMATOID ARTHRITIS, SYSTEMIC SCLERODERMA, ULCERATIVE COLITIS, UPPER AERODIGESTIVE TRACT NEOPLASM, URTICARIA | Dihydrofolate reductase inhibitor | 7 | 0.252482477 | 0.265395632 | 3369.244517 | 4 | 0.000643071 | 6 | 6 | 6 | 0.30841955 | 0.334461153 | 14777.57427 | 4 | 0.001808992 | 23 | 23 |
| METHOTREXATE | actual | 6.919470153 | Y | Prelamin-A/C | Homo sapiens | 5.639823384 | 6.919470153 | 7.55 | 0 | 1 | 0.5 | 3 | ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, ALOPECIA AREATA, ASTHMA, ATOPIC ECZEMA, CANCER, CARCINOMA, CARDIOVASCULAR DISEASE, CHRONIC CHILDHOOD ARTHRITIS, CORONARY ARTERY DISEASE, CROHN'S DISEASE, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HISTIOCYTOSIS, HYDATIDIFORM MOLE, IMMUNE SYSTEM DISEASE, LYMPHOMA, MALARIA, MYASTHENIA GRAVIS, MYCOSIS FUNGOIDES, MYOCARDIAL INFARCTION, NEOPLASM, OSTEOARTHRITIS, OSTEOSARCOMA, PAIN, POSTERIOR UVEITIS, PSORIASIS, PSORIATIC ARTHRITIS, RETINOPATHY, RHEUMATOID ARTHRITIS, SYSTEMIC SCLERODERMA, ULCERATIVE COLITIS, UPPER AERODIGESTIVE TRACT NEOPLASM, URTICARIA | Dihydrofolate reductase inhibitor | 6 | 0.300591099 | 0.336495084 | 23750.15287 | 4 | 0.003255772 | 46 | 46 | 6 | 0.30841955 | 0.334461153 | 14777.57427 | 4 | 0.001808992 | 23 | 23 |
| METHOTREXATE | actual | 6.919470153 | Y | Dihydrofolate reductase | Lactobacillus casei | 8.973156718 | 6.919470153 | 7.916119559 | 1 | 1 | 1 | 37 | ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, ALOPECIA AREATA, ASTHMA, ATOPIC ECZEMA, CANCER, CARCINOMA, CARDIOVASCULAR DISEASE, CHRONIC CHILDHOOD ARTHRITIS, CORONARY ARTERY DISEASE, CROHN'S DISEASE, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HISTIOCYTOSIS, HYDATIDIFORM MOLE, IMMUNE SYSTEM DISEASE, LYMPHOMA, MALARIA, MYASTHENIA GRAVIS, MYCOSIS FUNGOIDES, MYOCARDIAL INFARCTION, NEOPLASM, OSTEOARTHRITIS, OSTEOSARCOMA, PAIN, POSTERIOR UVEITIS, PSORIASIS, PSORIATIC ARTHRITIS, RETINOPATHY, RHEUMATOID ARTHRITIS, SYSTEMIC SCLERODERMA, ULCERATIVE COLITIS, UPPER AERODIGESTIVE TRACT NEOPLASM, URTICARIA | Dihydrofolate reductase inhibitor | 7 | 0.252482477 | 0.265395632 | 3369.244517 | 4 | 0.000643071 | 6 | 6 | 6 | 0.30841955 | 0.334461153 | 14777.57427 | 4 | 0.001808992 | 23 | 23 |
| METHOTREXATE | actual | 6.919470153 | Y | Dihydrofolate reductase | Pneumocystis carinii | 8.973156718 | 6.919470153 | 8.794742501 | 1 | 1 | 1 | 12 | ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, ALOPECIA AREATA, ASTHMA, ATOPIC ECZEMA, CANCER, CARCINOMA, CARDIOVASCULAR DISEASE, CHRONIC CHILDHOOD ARTHRITIS, CORONARY ARTERY DISEASE, CROHN'S DISEASE, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HISTIOCYTOSIS, HYDATIDIFORM MOLE, IMMUNE SYSTEM DISEASE, LYMPHOMA, MALARIA, MYASTHENIA GRAVIS, MYCOSIS FUNGOIDES, MYOCARDIAL INFARCTION, NEOPLASM, OSTEOARTHRITIS, OSTEOSARCOMA, PAIN, POSTERIOR UVEITIS, PSORIASIS, PSORIATIC ARTHRITIS, RETINOPATHY, RHEUMATOID ARTHRITIS, SYSTEMIC SCLERODERMA, ULCERATIVE COLITIS, UPPER AERODIGESTIVE TRACT NEOPLASM, URTICARIA | Dihydrofolate reductase inhibitor | 7 | 0.252482477 | 0.265395632 | 3369.244517 | 4 | 0.000643071 | 6 | 6 | 6 | 0.30841955 | 0.334461153 | 14777.57427 | 4 | 0.001808992 | 23 | 23 |
| METHOTREXATE | actual | 6.919470153 | Y | Dihydrofolate reductase | Escherichia coli | 8.973156718 | 6.873742908 | 7.779982734 | 1 | 1 | 1 | 26 | ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, ALOPECIA AREATA, ASTHMA, ATOPIC ECZEMA, CANCER, CARCINOMA, CARDIOVASCULAR DISEASE, CHRONIC CHILDHOOD ARTHRITIS, CORONARY ARTERY DISEASE, CROHN'S DISEASE, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HISTIOCYTOSIS, HYDATIDIFORM MOLE, IMMUNE SYSTEM DISEASE, LYMPHOMA, MALARIA, MYASTHENIA GRAVIS, MYCOSIS FUNGOIDES, MYOCARDIAL INFARCTION, NEOPLASM, OSTEOARTHRITIS, OSTEOSARCOMA, PAIN, POSTERIOR UVEITIS, PSORIASIS, PSORIATIC ARTHRITIS, RETINOPATHY, RHEUMATOID ARTHRITIS, SYSTEMIC SCLERODERMA, ULCERATIVE COLITIS, UPPER AERODIGESTIVE TRACT NEOPLASM, URTICARIA | Dihydrofolate reductase inhibitor | 7 | 0.252482477 | 0.265395632 | 3369.244517 | 4 | 0.000643071 | 6 | 6 | 6 | 0.30841955 | 0.334461153 | 14777.57427 | 4 | 0.001808992 | 23 | 23 |
| METHOTREXATE | actual | 6.919470153 | Y | Isocitrate dehydrogenase [NADP] cytoplasmic | Homo sapiens | 5.639823384 | 6.919470153 | 8.283996656 | 0 | 1 | 0.5 | 1 | ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, ALOPECIA AREATA, ASTHMA, ATOPIC ECZEMA, CANCER, CARCINOMA, CARDIOVASCULAR DISEASE, CHRONIC CHILDHOOD ARTHRITIS, CORONARY ARTERY DISEASE, CROHN'S DISEASE, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HISTIOCYTOSIS, HYDATIDIFORM MOLE, IMMUNE SYSTEM DISEASE, LYMPHOMA, MALARIA, MYASTHENIA GRAVIS, MYCOSIS FUNGOIDES, MYOCARDIAL INFARCTION, NEOPLASM, OSTEOARTHRITIS, OSTEOSARCOMA, PAIN, POSTERIOR UVEITIS, PSORIASIS, PSORIATIC ARTHRITIS, RETINOPATHY, RHEUMATOID ARTHRITIS, SYSTEMIC SCLERODERMA, ULCERATIVE COLITIS, UPPER AERODIGESTIVE TRACT NEOPLASM, URTICARIA | Dihydrofolate reductase inhibitor | 6 | 0.28196347 | 0.310535955 | 7654.130812 | 4 | 0.002205777 | 32 | 32 | 6 | 0.30841955 | 0.334461153 | 14777.57427 | 4 | 0.001808992 | 23 | 23 |
| METHOTREXATE | actual | 6.919470153 | Y | Dihydrofolate reductase | Leishmania major | 8.973156718 | 6.919470153 | 9.89 | 1 | 1 | 1 | 1 | ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, ALOPECIA AREATA, ASTHMA, ATOPIC ECZEMA, CANCER, CARCINOMA, CARDIOVASCULAR DISEASE, CHRONIC CHILDHOOD ARTHRITIS, CORONARY ARTERY DISEASE, CROHN'S DISEASE, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HISTIOCYTOSIS, HYDATIDIFORM MOLE, IMMUNE SYSTEM DISEASE, LYMPHOMA, MALARIA, MYASTHENIA GRAVIS, MYCOSIS FUNGOIDES, MYOCARDIAL INFARCTION, NEOPLASM, OSTEOARTHRITIS, OSTEOSARCOMA, PAIN, POSTERIOR UVEITIS, PSORIASIS, PSORIATIC ARTHRITIS, RETINOPATHY, RHEUMATOID ARTHRITIS, SYSTEMIC SCLERODERMA, ULCERATIVE COLITIS, UPPER AERODIGESTIVE TRACT NEOPLASM, URTICARIA | Dihydrofolate reductase inhibitor | 7 | 0.252482477 | 0.265395632 | 3369.244517 | 4 | 0.000643071 | 6 | 6 | 6 | 0.30841955 | 0.334461153 | 14777.57427 | 4 | 0.001808992 | 23 | 23 |
| METHOTREXATE | actual | 6.919470153 | Y | Dihydrofolate reductase | Enterococcus faecium | 8.973156718 | 6.919470153 | 8.85 | 1 | 1 | 1 | 1 | ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, ALOPECIA AREATA, ASTHMA, ATOPIC ECZEMA, CANCER, CARCINOMA, CARDIOVASCULAR DISEASE, CHRONIC CHILDHOOD ARTHRITIS, CORONARY ARTERY DISEASE, CROHN'S DISEASE, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HISTIOCYTOSIS, HYDATIDIFORM MOLE, IMMUNE SYSTEM DISEASE, LYMPHOMA, MALARIA, MYASTHENIA GRAVIS, MYCOSIS FUNGOIDES, MYOCARDIAL INFARCTION, NEOPLASM, OSTEOARTHRITIS, OSTEOSARCOMA, PAIN, POSTERIOR UVEITIS, PSORIASIS, PSORIATIC ARTHRITIS, RETINOPATHY, RHEUMATOID ARTHRITIS, SYSTEMIC SCLERODERMA, ULCERATIVE COLITIS, UPPER AERODIGESTIVE TRACT NEOPLASM, URTICARIA | Dihydrofolate reductase inhibitor | 7 | 0.252482477 | 0.265395632 | 3369.244517 | 4 | 0.000643071 | 6 | 6 | 6 | 0.30841955 | 0.334461153 | 14777.57427 | 4 | 0.001808992 | 23 | 23 |
| METHOTREXATE | actual | 6.919470153 | Y | Dihydrofolate reductase | Gallus gallus | 8.973156718 | 6.919470153 | 7.385 | 1 | 1 | 1 | 2 | ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, ALOPECIA AREATA, ASTHMA, ATOPIC ECZEMA, CANCER, CARCINOMA, CARDIOVASCULAR DISEASE, CHRONIC CHILDHOOD ARTHRITIS, CORONARY ARTERY DISEASE, CROHN'S DISEASE, HEAD AND NECK SQUAMOUS CELL CARCINOMA, HISTIOCYTOSIS, HYDATIDIFORM MOLE, IMMUNE SYSTEM DISEASE, LYMPHOMA, MALARIA, MYASTHENIA GRAVIS, MYCOSIS FUNGOIDES, MYOCARDIAL INFARCTION, NEOPLASM, OSTEOARTHRITIS, OSTEOSARCOMA, PAIN, POSTERIOR UVEITIS, PSORIASIS, PSORIATIC ARTHRITIS, RETINOPATHY, RHEUMATOID ARTHRITIS, SYSTEMIC SCLERODERMA, ULCERATIVE COLITIS, UPPER AERODIGESTIVE TRACT NEOPLASM, URTICARIA | Dihydrofolate reductase inhibitor | 7 | 0.252482477 | 0.265395632 | 3369.244517 | 4 | 0.000643071 | 6 | 6 | 6 | 0.30841955 | 0.334461153 | 14777.57427 | 4 | 0.001808992 | 23 | 23 |
| EPROSARTAN | predicted | Type-1B angiotensin II receptor | Rattus norvegicus | 7.548034018 | 2.644102053 | 9 | 1 | 1 | 1 | 1 | CARDIOVASCULAR DISEASE, HYPERTENSION | unknown | 8 | 0.234790875 | 0.247117106 | 1168.581636 | 11 | 0.000467643 | 4 | 4 | 8 | 0.198279817 | 0.205949627 | 27.11194876 | 11 | 0.000467106 | 4 | 4 | ||
| EPROSARTAN | predicted | Angiotensin II type 2 (AT-2) receptor | Rattus norvegicus | 7.812622979 | 3.437868936 | 9 | 1 | 1 | 1 | 1 | CARDIOVASCULAR DISEASE, HYPERTENSION | unknown | 8 | 0.234727125 | 0.246731527 | 481.6204227 | 11 | 0.000349133 | 3 | 3 | 8 | 0.198279817 | 0.205949627 | 27.11194876 | 11 | 0.000467106 | 4 | 4 | ||
| EPROSARTAN | predicted | Angiotensin II receptor | Homo sapiens | 8.208410456 | 4.625231367 | 8.321542101 | 1 | 1 | 1 | 6 | CARDIOVASCULAR DISEASE, HYPERTENSION | unknown | 8 | 0.232392473 | 0.246182765 | 3858.195318 | 11 | 0.001013954 | 9 | 9 | 8 | 0.198279817 | 0.205949627 | 27.11194876 | 11 | 0.000467106 | 4 | 4 | ||
| LOXAPINE | predicted | Dopamine D3 receptor | Homo sapiens | 7.333333333 | 2 | 7.66 | 1 | 1 | 1 | 1 | ASTHMA, BIPOLAR DISORDER, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, NICOTINE DEPENDENCE, PSYCHOSIS, SCHIZOPHRENIA | D2-like dopamine receptor antagonist, Serotonin 2a (5-HT2a) receptor antagonist, Serotonin 2c (5-HT2c) receptor antagonist | 6 | 0.28961474 | 0.320946597 | 9204.657659 | 0 | 0.002356341 | 42 | 42 | 7 | 0.242360527 | 0.26058553 | 53.24216142 | 0 | 0.000333488 | 5 | 5 | ||
| LOXAPINE | predicted | Dopamine D2 receptor | Rattus norvegicus | 7.333333333 | 2 | 7.68 | 1 | 1 | 1 | 1 | ASTHMA, BIPOLAR DISORDER, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, NICOTINE DEPENDENCE, PSYCHOSIS, SCHIZOPHRENIA | D2-like dopamine receptor antagonist, Serotonin 2a (5-HT2a) receptor antagonist, Serotonin 2c (5-HT2c) receptor antagonist | 6 | 0.2855963 | 0.314121843 | 9635.285337 | 0 | 0.002095645 | 35 | 35 | 7 | 0.242360527 | 0.26058553 | 53.24216142 | 0 | 0.000333488 | 5 | 5 | ||
| BOSUTINIB | predicted | Tyrosine-protein kinase ABL | Homo sapiens | 7.683267093 | 3.049801279 | 8.98 | 1 | 1 | 1 | 4 | BREAST NEOPLASM, CHRONIC MYELOGENOUS LEUKEMIA, GLIOBLASTOMA MULTIFORME, LEUKEMIA, NEOPLASM | Tyrosine-protein kinase ABL inhibitor, Tyrosine-protein kinase HCK inhibitor, Tyrosine-protein kinase Lyn inhibitor, Tyrosine-protein kinase SRC inhibitor | 6 | 0.299134948 | 0.335579333 | 3196.709319 | 35 | 0.000616628 | 14 | 14 | 7 | 0.268145161 | 0.313875348 | 3761.167 | 35 | 0.003559312 | 93 | 93 | ||
| MYCOPHENOLIC ACID | actual | 7.144480844 | Y | Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens | 8.290584524 | 7.144480844 | 7.730909091 | 0.772727273 | 1 | 0.886363636 | 22 | ACUTE GRAFT VS. HOST DISEASE, CHRONIC KIDNEY DISEASE, IMMUNE SYSTEM DISEASE, INFECTION, INJURY | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | 7 | 0.237044146 | 0.247689278 | 0 | 4 | 0.000150898 | 1 | 1 | 6 | 0.310636004 | 0.336070947 | 6460.970115 | 4 | 0.001106446 | 14 | 14 |
| MYCOPHENOLIC ACID | actual | 7.144480844 | Y | Inosine-5'-monophosphate dehydrogenase 1 | Homo sapiens | 9.048160281 | 7.144480844 | 7.473636364 | 1 | 1 | 1 | 11 | ACUTE GRAFT VS. HOST DISEASE, CHRONIC KIDNEY DISEASE, IMMUNE SYSTEM DISEASE, INFECTION, INJURY | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | 7 | 0.237044146 | 0.247689278 | 0 | 4 | 0.000150898 | 1 | 1 | 6 | 0.310636004 | 0.336070947 | 6460.970115 | 4 | 0.001106446 | 14 | 14 |
| VANCOMYCIN | predicted | Norepinephrine transporter | Rattus norvegicus | 8.540317404 | 5.620952211 | 7.8 | 1 | 1 | 1 | 1 | CELLULITIS, CONSTIPATION, CORONARY ARTERY DISEASE, CYSTIC FIBROSIS, ENDOCARDITIS, INFECTION, PNEUMONIA, SCLEROSING CHOLANGITIS, SKIN DISEASE | unknown | 6 | 0.291765103 | 0.323057644 | 15803.70688 | 0 | 0.002617056 | 42 | 42 | 7 | 0.236073184 | 0.254354292 | 1996.178751 | 0 | 0.00050459 | 6 | 6 | ||
| KETOCONAZOLE | predicted | Gonadotropin-releasing hormone receptor | Rattus norvegicus | 7.802367023 | 3.407101068 | 7.72 | 1 | 1 | 1 | 4 | ASTHMA, CANCER, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INFECTION, LYMPHOMA, MELANOMA, MULTIPLE SCLEROSIS, NEOPLASM, PREMATURE BIRTH, PROSTATE CARCINOMA, RETINOPATHY, SEBORRHEIC DERMATITIS | Cytochrome P450 51 inhibitor | 8 | 0.226249673 | 0.24017117 | 6906 | 17 | 0.001040428 | 5 | 5 | 7 | 0.291962175 | 0.321902283 | 20186.19768 | 0 | 0.001914031 | 23 | 23 | ||
| DOXORUBICIN | predicted | Serine/threonine-protein kinase Aurora-A | Homo sapiens | 8.390103699 | 5.170311097 | 7.4 | 1 | 1 | 1 | 1 | ACUTE LYMPHOBLASTIC LEUKEMIA, BREAST CARCINOMA, CANCER, CARCINOMA, CUTANEOUS T-CELL LYMPHOMA, ENDOMETRIAL NEOPLASM, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LYMPHOID LEUKEMIA, LYMPHOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, OSTEOSARCOMA, OVARIAN CARCINOMA, OVARIAN NEOPLASM, PRIMARY SYSTEMIC AMYLOIDOSIS, PROSTATE CARCINOMA, SARCOMA, SMALL CELL LUNG CARCINOMA, THYROID CARCINOMA | unknown | 6 | 0.2902955 | 0.326576056 | 3354.359991 | 35 | 0.000532934 | 9 | 9 | 7 | 0.273575949 | 0.294600512 | 7334.632599 | 0 | 0.001100045 | 13 | 13 | ||
| TEZOSENTAN | predicted | Endothelin receptor ET-A | Homo sapiens | 7.958925439 | 3.876776317 | 7.64 | 1 | 1 | 1 | 1 | HEART FAILURE, PULMONARY HYPERTENSION | Endothelin receptor ET-A antagonist, Endothelin receptor ET-B antagonist | 8 | 0.202411613 | 0.213192321 | 3455 | 11 | 0.000679054 | 3 | 3 | 9 | 0.16835443 | 0.174367237 | 0 | 11 | 0.000276094 | 1 | 1 | ||
| CLOTHIAPINE | predicted | Dopamine D2 receptor | Homo sapiens | 7.333333333 | 2 | 9.31 | 1 | 1 | 1 | 1 | PSYCHOSIS | unknown | 6 | 0.2855963 | 0.314121843 | 9635.285337 | 0 | 0.002095645 | 35 | 35 | 7 | 0.22344275 | 0.235949765 | 9.225780384 | 0 | 0.000246245 | 3 | 3 | ||
| LOSARTAN POTASSIUM | predicted | Angiotensin II receptor | Homo sapiens | 8.128041094 | 4.384123281 | 8.52 | 1 | 1 | 1 | 2 | ATRIAL FIBRILLATION, EOSINOPHILIC ESOPHAGITIS, HYPERTENSION, MARFAN SYNDROME, PROTEINURIA | Type-1 angiotensin II receptor antagonist | 8 | 0.232392473 | 0.246182765 | 3858.195318 | 11 | 0.001013954 | 9 | 9 | 8 | 0.198188904 | 0.205178468 | 8.079277503 | 11 | 0.000278815 | 2 | 2 | ||
| TASOSARTAN | predicted | Angiotensin II receptor | Homo sapiens | 7.618339973 | 2.855019918 | 8.4 | 1 | 1 | 1 | 2 | CARDIOVASCULAR DISEASE | unknown | 8 | 0.232392473 | 0.246182765 | 3858.195318 | 11 | 0.001013954 | 9 | 9 | 8 | 0.198188904 | 0.205178468 | 5.506447179 | 11 | 0.000268838 | 2 | 2 | ||
| VALSARTAN | predicted | Type-1A angiotensin II receptor | Rattus norvegicus | 7.812622979 | 3.437868936 | 8.47 | 1 | 1 | 1 | 1 | ATRIAL FIBRILLATION, CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, CONGESTIVE HEART FAILURE, CORONARY ARTERY DISEASE, DIABETES MELLITUS, DILATED CARDIOMYOPATHY, HEART FAILURE, HYPERTENSION, HYPERTROPHIC CARDIOMYOPATHY, IGA GLOMERULONEPHRITIS, METABOLIC SYNDROME, MYOCARDIAL INFARCTION, NON-HODGKINS LYMPHOMA, OBSTRUCTIVE SLEEP APNEA, PROTEINURIA, TYPE II DIABETES MELLITUS, VITAMIN D DEFICIENCY | Type-1 angiotensin II receptor antagonist | 7 | 0.24490085 | 0.256733868 | 2159.703983 | 11 | 0.00046801 | 4 | 4 | 8 | 0.196745562 | 0.202651546 | 0 | 11 | 0.000183143 | 1 | 1 | ||
| PATUPILONE | predicted | Nuclear receptor subfamily 1 group I member 2 | Rattus norvegicus | 7.974217214 | 3.922651643 | 8 | 1 | 1 | 1 | 1 | CANCER, COLORECTAL ADENOCARCINOMA, HEPATOCELLULAR CARCINOMA, NEOPLASM, PROSTATE CARCINOMA | unknown | 6 | 0.264777948 | 0.281945248 | 2526.423004 | 4 | 0.00077363 | 9 | 9 | 7 | 0.209372729 | 0.217129362 | 0 | 4 | 0.000156755 | 1 | 1 | ||
| LASOFOXIFENE | predicted | Estrogen receptor beta | Homo sapiens | 8.239586668 | 4.718760003 | 8.2475 | 1 | 1 | 1 | 4 | OSTEOPOROSIS | unknown | 7 | 0.261494253 | 0.275950866 | 737.9841276 | 4 | 0.00057009 | 7 | 7 | 8 | 0.216612378 | 0.227035997 | 7.207485249 | 4 | 0.000277591 | 3 | 3 | ||
| LASOFOXIFENE | predicted | Estrogen receptor | Homo sapiens | 7.955575917 | 3.86672775 | 7.750379883 | 1 | 1 | 1 | 3 | OSTEOPOROSIS | unknown | 7 | 0.266 | 0.283093723 | 1220.637797 | 4 | 0.00090602 | 12 | 12 | 8 | 0.216612378 | 0.227035997 | 7.207485249 | 4 | 0.000277591 | 3 | 3 | ||
| LASOFOXIFENE | predicted | Estrogen receptor | Homo sapiens | 7.955575917 | 3.86672775 | 7.750379883 | 1 | 1 | 1 | 3 | OSTEOPOROSIS | unknown | 7 | 0.266 | 0.283093723 | 1220.637797 | 4 | 0.00090602 | 12 | 12 | 8 | 0.216612378 | 0.227035997 | 7.207485249 | 4 | 0.000277591 | 3 | 3 | ||
| CLEBOPRIDE | predicted | Dopamine D4 receptor | Homo sapiens | 7.333333333 | 2 | 8.49 | 1 | 1 | 1 | 1 | DIGESTIVE SYSTEM DISEASE | unknown | 6 | 0.278691167 | 0.299749373 | 1729.437792 | 0 | 0.000998692 | 17 | 17 | 7 | 0.229371186 | 0.244801564 | 74.2042122 | 0 | 0.000308064 | 4 | 4 | ||
| BORTEZOMIB | actual | 7.925390444 | Y | Proteasome Macropain subunit MB1 | Homo sapiens | 9.308463481 | 5.791820782 | 7.703082613 | 1 | 1 | 1 | 11 | ACUTE GRAFT VS. HOST DISEASE, ACUTE MYELOID LEUKEMIA, ACUTE PROMYELOCYTIC LEUKEMIA, AL AMYLOIDOSIS, BREAST CARCINOMA, CANCER, CHRONIC LYMPHOCYTIC LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MACROGLOBULINEMIA, MANTLE CELL LYMPHOMA, MELANOMA, MESOTHELIOMA, MULTIPLE MYELOMA, MYELODYSPLASTIC SYNDROME, NEOPLASM, NEOPLASM OF MATURE B-CELLS, NEUROBLASTOMA, NON-SMALL CELL LUNG CARCINOMA, QUALITATIVE OR QUANTITATIVE DEFECTS OF DYSFERLIN, RENAL CARCINOMA | 26S proteosome inhibitor | 7 | 0.235046221 | 0.246707428 | 28.80497982 | 3 | 0.00028167 | 2 | 2 | 6 | 0.299031477 | 0.325139773 | 27135.54473 | 3 | 0.002714301 | 19 | 19 |
| BORTEZOMIB | actual | 7.925390444 | Y | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | 9.308463481 | 5.614917471 | 7.625251654 | 1 | 1 | 1 | 1 | ACUTE GRAFT VS. HOST DISEASE, ACUTE MYELOID LEUKEMIA, ACUTE PROMYELOCYTIC LEUKEMIA, AL AMYLOIDOSIS, BREAST CARCINOMA, CANCER, CHRONIC LYMPHOCYTIC LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MACROGLOBULINEMIA, MANTLE CELL LYMPHOMA, MELANOMA, MESOTHELIOMA, MULTIPLE MYELOMA, MYELODYSPLASTIC SYNDROME, NEOPLASM, NEOPLASM OF MATURE B-CELLS, NEUROBLASTOMA, NON-SMALL CELL LUNG CARCINOMA, QUALITATIVE OR QUANTITATIVE DEFECTS OF DYSFERLIN, RENAL CARCINOMA | 26S proteosome inhibitor | 6 | 0.360659157 | 0.411480625 | 88987.91874 | 4 | 0.006038175 | 82 | 82 | 6 | 0.299031477 | 0.325139773 | 27135.54473 | 3 | 0.002714301 | 19 | 19 |
| BORTEZOMIB | actual | 7.925390444 | Y | Nuclear factor NF-kappa-B complex | Homo sapiens | 9.308463481 | 7.925390444 | 8.01 | 1 | 1 | 1 | 3 | ACUTE GRAFT VS. HOST DISEASE, ACUTE MYELOID LEUKEMIA, ACUTE PROMYELOCYTIC LEUKEMIA, AL AMYLOIDOSIS, BREAST CARCINOMA, CANCER, CHRONIC LYMPHOCYTIC LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MACROGLOBULINEMIA, MANTLE CELL LYMPHOMA, MELANOMA, MESOTHELIOMA, MULTIPLE MYELOMA, MYELODYSPLASTIC SYNDROME, NEOPLASM, NEOPLASM OF MATURE B-CELLS, NEUROBLASTOMA, NON-SMALL CELL LUNG CARCINOMA, QUALITATIVE OR QUANTITATIVE DEFECTS OF DYSFERLIN, RENAL CARCINOMA | 26S proteosome inhibitor | 7 | 0.245526839 | 0.25716489 | 1805.678086 | 3 | 0.000464308 | 3 | 3 | 6 | 0.299031477 | 0.325139773 | 27135.54473 | 3 | 0.002714301 | 19 | 19 |
| BORTEZOMIB | actual | 7.925390444 | Y | Nuclear factor NF-kappa-B complex | Homo sapiens | 9.308463481 | 6.242061593 | 8.01 | 1 | 1 | 1 | 2 | ACUTE GRAFT VS. HOST DISEASE, ACUTE MYELOID LEUKEMIA, ACUTE PROMYELOCYTIC LEUKEMIA, AL AMYLOIDOSIS, BREAST CARCINOMA, CANCER, CHRONIC LYMPHOCYTIC LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MACROGLOBULINEMIA, MANTLE CELL LYMPHOMA, MELANOMA, MESOTHELIOMA, MULTIPLE MYELOMA, MYELODYSPLASTIC SYNDROME, NEOPLASM, NEOPLASM OF MATURE B-CELLS, NEUROBLASTOMA, NON-SMALL CELL LUNG CARCINOMA, QUALITATIVE OR QUANTITATIVE DEFECTS OF DYSFERLIN, RENAL CARCINOMA | 26S proteosome inhibitor | 7 | 0.245526839 | 0.25716489 | 1805.678086 | 3 | 0.000464308 | 3 | 3 | 6 | 0.299031477 | 0.325139773 | 27135.54473 | 3 | 0.002714301 | 19 | 19 |
| NORETHINDRONE | predicted | Estrogen receptor | Rattus norvegicus | 7.793755474 | 3.381266422 | 9.2 | 1 | 1 | 1 | 1 | MENOPAUSE | Progesterone receptor agonist | 7 | 0.266 | 0.283093723 | 1220.637797 | 4 | 0.00090602 | 12 | 12 | 7 | 0.279954663 | 0.302018783 | 204.8814452 | 4 | 0.000338947 | 4 | 4 | ||
| NORETHINDRONE | predicted | Progesterone receptor | Bos taurus | 8.132258151 | 4.396774452 | 8.47 | 1 | 1 | 1 | 2 | MENOPAUSE | Progesterone receptor agonist | 7 | 0.27593361 | 0.299162742 | 3766.447636 | 4 | 0.001493001 | 21 | 21 | 7 | 0.279954663 | 0.302018783 | 204.8814452 | 4 | 0.000338947 | 4 | 4 | ||
| DILAZEP | predicted | Equilibrative nucleoside transporter 1 | Homo sapiens | 7.333333333 | 2 | 7.76 | 1 | 1 | 1 | 1 | CARDIOVASCULAR DISEASE | unknown | 8 | 0.237044146 | 0.248043185 | 317.4629326 | 3 | 0.000300667 | 2 | 2 | 8 | 0.209830097 | 0.217795863 | 29.72857537 | 3 | 0.000309265 | 2 | 2 | ||
| TOLVAPTAN | predicted | Vasopressin V2 receptor | Homo sapiens | 7.543755487 | 2.631266462 | 9.37 | 1 | 1 | 1 | 1 | CANCER, CARCINOMA, CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, CIRRHOSIS OF LIVER, CONGESTIVE HEART FAILURE, HEART FAILURE, HYPONATREMIA, KIDNEY DISEASE | Vasopressin V2 receptor antagonist | 8 | 0.234281843 | 0.245693217 | 3856.010924 | 7 | 0.000806406 | 6 | 6 | 9 | 0.189833114 | 0.195597051 | 0 | 7 | 0.000197932 | 1 | 1 | ||
| FROVATRIPTAN | predicted | Serotonin 1b (5-HT1b) receptor | Homo sapiens | 7.404166679 | 2.212500038 | 7.99 | 1 | 1 | 1 | 1 | MIGRAINE DISORDER, PAIN | unknown | 6 | 0.278153153 | 0.298775786 | 2652.54995 | 0 | 0.001011191 | 17 | 17 | 7 | 0.232956077 | 0.246644083 | 3.183148971 | 0 | 0.000182173 | 2 | 2 | ||
| BOPINDOLOL | predicted | Beta-1 adrenergic receptor | Homo sapiens | 8.224927735 | 4.674783206 | 7.45 | 1 | 1 | 1 | 2 | CARDIOVASCULAR DISEASE | unknown | 7 | 0.273575949 | 0.294612906 | 2721.280158 | 0 | 0.00109185 | 17 | 17 | 7 | 0.245666382 | 0.265443829 | 227.5490688 | 0 | 0.000469364 | 7 | 7 | ||
| BOPINDOLOL | predicted | Beta-2 adrenergic receptor | Homo sapiens | 8.224927735 | 4.674783206 | 7.775 | 1 | 1 | 1 | 2 | CARDIOVASCULAR DISEASE | unknown | 7 | 0.262287621 | 0.279016222 | 1113.258603 | 0 | 0.000623933 | 9 | 9 | 7 | 0.245666382 | 0.265443829 | 227.5490688 | 0 | 0.000469364 | 7 | 7 | ||
| LISURIDE | predicted | Alpha-2c adrenergic receptor | Homo sapiens | 7.62009429 | 2.860282869 | 8.785 | 1 | 1 | 1 | 2 | MIGRAINE DISORDER | unknown | 6 | 0.279321486 | 0.302544824 | 2596.316271 | 0 | 0.001323976 | 24 | 24 | 7 | 0.249422966 | 0.273188466 | 454.0311504 | 0 | 0.000879082 | 16 | 16 | ||
| LISURIDE | predicted | Alpha-2a adrenergic receptor | Homo sapiens | 7.688099695 | 3.064299085 | 9.725 | 1 | 1 | 1 | 2 | MIGRAINE DISORDER | unknown | 6 | 0.287304752 | 0.316396761 | 9934.046794 | 0 | 0.002098773 | 36 | 36 | 7 | 0.249422966 | 0.273188466 | 454.0311504 | 0 | 0.000879082 | 16 | 16 | ||
| LISURIDE | predicted | Alpha-2b adrenergic receptor | Homo sapiens | 7.688099695 | 3.064299085 | 9.46 | 1 | 1 | 1 | 2 | MIGRAINE DISORDER | unknown | 6 | 0.291273585 | 0.321226142 | 10541.0208 | 0 | 0.002040305 | 36 | 36 | 7 | 0.249422966 | 0.273188466 | 454.0311504 | 0 | 0.000879082 | 16 | 16 | ||
| LISURIDE | predicted | Serotonin 6 (5-HT6) receptor | Homo sapiens | 7.552088885 | 2.656266654 | 8.09 | 1 | 1 | 1 | 2 | MIGRAINE DISORDER | unknown | 6 | 0.306234502 | 0.3399171 | 12310.50404 | 0 | 0.001709791 | 28 | 28 | 7 | 0.249422966 | 0.273188466 | 454.0311504 | 0 | 0.000879082 | 16 | 16 | ||
| LISURIDE | predicted | Serotonin 1a (5-HT1a) receptor | Rattus norvegicus | 7.688099695 | 3.064299085 | 9.455 | 1 | 1 | 1 | 2 | MIGRAINE DISORDER | unknown | 6 | 0.297385621 | 0.3287353 | 8105.209398 | 0 | 0.001297152 | 23 | 23 | 7 | 0.249422966 | 0.273188466 | 454.0311504 | 0 | 0.000879082 | 16 | 16 | ||
| LISURIDE | predicted | Serotonin 2b (5-HT2b) receptor | Homo sapiens | 7.552088885 | 2.656266654 | 8.39 | 1 | 1 | 1 | 2 | MIGRAINE DISORDER | unknown | 6 | 0.311419308 | 0.348293811 | 18639.72588 | 0 | 0.00222842 | 38 | 38 | 7 | 0.249422966 | 0.273188466 | 454.0311504 | 0 | 0.000879082 | 16 | 16 | ||
| LISURIDE | predicted | Serotonin 1b (5-HT1b) receptor | Rattus norvegicus | 7.660422825 | 2.981268476 | 8.17 | 1 | 1 | 1 | 2 | MIGRAINE DISORDER | unknown | 6 | 0.278153153 | 0.298775786 | 2652.54995 | 0 | 0.001011191 | 17 | 17 | 7 | 0.249422966 | 0.273188466 | 454.0311504 | 0 | 0.000879082 | 16 | 16 | ||
| LISURIDE | predicted | Serotonin 2c (5-HT2c) receptor | Homo sapiens | 7.552088885 | 2.656266654 | 7.85 | 1 | 1 | 1 | 2 | MIGRAINE DISORDER | unknown | 6 | 0.303759663 | 0.337989204 | 9528.005115 | 0 | 0.001670615 | 31 | 31 | 7 | 0.249422966 | 0.273188466 | 454.0311504 | 0 | 0.000879082 | 16 | 16 | ||
| LISURIDE | predicted | Serotonin 2a (5-HT2a) receptor | Homo sapiens | 7.552088885 | 2.656266654 | 8.79 | 1 | 1 | 1 | 2 | MIGRAINE DISORDER | unknown | 6 | 0.305153547 | 0.341170233 | 14148.52943 | 0 | 0.002040502 | 36 | 36 | 7 | 0.249422966 | 0.273188466 | 454.0311504 | 0 | 0.000879082 | 16 | 16 | ||
| SORAFENIB | predicted | Platelet-derived growth factor receptor beta | Homo sapiens | 7.582858663 | 4.748575989 | 7.538 | 1 | 0.8 | 0.9 | 10 | ACUTE MYELOID LEUKEMIA, BLADDER CARCINOMA, BREAST CARCINOMA, CANCER, CARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, COLORECTAL ADENOCARCINOMA, GASTRIC CARCINOMA, GASTROINTESTINAL STROMAL TUMOR, HEPATOCELLULAR CARCINOMA, KELOID, KIDNEY NEOPLASM, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MELANOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, OSTEOSARCOMA, OVARIAN CARCINOMA, PANCREATIC CARCINOMA, PORTAL HYPERTENSION, PROSTATE CARCINOMA, PULMONARY HYPERTENSION, RENAL CARCINOMA, RENAL CELL CARCINOMA, SARCOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL CARCINOMA, TESTICULAR CARCINOMA, THYROID CARCINOMA | unknown | 7 | 0.283256881 | 0.322508194 | 516.7195661 | 35 | 0.000513462 | 13 | 13 | 7 | 0.297385621 | 0.373850836 | 50846.88839 | 35 | 0.007181182 | 194 | 194 | ||
| SORAFENIB | predicted | Homeodomain-interacting protein kinase 4 | Homo sapiens | 8.285780516 | 4.857341547 | 8.35 | 1 | 1 | 1 | 3 | ACUTE MYELOID LEUKEMIA, BLADDER CARCINOMA, BREAST CARCINOMA, CANCER, CARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, COLORECTAL ADENOCARCINOMA, GASTRIC CARCINOMA, GASTROINTESTINAL STROMAL TUMOR, HEPATOCELLULAR CARCINOMA, KELOID, KIDNEY NEOPLASM, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MELANOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, OSTEOSARCOMA, OVARIAN CARCINOMA, PANCREATIC CARCINOMA, PORTAL HYPERTENSION, PROSTATE CARCINOMA, PULMONARY HYPERTENSION, RENAL CARCINOMA, RENAL CELL CARCINOMA, SARCOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL CARCINOMA, TESTICULAR CARCINOMA, THYROID CARCINOMA | unknown | 7 | 0.280955476 | 0.319185326 | 213.0958395 | 35 | 0.000410718 | 10 | 10 | 7 | 0.297385621 | 0.373850836 | 50846.88839 | 35 | 0.007181182 | 194 | 194 | ||
| DARIFENACIN | predicted | Muscarinic acetylcholine receptor M4 | Homo sapiens | 7.597922294 | 2.793766883 | 8.07 | 1 | 1 | 1 | 1 | NOCTURIA, POLYURIA, URINARY INCONTINENCE | unknown | 6 | 0.280136099 | 0.303663004 | 2650.84323 | 0 | 0.001281184 | 23 | 23 | 7 | 0.231583177 | 0.248333746 | 63.68510786 | 0 | 0.000346206 | 5 | 5 | ||
| DARIFENACIN | predicted | Muscarinic acetylcholine receptor M3 | Rattus norvegicus | 7.597922294 | 2.793766883 | 8.6 | 1 | 1 | 1 | 1 | NOCTURIA, POLYURIA, URINARY INCONTINENCE | unknown | 6 | 0.280499676 | 0.304347407 | 3029.87758 | 0 | 0.001343026 | 24 | 24 | 7 | 0.231583177 | 0.248333746 | 63.68510786 | 0 | 0.000346206 | 5 | 5 | ||
| NERATINIB | predicted | Receptor protein-tyrosine kinase erbB-2 | Homo sapiens | 7.700386612 | 3.101159835 | 7.728888889 | 1 | 1 | 1 | 9 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 6 | 0.304187192 | 0.340341238 | 7127.398779 | 35 | 0.000677003 | 13 | 13 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| NERATINIB | predicted | Epidermal growth factor receptor erbB1 | Homo sapiens | 7.445061603 | 3.698821171 | 8.581818182 | 1 | 0.863636364 | 0.931818182 | 22 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 6 | 0.325 | 0.362945826 | 30142.6809 | 0 | 0.00130342 | 24 | 24 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| NERATINIB | predicted | Mitogen-activated protein kinase kinase kinase kinase 5 | Homo sapiens | 8.059484033 | 4.178452098 | 9.19 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 7 | 0.282886126 | 0.321206863 | 192.2134847 | 35 | 0.000408997 | 10 | 10 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| NERATINIB | predicted | SPS1/STE20-related protein kinase YSK4 | Homo sapiens | 7.650005506 | 2.950016519 | 7.8 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 7 | 0.2855963 | 0.324606847 | 534.4683177 | 35 | 0.000543908 | 14 | 14 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| NERATINIB | predicted | Receptor protein-tyrosine kinase erbB-4 | Homo sapiens | 8.059484033 | 4.178452098 | 8.62 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 7 | 0.279864034 | 0.318259936 | 317.7099087 | 35 | 0.000416856 | 10 | 10 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| NERATINIB | predicted | Receptor tyrosine-protein kinase erbB-3 | Homo sapiens | 7.829172162 | 3.487516486 | 8.11 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 7 | 0.280045351 | 0.318790107 | 336.7502737 | 35 | 0.000447603 | 11 | 11 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| NERATINIB | predicted | Serine/threonine-protein kinase 10 | Homo sapiens | 7.650005506 | 2.950016519 | 7.89 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 6 | 0.296569468 | 0.332620012 | 562.8802929 | 35 | 0.000451507 | 11 | 11 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| NERATINIB | predicted | Serine/threonine-protein kinase 25 | Homo sapiens | 7.650005506 | 2.950016519 | 7.92 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 7 | 0.284843493 | 0.32268859 | 162.7060256 | 35 | 0.000405003 | 10 | 10 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| NERATINIB | predicted | Serine/threonine-protein kinase MST4 | Homo sapiens | 7.829172162 | 3.487516486 | 8.13 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 7 | 0.284843493 | 0.32268859 | 162.7060256 | 35 | 0.000405003 | 10 | 10 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| NERATINIB | predicted | Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens | 7.650005506 | 2.950016519 | 7.59 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 7 | 0.277706393 | 0.316170922 | 845.1100231 | 35 | 0.000415694 | 9 | 9 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| NERATINIB | predicted | Misshapen-like kinase 1 | Homo sapiens | 7.650005506 | 2.950016519 | 7.54 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 6 | 0.295353604 | 0.331819934 | 488.2580229 | 35 | 0.000446843 | 11 | 11 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| NERATINIB | predicted | Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens | 7.650005506 | 2.950016519 | 7.85 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 6 | 0.290198053 | 0.326739927 | 2976.33696 | 35 | 0.000533093 | 10 | 10 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| NERATINIB | predicted | Serine/threonine-protein kinase 24 | Homo sapiens | 7.829172162 | 3.487516486 | 8.19 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 7 | 0.284468575 | 0.322245173 | 140.2407465 | 35 | 0.000403438 | 10 | 10 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| NERATINIB | predicted | Mitogen-activated protein kinase kinase kinase kinase 3 | Homo sapiens | 7.829172162 | 3.487516486 | 8.11 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, BREAST NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA | Epidermal growth factor receptor erbB1 inhibitor, Receptor protein-tyrosine kinase erbB-2 inhibitor | 7 | 0.285313531 | 0.323450109 | 194.5186162 | 35 | 0.000437482 | 11 | 11 | 7 | 0.255089997 | 0.285312182 | 866.7483148 | 35 | 0.001728944 | 45 | 45 | ||
| BRIVANIB | predicted | Platelet-derived growth factor receptor alpha | Homo sapiens | 7.378124997 | 2.134374992 | 7.96 | 1 | 1 | 1 | 1 | CARCINOMA, HEPATOCELLULAR CARCINOMA, NEOPLASM | Fibroblast growth factor receptor inhibitor, Vascular endothelial growth factor receptor inhibitor | 7 | 0.283256881 | 0.323366108 | 1951.467821 | 35 | 0.000664329 | 16 | 16 | 8 | 0.222293649 | 0.240432813 | 3.414061639 | 35 | 0.000213903 | 3 | 3 | ||
| VINBLASTINE SULFATE | actual | 7.875719129 | Y | Hypoxia-inducible factor 1 alpha | Homo sapiens | 5.958573043 | 7.875719129 | 7.5 | 0 | 1 | 0.5 | 2 | CENTRAL NERVOUS SYSTEM CANCER | Tubulin inhibitor | 6 | 0.275493945 | 0.296144207 | 947.8935296 | 4 | 0.000928179 | 14 | 14 | 6 | 0.311981234 | 0.337092732 | 2573.177861 | 4 | 0.000990335 | 15 | 15 |
| VINBLASTINE SULFATE | actual | 7.875719129 | Y | Geminin | Homo sapiens | 5.958573043 | 7.875719129 | 7.835647144 | 0 | 1 | 0.5 | 1 | CENTRAL NERVOUS SYSTEM CANCER | Tubulin inhibitor | 6 | 0.358564911 | 0.408916522 | 90556.91834 | 4 | 0.005157074 | 75 | 75 | 6 | 0.311981234 | 0.337092732 | 2573.177861 | 4 | 0.000990335 | 15 | 15 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase SRC | Homo sapiens | 9.008342669 | 6.944627558 | 7.538939694 | 1 | 1 | 1 | 25 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.301639916 | 0.338181993 | 5049.133609 | 35 | 0.000694693 | 14 | 14 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase ABL | Homo sapiens | 9.008342669 | 7.025028006 | 8.935472776 | 1 | 1 | 1 | 37 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.299134948 | 0.335579333 | 3196.709319 | 35 | 0.000616628 | 14 | 14 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Epithelial discoidin domain-containing receptor 1 | Homo sapiens | 9.008342669 | 7.025028006 | 8.152781748 | 1 | 1 | 1 | 5 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.2855963 | 0.324606847 | 530.1347413 | 35 | 0.000543078 | 14 | 14 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Ephrin type-B receptor 1 | Homo sapiens | 9.008342669 | 7.025028006 | 9.35 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.284188034 | 0.321329422 | 99.87537754 | 35 | 0.000340004 | 8 | 8 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Stem cell growth factor receptor | Homo sapiens | 9.008342669 | 7.025028006 | 7.859212125 | 1 | 1 | 1 | 20 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.283535585 | 0.324522846 | 3010.536614 | 35 | 0.000815755 | 19 | 19 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Serine/threonine-protein kinase SIK2 | Homo sapiens | 9.008342669 | 7.025028006 | 8.493333333 | 1 | 1 | 1 | 3 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.279592497 | 0.317344185 | 75.90100671 | 35 | 0.000340825 | 8 | 8 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase YES | Homo sapiens | 9.008342669 | 6.953241891 | 9.222826965 | 1 | 1 | 1 | 7 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.277172171 | 0.314956347 | 76.22210733 | 35 | 0.000313548 | 7 | 7 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Dual specificity mitogen-activated protein kinase kinase 5 | Homo sapiens | 9.008342669 | 7.025028006 | 8.48 | 1 | 1 | 1 | 1 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.280136099 | 0.319590184 | 282.7777954 | 35 | 0.000541349 | 14 | 14 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase FYN | Homo sapiens | 9.008342669 | 7.025028006 | 9.3 | 1 | 1 | 1 | 3 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.324877865 | 0.361210719 | 29344.72315 | 0 | 0.001025254 | 19 | 19 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine kinase non-receptor protein 2 | Homo sapiens | 9.008342669 | 7.025028006 | 8.33 | 1 | 1 | 1 | 4 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.276817163 | 0.314609326 | 71.45080189 | 35 | 0.000312304 | 7 | 7 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Dual specificity testis-specific protein kinase 1 | Homo sapiens | 9.008342669 | 7.025028006 | 7.48 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.285407725 | 0.323835688 | 199.5218488 | 35 | 0.00046817 | 12 | 12 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Discoidin domain-containing receptor 2 | Homo sapiens | 9.008342669 | 7.025028006 | 8.515 | 1 | 1 | 1 | 8 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.296773086 | 0.332947754 | 1889.209683 | 35 | 0.000500484 | 12 | 12 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase BRK | Homo sapiens | 8.175009335 | 7.025028006 | 8.1425 | 0.75 | 1 | 0.875 | 4 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.276728553 | 0.314194828 | 31.42376407 | 35 | 0.000279187 | 6 | 6 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Platelet-derived growth factor receptor beta | Homo sapiens | 9.008342669 | 7.025028006 | 8.7125 | 1 | 1 | 1 | 4 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.283256881 | 0.322508194 | 516.7195661 | 35 | 0.000513462 | 13 | 13 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Ephrin type-A receptor 5 | Homo sapiens | 9.008342669 | 7.025028006 | 9.62 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.282424044 | 0.320445344 | 306.9660758 | 35 | 0.000384341 | 9 | 9 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Receptor tyrosine-protein kinase erbB-3 | Homo sapiens | 9.008342669 | 7.025028006 | 7.74 | 1 | 1 | 1 | 1 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.280045351 | 0.318790107 | 336.7502737 | 35 | 0.000447603 | 11 | 11 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase ABL2 | Homo sapiens | 9.008342669 | 7.025028006 | 9.77 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.282331809 | 0.319992288 | 127.1367992 | 35 | 0.00034504 | 8 | 8 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Mitogen-activated protein kinase kinase kinase kinase 5 | Homo sapiens | 9.008342669 | 7.025028006 | 7.5 | 1 | 1 | 1 | 3 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.282886126 | 0.321206863 | 192.2134847 | 35 | 0.000408997 | 10 | 10 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase LCK | Homo sapiens | 9.008342669 | 7.025028006 | 9.16 | 1 | 1 | 1 | 7 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.302272727 | 0.339714671 | 6045.93275 | 35 | 0.000704582 | 16 | 16 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Bcr/Abl fusion protein | Homo sapiens | 9.008342669 | 7.025028006 | 8.057142857 | 1 | 1 | 1 | 7 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.257982692 | 0.28887879 | 73.34461828 | 35 | 0.000198861 | 3 | 3 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Ephrin type-A receptor 3 | Homo sapiens | 9.008342669 | 7.025028006 | 10.03 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.281871536 | 0.319230769 | 1791.5195 | 35 | 0.000389472 | 7 | 7 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Ephrin type-B receptor 2 | Homo sapiens | 9.008342669 | 7.025028006 | 8.274235275 | 1 | 1 | 1 | 4 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.284937376 | 0.323074169 | 369.1424499 | 35 | 0.00044616 | 11 | 11 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Ephrin type-B receptor 3 | Homo sapiens | 9.008342669 | 7.025028006 | 8.16 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.295051195 | 0.331588587 | 501.2782224 | 35 | 0.000446866 | 11 | 11 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Ephrin type-B receptor 4 | Homo sapiens | 9.008342669 | 7.025028006 | 9.313333333 | 1 | 1 | 1 | 3 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.282239634 | 0.319674185 | 95.63012036 | 35 | 0.000310498 | 7 | 7 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase BLK | Homo sapiens | 9.008342669 | 7.025028006 | 9.68 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.294950529 | 0.331376518 | 473.8693106 | 35 | 0.000448906 | 11 | 11 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase TXK | Homo sapiens | 9.008342669 | 7.025028006 | 8.96 | 1 | 1 | 1 | 3 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.287400266 | 0.325599714 | 380.6699394 | 35 | 0.00047622 | 12 | 12 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Serine/threonine-protein kinase SIK1 | Homo sapiens | 9.008342669 | 7.025028006 | 8.41 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.284843493 | 0.322621113 | 152.509037 | 35 | 0.000405104 | 10 | 10 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase HCK | Homo sapiens | 9.008342669 | 7.025028006 | 9.355 | 1 | 1 | 1 | 4 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.290198053 | 0.326016965 | 254.6268434 | 35 | 0.000317807 | 7 | 7 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase FGR | Homo sapiens | 9.008342669 | 7.025028006 | 9.3 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.290490591 | 0.326797764 | 796.0456347 | 35 | 0.000408753 | 9 | 9 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase Srms | Homo sapiens | 9.008342669 | 7.025028006 | 8.326666667 | 1 | 1 | 1 | 3 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.282239634 | 0.319674185 | 95.63012036 | 35 | 0.000310498 | 7 | 7 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Receptor protein-tyrosine kinase erbB-4 | Homo sapiens | 9.008342669 | 7.025028006 | 7.33 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.279864034 | 0.318259936 | 317.7099087 | 35 | 0.000416856 | 10 | 10 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Platelet-derived growth factor receptor alpha | Homo sapiens | 9.008342669 | 7.025028006 | 8.465 | 1 | 1 | 1 | 4 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.283256881 | 0.323366108 | 1951.467821 | 35 | 0.000664329 | 16 | 16 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase Lyn | Homo sapiens | 9.008342669 | 7.025028006 | 9.24 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.294548552 | 0.331000578 | 681.2522158 | 35 | 0.000465064 | 11 | 11 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Serine/threonine-protein kinase TNNI3K | Homo sapiens | 9.008342669 | 7.025028006 | 7.96 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.284749671 | 0.32230301 | 134.4552989 | 35 | 0.000372316 | 9 | 9 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Ephrin type-A receptor 1 | Homo sapiens | 9.008342669 | 7.025028006 | 8.39 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.284281486 | 0.321474015 | 98.63244561 | 35 | 0.000339938 | 8 | 8 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Serine/threonine-protein kinase SIK3 | Homo sapiens | 9.008342669 | 7.025028006 | 7.55 | 1 | 1 | 1 | 1 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.279682951 | 0.317729764 | 87.3417866 | 35 | 0.000371638 | 9 | 9 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase FRK | Homo sapiens | 9.008342669 | 7.025028006 | 9.51 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.296061644 | 0.331858492 | 526.4484638 | 35 | 0.000420723 | 10 | 10 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Ephrin type-A receptor 4 | Homo sapiens | 9.008342669 | 7.025028006 | 8.92 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.28196347 | 0.319616349 | 265.2980022 | 35 | 0.000351962 | 8 | 8 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase SRC | Gallus gallus | 9.008342669 | 7.025028006 | 8.68 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.301639916 | 0.338181993 | 5049.133609 | 35 | 0.000694693 | 14 | 14 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase CSK | Homo sapiens | 9.008342669 | 7.025028006 | 9 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.290490591 | 0.326797764 | 338.8741445 | 35 | 0.000382407 | 9 | 9 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Bcr/Abl fusion protein | Homo sapiens | 9.008342669 | 7.025028006 | 8.057142857 | 1 | 1 | 1 | 7 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.257982692 | 0.28887879 | 73.34461828 | 35 | 0.000198861 | 3 | 3 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Ephrin type-B receptor 6 | Homo sapiens | 9.008342669 | 4.093761669 | 10.41 | 1 | 1 | 1 | 1 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.284749671 | 0.322476521 | 227.4771825 | 35 | 0.000408695 | 10 | 10 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Serine/threonine-protein kinase RIPK2 | Homo sapiens | 9.008342669 | 7.025028006 | 7.326666667 | 1 | 1 | 1 | 3 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.2902955 | 0.326402545 | 302.1522585 | 35 | 0.000352188 | 8 | 8 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Serine/threonine-protein kinase GAK | Homo sapiens | 9.008342669 | 7.025028006 | 8.59 | 1 | 1 | 1 | 3 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.279682951 | 0.317903275 | 135.1755708 | 35 | 0.000409806 | 10 | 10 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Ephrin type-A receptor 8 | Homo sapiens | 9.008342669 | 7.025028006 | 9.62 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.293648098 | 0.329419703 | 554.2402091 | 35 | 0.00039207 | 9 | 9 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase LCK | Mus musculus | 9.008342669 | 7.025028006 | 10.19 | 1 | 1 | 1 | 1 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.302272727 | 0.339714671 | 6045.93275 | 35 | 0.000704582 | 16 | 16 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Bcr/Abl fusion protein | Homo sapiens | 9.008342669 | 7.025028006 | 8.057142857 | 1 | 1 | 1 | 7 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 7 | 0.257982692 | 0.28887879 | 73.34461828 | 35 | 0.000198861 | 3 | 3 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase BMX | Homo sapiens | 9.008342669 | 7.025028006 | 8.85 | 1 | 1 | 1 | 2 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.288744155 | 0.324416811 | 381.6415807 | 35 | 0.00033432 | 7 | 7 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| DASATINIB | actual | 7.025028006 | Y | Tyrosine-protein kinase BLK | Mus musculus | 9.008342669 | 7.025028006 | 8.1 | 1 | 1 | 1 | 1 | ABNORMALITY OF BLOOD AND BLOOD-FORMING TISSUES, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHOLANGIOCARCINOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, LEUKEMIA, LUNG CARCINOMA, LYMPHOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, MESOTHELIOMA, METASTATIC MELANOMA, MULTIPLE MYELOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, NON-SMALL CELL LUNG CARCINOMA, PANCREATIC CARCINOMA, POLYCYTHEMIA VERA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SMALL CELL LUNG CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA | Ephrin type-A receptor 2 inhibitor, Platelet-derived growth factor receptor beta inhibitor, SRC inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase ABL inhibitor | 6 | 0.294950529 | 0.331376518 | 473.8693106 | 35 | 0.000448906 | 11 | 11 | 6 | 0.347049378 | 0.441902834 | 103685.357 | 35 | 0.010730223 | 283 | 283 |
| TARANABANT | predicted | Cytochrome P450 2D6 | Homo sapiens | 7.791048642 | 3.373145927 | 9.23 | 1 | 1 | 1 | 1 | OBESITY, TYPE II DIABETES MELLITUS | Cannabinoid CB1 receptor inverse agonist | 7 | 0.2784219 | 0.301572613 | 11858.2872 | 0 | 0.001801674 | 22 | 22 | 7 | 0.256680523 | 0.274171693 | 129.3949412 | 3 | 0.000335589 | 4 | 4 | ||
| TARANABANT | predicted | Cytochrome P450 2C9 | Homo sapiens | 7.791048642 | 3.373145927 | 9.03 | 1 | 1 | 1 | 1 | OBESITY, TYPE II DIABETES MELLITUS | Cannabinoid CB1 receptor inverse agonist | 6 | 0.303759663 | 0.336022749 | 14261.79287 | 3 | 0.001910128 | 28 | 28 | 7 | 0.256680523 | 0.274171693 | 129.3949412 | 3 | 0.000335589 | 4 | 4 | ||
| TARANABANT | predicted | Cytochrome P450 3A4 | Homo sapiens | 7.597922294 | 2.793766883 | 7.698970004 | 1 | 1 | 1 | 1 | OBESITY, TYPE II DIABETES MELLITUS | Cannabinoid CB1 receptor inverse agonist | 6 | 0.314021068 | 0.350800077 | 18362.39183 | 3 | 0.001678849 | 23 | 23 | 7 | 0.256680523 | 0.274171693 | 129.3949412 | 3 | 0.000335589 | 4 | 4 | ||
| TARANABANT | predicted | Cytochrome P450 1A2 | Homo sapiens | 7.597922294 | 2.793766883 | 7.698970004 | 1 | 1 | 1 | 1 | OBESITY, TYPE II DIABETES MELLITUS | Cannabinoid CB1 receptor inverse agonist | 7 | 0.274618806 | 0.295167865 | 2463.117725 | 3 | 0.001026202 | 14 | 14 | 7 | 0.256680523 | 0.274171693 | 129.3949412 | 3 | 0.000335589 | 4 | 4 | ||
| VASOPRESSIN | predicted | Vasopressin V2 receptor | Sus scrofa | 8.312844996 | 4.938534989 | 8.48 | 1 | 1 | 1 | 1 | AUTISM SPECTRUM DISORDER, HEMORRHAGE, INJURY, SEPTIC SHOCK, SUDDEN CARDIAC ARREST, UNIPOLAR DEPRESSION, UTERINE FIBROID | Vasopressin receptor agonist | 8 | 0.234281843 | 0.245693217 | 3856.010924 | 7 | 0.000806406 | 6 | 6 | 7 | 0.260234798 | 0.279014845 | 3296.53046 | 7 | 0.000526866 | 4 | 4 | ||
| VASOPRESSIN | predicted | Vasopressin V2 receptor | Rattus norvegicus | 8.035324313 | 4.105972939 | 9.221616674 | 1 | 1 | 1 | 3 | AUTISM SPECTRUM DISORDER, HEMORRHAGE, INJURY, SEPTIC SHOCK, SUDDEN CARDIAC ARREST, UNIPOLAR DEPRESSION, UTERINE FIBROID | Vasopressin receptor agonist | 8 | 0.234281843 | 0.245693217 | 3856.010924 | 7 | 0.000806406 | 6 | 6 | 7 | 0.260234798 | 0.279014845 | 3296.53046 | 7 | 0.000526866 | 4 | 4 | ||
| VASOPRESSIN | predicted | Vasopressin V2 receptor | Bos taurus | 8.207012307 | 4.621036921 | 8.82 | 1 | 1 | 1 | 1 | AUTISM SPECTRUM DISORDER, HEMORRHAGE, INJURY, SEPTIC SHOCK, SUDDEN CARDIAC ARREST, UNIPOLAR DEPRESSION, UTERINE FIBROID | Vasopressin receptor agonist | 8 | 0.234281843 | 0.245693217 | 3856.010924 | 7 | 0.000806406 | 6 | 6 | 7 | 0.260234798 | 0.279014845 | 3296.53046 | 7 | 0.000526866 | 4 | 4 | ||
| VASOPRESSIN | predicted | Vasopressin V1a receptor | Rattus norvegicus | 8.000986714 | 4.002960143 | 9.508 | 1 | 1 | 1 | 5 | AUTISM SPECTRUM DISORDER, HEMORRHAGE, INJURY, SEPTIC SHOCK, SUDDEN CARDIAC ARREST, UNIPOLAR DEPRESSION, UTERINE FIBROID | Vasopressin receptor agonist | 7 | 0.245736214 | 0.257741882 | 3265.002883 | 7 | 0.000704922 | 6 | 6 | 7 | 0.260234798 | 0.279014845 | 3296.53046 | 7 | 0.000526866 | 4 | 4 | ||
| VASOPRESSIN | predicted | Vasopressin V2 receptor | Homo sapiens | 7.99762736 | 3.99288208 | 9.328622445 | 1 | 1 | 1 | 9 | AUTISM SPECTRUM DISORDER, HEMORRHAGE, INJURY, SEPTIC SHOCK, SUDDEN CARDIAC ARREST, UNIPOLAR DEPRESSION, UTERINE FIBROID | Vasopressin receptor agonist | 8 | 0.234281843 | 0.245693217 | 3856.010924 | 7 | 0.000806406 | 6 | 6 | 7 | 0.260234798 | 0.279014845 | 3296.53046 | 7 | 0.000526866 | 4 | 4 | ||
| VASOPRESSIN | predicted | Vasopressin V1a receptor | Homo sapiens | 7.864291535 | 4.307160319 | 8.657857143 | 1 | 0.928571429 | 0.964285714 | 14 | AUTISM SPECTRUM DISORDER, HEMORRHAGE, INJURY, SEPTIC SHOCK, SUDDEN CARDIAC ARREST, UNIPOLAR DEPRESSION, UTERINE FIBROID | Vasopressin receptor agonist | 7 | 0.245736214 | 0.257741882 | 3265.002883 | 7 | 0.000704922 | 6 | 6 | 7 | 0.260234798 | 0.279014845 | 3296.53046 | 7 | 0.000526866 | 4 | 4 | ||
| LINIFANIB | predicted | Tyrosine-protein kinase receptor FLT3 | Homo sapiens | 7.401457981 | 2.792609236 | 8.261764706 | 1 | 0.941176471 | 0.970588235 | 17 | HEPATOCELLULAR CARCINOMA, NEOPLASM, RENAL CELL CARCINOMA | Macrophage colony stimulating factor receptor inhibitor, Platelet-derived growth factor receptor inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Vascular endothelial growth factor receptor inhibitor | 7 | 0.276109869 | 0.316009805 | 1180.098712 | 35 | 0.000588806 | 14 | 14 | 7 | 0.235687023 | 0.259346168 | 104.0351649 | 35 | 0.000831651 | 21 | 21 | ||
| LINIFANIB | predicted | Vascular endothelial growth factor receptor 3 | Homo sapiens | 7.503247172 | 2.509741517 | 7.644 | 1 | 1 | 1 | 5 | HEPATOCELLULAR CARCINOMA, NEOPLASM, RENAL CELL CARCINOMA | Macrophage colony stimulating factor receptor inhibitor, Platelet-derived growth factor receptor inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Vascular endothelial growth factor receptor inhibitor | 7 | 0.291666667 | 0.329145666 | 1284.365223 | 35 | 0.000541215 | 13 | 13 | 7 | 0.235687023 | 0.259346168 | 104.0351649 | 35 | 0.000831651 | 21 | 21 | ||
| LINIFANIB | predicted | Macrophage colony stimulating factor receptor | Homo sapiens | 7.545725632 | 2.637176897 | 8.39 | 1 | 1 | 1 | 4 | HEPATOCELLULAR CARCINOMA, NEOPLASM, RENAL CELL CARCINOMA | Macrophage colony stimulating factor receptor inhibitor, Platelet-derived growth factor receptor inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Vascular endothelial growth factor receptor inhibitor | 6 | 0.296773086 | 0.334490071 | 1710.245087 | 35 | 0.00068056 | 17 | 17 | 7 | 0.235687023 | 0.259346168 | 104.0351649 | 35 | 0.000831651 | 21 | 21 | ||
| LINIFANIB | predicted | Platelet-derived growth factor receptor alpha | Homo sapiens | 7.557543159 | 2.672629476 | 8.02 | 1 | 1 | 1 | 3 | HEPATOCELLULAR CARCINOMA, NEOPLASM, RENAL CELL CARCINOMA | Macrophage colony stimulating factor receptor inhibitor, Platelet-derived growth factor receptor inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Vascular endothelial growth factor receptor inhibitor | 7 | 0.283256881 | 0.323366108 | 1951.467821 | 35 | 0.000664329 | 16 | 16 | 7 | 0.235687023 | 0.259346168 | 104.0351649 | 35 | 0.000831651 | 21 | 21 | ||
| LINIFANIB | predicted | Muscle- skeletal receptor tyrosine protein kinase | Homo sapiens | 7.606106395 | 2.818319185 | 8 | 1 | 1 | 1 | 2 | HEPATOCELLULAR CARCINOMA, NEOPLASM, RENAL CELL CARCINOMA | Macrophage colony stimulating factor receptor inhibitor, Platelet-derived growth factor receptor inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Vascular endothelial growth factor receptor inhibitor | 6 | 0.294648943 | 0.331145171 | 483.4268958 | 35 | 0.000446296 | 11 | 11 | 7 | 0.235687023 | 0.259346168 | 104.0351649 | 35 | 0.000831651 | 21 | 21 | ||
| LINIFANIB | predicted | Ephrin type-B receptor 6 | Homo sapiens | 7.571666706 | 2.715000118 | 7.48 | 1 | 1 | 1 | 1 | HEPATOCELLULAR CARCINOMA, NEOPLASM, RENAL CELL CARCINOMA | Macrophage colony stimulating factor receptor inhibitor, Platelet-derived growth factor receptor inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Vascular endothelial growth factor receptor inhibitor | 7 | 0.284749671 | 0.322476521 | 227.4771825 | 35 | 0.000408695 | 10 | 10 | 7 | 0.235687023 | 0.259346168 | 104.0351649 | 35 | 0.000831651 | 21 | 21 | ||
| BEDAQUILINE | predicted | Putative uncharacterized protein atpE | Mycobacterium smegmatis | 8.363386017 | 5.09015805 | 8.2 | 1 | 1 | 1 | 3 | LIVER DISEASE, TUBERCULOSIS | unknown | 1 | 1 | 1 | 0 | 21 | 0.000558036 | 1 | 1 | 1 | 1 | 1 | 0 | 21 | 0.000558036 | 1 | 1 | ||
| APIXABAN | predicted | Coagulation factor X | Homo sapiens | 7.805918407 | 3.417755222 | 10.1 | 1 | 1 | 1 | 8 | ACUTE CORONARY SYNDROME, ATRIAL FIBRILLATION, CHRONIC KIDNEY DISEASE, DEEP VEIN THROMBOSIS, OBESITY, PULMONARY EMBOLISM, RECURRENT THROMBOPHLEBITIS, SICKLE CELL ANEMIA, STROKE, VENOUS THROMBOEMBOLISM, VENOUS THROMBOSIS, VENTRICULAR TACHYCARDIA | Coagulation factor X inhibitor | 1 | 1 | 1 | 0 | 22 | 0.000558036 | 1 | 1 | 1 | 1 | 1 | 0 | 22 | 0.000558036 | 1 | 1 | ||
| APIXABAN | predicted | Coagulation factor X | Oryctolagus cuniculus | 7.864565061 | 3.593695184 | 9.77 | 1 | 1 | 1 | 1 | ACUTE CORONARY SYNDROME, ATRIAL FIBRILLATION, CHRONIC KIDNEY DISEASE, DEEP VEIN THROMBOSIS, OBESITY, PULMONARY EMBOLISM, RECURRENT THROMBOPHLEBITIS, SICKLE CELL ANEMIA, STROKE, VENOUS THROMBOEMBOLISM, VENOUS THROMBOSIS, VENTRICULAR TACHYCARDIA | Coagulation factor X inhibitor | 1 | 1 | 1 | 0 | 22 | 0.000558036 | 1 | 1 | 1 | 1 | 1 | 0 | 22 | 0.000558036 | 1 | 1 | ||
| DIGITOXIN | actual | 7.669131508 | Y | Nuclear factor NF-kappa-B p105 subunit | Homo sapiens | 9.223043836 | 7.669131508 | 7.488835312 | 1 | 1 | 1 | 2 | CARDIOVASCULAR DISEASE, CYSTIC FIBROSIS | Sodium/potassium-transporting ATPase inhibitor | 6 | 0.289808917 | 0.32014652 | 21962.29414 | 4 | 0.002876854 | 38 | 38 | 6 | 0.332627934 | 0.358656256 | 11993.65566 | 4 | 0.001719868 | 25 | 25 |
| DIGITOXIN | actual | 7.669131508 | Y | Sodium/potassium-transporting ATPase | Homo sapiens | 9.223043836 | 7.669131508 | 8.1 | 1 | 1 | 1 | 7 | CARDIOVASCULAR DISEASE, CYSTIC FIBROSIS | Sodium/potassium-transporting ATPase inhibitor | 7 | 0.251820565 | 0.262841169 | 1.091732306 | 4 | 0.000200762 | 2 | 2 | 6 | 0.332627934 | 0.358656256 | 11993.65566 | 4 | 0.001719868 | 25 | 25 |
| DIGITOXIN | actual | 7.669131508 | Y | Nuclear factor NF-kappa-B p105 subunit | Homo sapiens | 9.223043836 | 7.669131508 | 7.488835312 | 1 | 1 | 1 | 2 | CARDIOVASCULAR DISEASE, CYSTIC FIBROSIS | Sodium/potassium-transporting ATPase inhibitor | 6 | 0.289808917 | 0.32014652 | 21962.29414 | 4 | 0.002876854 | 38 | 38 | 6 | 0.332627934 | 0.358656256 | 11993.65566 | 4 | 0.001719868 | 25 | 25 |
| DIGITOXIN | actual | 7.669131508 | Y | Sodium/potassium-transporting ATPase | Homo sapiens | 9.223043836 | 7.669131508 | 8.1 | 1 | 1 | 1 | 7 | CARDIOVASCULAR DISEASE, CYSTIC FIBROSIS | Sodium/potassium-transporting ATPase inhibitor | 7 | 0.251820565 | 0.262841169 | 1.091732306 | 4 | 0.000200762 | 2 | 2 | 6 | 0.332627934 | 0.358656256 | 11993.65566 | 4 | 0.001719868 | 25 | 25 |
| DIGITOXIN | actual | 7.669131508 | Y | Sodium/potassium-transporting ATPase | Homo sapiens | 9.223043836 | 7.669131508 | 8.1 | 1 | 1 | 1 | 1 | CARDIOVASCULAR DISEASE, CYSTIC FIBROSIS | Sodium/potassium-transporting ATPase inhibitor | 7 | 0.251820565 | 0.262841169 | 1.091732306 | 4 | 0.000200762 | 2 | 2 | 6 | 0.332627934 | 0.358656256 | 11993.65566 | 4 | 0.001719868 | 25 | 25 |
| DIGITOXIN | actual | 7.669131508 | Y | Retinoid X receptor alpha | Homo sapiens | 9.223043836 | 7.669131508 | 7.62503913 | 1 | 1 | 1 | 2 | CARDIOVASCULAR DISEASE, CYSTIC FIBROSIS | Sodium/potassium-transporting ATPase inhibitor | 6 | 0.283442623 | 0.309726239 | 6386.98569 | 4 | 0.001646278 | 24 | 24 | 6 | 0.332627934 | 0.358656256 | 11993.65566 | 4 | 0.001719868 | 25 | 25 |
| DIGITOXIN | actual | 7.669131508 | Y | Cellular tumor antigen p53 | Homo sapiens | 5.889710503 | 7.669131508 | 7.5 | 0 | 1 | 0.5 | 1 | CARDIOVASCULAR DISEASE, CYSTIC FIBROSIS | Sodium/potassium-transporting ATPase inhibitor | 6 | 0.281596091 | 0.304087141 | 1600.184122 | 4 | 0.00091984 | 14 | 14 | 6 | 0.332627934 | 0.358656256 | 11993.65566 | 4 | 0.001719868 | 25 | 25 |
| DIGITOXIN | actual | 7.669131508 | Y | Sodium/potassium-transporting ATPase alpha-1 chain | Canis lupus familiaris | 9.223043836 | 7.669131508 | 8.1 | 1 | 1 | 1 | 1 | CARDIOVASCULAR DISEASE, CYSTIC FIBROSIS | Sodium/potassium-transporting ATPase inhibitor | 7 | 0.257521597 | 0.269791236 | 40.42309507 | 4 | 0.000256455 | 3 | 3 | 6 | 0.332627934 | 0.358656256 | 11993.65566 | 4 | 0.001719868 | 25 | 25 |
| DIGITOXIN | actual | 7.669131508 | Y | Sodium/potassium-transporting ATPase alpha-1 chain | Canis lupus familiaris | 9.223043836 | 7.669131508 | 8.1 | 1 | 1 | 1 | 1 | CARDIOVASCULAR DISEASE, CYSTIC FIBROSIS | Sodium/potassium-transporting ATPase inhibitor | 7 | 0.257521597 | 0.269791236 | 40.42309507 | 4 | 0.000256455 | 3 | 3 | 6 | 0.332627934 | 0.358656256 | 11993.65566 | 4 | 0.001719868 | 25 | 25 |
| IRBESARTAN | predicted | Angiotensin II receptor | Homo sapiens | 7.880839757 | 3.642519272 | 8.52 | 1 | 1 | 1 | 2 | ATRIAL FIBRILLATION, CARDIOVASCULAR DISEASE, CHRONIC HEPATITIS C INFECTION, CHRONIC KIDNEY DISEASE, CONGESTIVE HEART FAILURE, FOCAL SEGMENTAL GLOMERULOSCLEROSIS, HEART DISEASE, HYPERCHOLESTEROLEMIA, HYPERTENSION, MARFAN SYNDROME, SEPSIS | Type-1 angiotensin II receptor antagonist | 8 | 0.232392473 | 0.246182765 | 3858.195318 | 11 | 0.001013954 | 9 | 9 | 7 | 0.253593429 | 0.274723898 | 5812.208615 | 11 | 0.000444548 | 3 | 3 | ||
| OLMESARTAN | predicted | Angiotensin II type 1a (AT-1a) receptor | Bos taurus | 7.664584128 | 2.993752384 | 8.096666667 | 1 | 1 | 1 | 3 | ATRIAL FIBRILLATION, HYPERTENSION | unknown | 8 | 0.230103806 | 0.242018508 | 2740.778757 | 11 | 0.000626337 | 5 | 5 | 9 | 0.188673069 | 0.195933286 | 4.938632371 | 11 | 0.000285918 | 2 | 2 | ||
| NILOTINIB | predicted | Tyrosine-protein kinase ABL2 | Homo sapiens | 8.037515425 | 4.112546276 | 7.59 | 1 | 1 | 1 | 1 | ACUTE GRAFT VS. HOST DISEASE, ACUTE LYMPHOBLASTIC LEUKEMIA, ACUTE MYELOID LEUKEMIA, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHORDOMA, CHRONIC MYELOGENOUS LEUKEMIA, CUTANEOUS MELANOMA, GASTROINTESTINAL STROMAL TUMOR, LEUKEMIA, MELANOMA, METASTATIC MELANOMA, NEOPLASM, NON-HODGKINS LYMPHOMA, PARKINSON'S DISEASE, PULMONARY HYPERTENSION | unknown | 7 | 0.282331809 | 0.319992288 | 127.1367992 | 35 | 0.00034504 | 8 | 8 | 7 | 0.254040552 | 0.277844336 | 516.1383992 | 35 | 0.000971672 | 24 | 24 | ||
| ANGIOTENSIN II | predicted | Angiotensin II type 2 (AT-2) receptor | Homo sapiens | 8.228786816 | 4.686360448 | 9.32 | 1 | 1 | 1 | 7 | SEPTIC SHOCK | unknown | 8 | 0.234727125 | 0.246731527 | 481.6204227 | 11 | 0.000349133 | 3 | 3 | 8 | 0.198461892 | 0.20700997 | 88.86996986 | 11 | 0.000673007 | 6 | 6 | ||
| ANGIOTENSIN II | predicted | Angiotensin II receptor | Rattus norvegicus | 8.31802103 | 4.954063089 | 8.714 | 1 | 1 | 1 | 15 | SEPTIC SHOCK | unknown | 8 | 0.232392473 | 0.246182765 | 3858.195318 | 11 | 0.001013954 | 9 | 9 | 8 | 0.198461892 | 0.20700997 | 88.86996986 | 11 | 0.000673007 | 6 | 6 | ||
| ANGIOTENSIN II | predicted | Type-1B angiotensin II receptor | Rattus norvegicus | 8.277567433 | 4.8327023 | 9.31 | 1 | 1 | 1 | 3 | SEPTIC SHOCK | unknown | 8 | 0.234790875 | 0.247117106 | 1168.581636 | 11 | 0.000467643 | 4 | 4 | 8 | 0.198461892 | 0.20700997 | 88.86996986 | 11 | 0.000673007 | 6 | 6 | ||
| ANGIOTENSIN II | predicted | Angiotensin II type 1a (AT-1a) receptor | Bos taurus | 8.207012307 | 4.621036921 | 8.24 | 1 | 1 | 1 | 1 | SEPTIC SHOCK | unknown | 8 | 0.230103806 | 0.242018508 | 2740.778757 | 11 | 0.000626337 | 5 | 5 | 8 | 0.198461892 | 0.20700997 | 88.86996986 | 11 | 0.000673007 | 6 | 6 | ||
| ANGIOTENSIN II | predicted | Type-1A angiotensin II receptor | Rattus norvegicus | 8.207012307 | 4.621036921 | 9.4 | 1 | 1 | 1 | 1 | SEPTIC SHOCK | unknown | 7 | 0.24490085 | 0.256733868 | 2159.703983 | 11 | 0.00046801 | 4 | 4 | 8 | 0.198461892 | 0.20700997 | 88.86996986 | 11 | 0.000673007 | 6 | 6 | ||
| DACTINOMYCIN | actual | 8.422180183 | Y | Thyroid hormone receptor beta-1 | Homo sapiens | 9.474060061 | 7.801484497 | 8.227532117 | 1 | 1 | 1 | 2 | HYDATIDIFORM MOLE | DNA inhibitor | 6 | 0.278781038 | 0.303865433 | 12097.90951 | 4 | 0.001979349 | 25 | 25 | 6 | 0.330592734 | 0.356641604 | 13196.73577 | 4 | 0.001701883 | 24 | 24 |
| DACTINOMYCIN | actual | 8.422180183 | Y | Peroxisome proliferator-activated receptor delta | Homo sapiens | 8.918504505 | 7.817782259 | 7.498423965 | 1 | 0.833333333 | 0.916666667 | 6 | HYDATIDIFORM MOLE | DNA inhibitor | 6 | 0.3490109 | 0.395508001 | 85678.01116 | 4 | 0.005261171 | 68 | 68 | 6 | 0.330592734 | 0.356641604 | 13196.73577 | 4 | 0.001701883 | 24 | 24 |
| DACTINOMYCIN | actual | 8.422180183 | Y | Androgen Receptor | Homo sapiens | 9.474060061 | 8.143794945 | 7.89025013 | 1 | 1 | 1 | 8 | HYDATIDIFORM MOLE | DNA inhibitor | 6 | 0.380837004 | 0.4451417 | 265199.9673 | 4 | 0.012134483 | 147 | 147 | 6 | 0.330592734 | 0.356641604 | 13196.73577 | 4 | 0.001701883 | 24 | 24 |
| DACTINOMYCIN | actual | 8.422180183 | Y | Nuclear receptor ROR-gamma | Homo sapiens | 9.474060061 | 8.257898428 | 7.575118363 | 1 | 1 | 1 | 1 | HYDATIDIFORM MOLE | DNA inhibitor | 6 | 0.290003355 | 0.319356083 | 8301.0164 | 4 | 0.001948329 | 29 | 29 | 6 | 0.330592734 | 0.356641604 | 13196.73577 | 4 | 0.001701883 | 24 | 24 |
| DACTINOMYCIN | actual | 8.422180183 | Y | Cellular tumor antigen p53 | Homo sapiens | 6.140726728 | 6.411115632 | 8.698970004 | 0 | 1 | 0.5 | 1 | HYDATIDIFORM MOLE | DNA inhibitor | 6 | 0.281596091 | 0.304087141 | 1600.184122 | 4 | 0.00091984 | 14 | 14 | 6 | 0.330592734 | 0.356641604 | 13196.73577 | 4 | 0.001701883 | 24 | 24 |
| DACTINOMYCIN | actual | 8.422180183 | Y | Retinoid X receptor alpha | Homo sapiens | 9.474060061 | 8.257898428 | 7.767291927 | 1 | 1 | 1 | 3 | HYDATIDIFORM MOLE | DNA inhibitor | 6 | 0.283442623 | 0.309726239 | 6386.98569 | 4 | 0.001646278 | 24 | 24 | 6 | 0.330592734 | 0.356641604 | 13196.73577 | 4 | 0.001701883 | 24 | 24 |
| DACTINOMYCIN | actual | 8.422180183 | Y | Huntingtin | Homo sapiens | 6.140726728 | 6.816635137 | 7.5 | 0 | 1 | 0.5 | 1 | HYDATIDIFORM MOLE | DNA inhibitor | 6 | 0.30798005 | 0.342490842 | 1958.987525 | 4 | 0.000526267 | 8 | 8 | 6 | 0.330592734 | 0.356641604 | 13196.73577 | 4 | 0.001701883 | 24 | 24 |
| ATROPINE | predicted | Muscarinic acetylcholine receptors; M1 & M2 | Homo sapiens | 7.552088885 | 2.656266654 | 9.17 | 1 | 1 | 1 | 2 | AMBLYOPIA, DIGESTIVE SYSTEM DISEASE, HYPOGLYCEMIA, MYOPIA, PAIN, PNEUMONIA, SEASONAL ALLERGIC RHINITIS | Muscarinic acetylcholine receptor M1 antagonist, Muscarinic acetylcholine receptor M2 antagonist, Muscarinic acetylcholine receptor M3 antagonist | 8 | 0.195058664 | 0.203908122 | 0 | 0 | 0.00014079 | 1 | 1 | 7 | 0.242292601 | 0.260681925 | 1760.685006 | 0 | 0.000537131 | 8 | 8 | ||
| ATROPINE | predicted | Muscarinic acetylcholine receptor M1 | Mus musculus | 7.333333333 | 2 | 9.22184875 | 1 | 1 | 1 | 1 | AMBLYOPIA, DIGESTIVE SYSTEM DISEASE, HYPOGLYCEMIA, MYOPIA, PAIN, PNEUMONIA, SEASONAL ALLERGIC RHINITIS | Muscarinic acetylcholine receptor M1 antagonist, Muscarinic acetylcholine receptor M2 antagonist, Muscarinic acetylcholine receptor M3 antagonist | 6 | 0.288840628 | 0.317466744 | 9434.894236 | 0 | 0.001795345 | 31 | 31 | 7 | 0.242292601 | 0.260681925 | 1760.685006 | 0 | 0.000537131 | 8 | 8 | ||
| BUPRENORPHINE | predicted | Delta opioid receptor | Mus musculus | 8.137379325 | 4.412137976 | 7.823908741 | 1 | 1 | 1 | 1 | CANCER, COCAINE DEPENDENCE, CONSTIPATION, DRUG DEPENDENCE, EATING DISORDER, EPILEPSY, HEROIN DEPENDENCE, HIV INFECTION, LUMBAR DISC DEGENERATION, NEONATAL ABSTINENCE SYNDROME, OPIATE DEPENDENCE, OSTEOARTHRITIS, PAIN, PRURITUS, RESTLESS LEGS SYNDROME, UNIPOLAR DEPRESSION | Kappa opioid receptor agonist, Mu opioid receptor agonist | 6 | 0.281321185 | 0.302033931 | 6952.403768 | 0 | 0.000919284 | 12 | 12 | 7 | 0.233711814 | 0.250338759 | 1103.640875 | 0 | 0.000541573 | 6 | 6 | ||
| CEDIRANIB | predicted | Epithelial discoidin domain-containing receptor 1 | Homo sapiens | 7.939594303 | 3.818782909 | 8.77 | 1 | 1 | 1 | 1 | CANCER, COLORECTAL ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, LUNG CARCINOMA, NEOPLASM, OVARIAN CARCINOMA, RENAL CELL CARCINOMA | Platelet-derived growth factor receptor inhibitor, Stem cell growth factor receptor inhibitor, Vascular endothelial growth factor receptor inhibitor | 7 | 0.2855963 | 0.324606847 | 530.1347413 | 35 | 0.000543078 | 14 | 14 | 7 | 0.252335085 | 0.301768157 | 1865.774202 | 35 | 0.003802884 | 105 | 105 | ||
| CEDIRANIB | predicted | Serine/threonine-protein kinase 35 | Homo sapiens | 7.939594303 | 3.818782909 | 8.27 | 1 | 1 | 1 | 1 | CANCER, COLORECTAL ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, LUNG CARCINOMA, NEOPLASM, OVARIAN CARCINOMA, RENAL CELL CARCINOMA | Platelet-derived growth factor receptor inhibitor, Stem cell growth factor receptor inhibitor, Vascular endothelial growth factor receptor inhibitor | 7 | 0.279773463 | 0.318115343 | 100.4506293 | 35 | 0.000404198 | 10 | 10 | 7 | 0.252335085 | 0.301768157 | 1865.774202 | 35 | 0.003802884 | 105 | 105 | ||
| APOMORPHINE HYDROCHLORIDE | predicted | Dopamine receptor | Rattus norvegicus | 8.191688707 | 4.575066121 | 8.43 | 1 | 1 | 1 | 5 | PARKINSON'S DISEASE | D2-like dopamine receptor agonist | 7 | 0.271173149 | 0.287952023 | 1573.127869 | 0 | 0.000652847 | 9 | 9 | 7 | 0.265021459 | 0.289581096 | 502.1554262 | 0 | 0.000367301 | 5 | 5 | ||
| CLEMASTINE | predicted | Muscarinic acetylcholine receptor M4 | Homo sapiens | 8.226186632 | 4.678559896 | 8.13 | 1 | 1 | 1 | 2 | OPTIC NEURITIS, PRURITUS, RELAPSING-REMITTING MULTIPLE SCLEROSIS | unknown | 6 | 0.280136099 | 0.303663004 | 2650.84323 | 0 | 0.001281184 | 23 | 23 | 7 | 0.266738661 | 0.297278912 | 1794.169331 | 0 | 0.001356984 | 25 | 25 | ||
| CLEMASTINE | predicted | Dopamine D3 receptor | Homo sapiens | 8.19236299 | 4.57708897 | 8.365 | 1 | 1 | 1 | 2 | OPTIC NEURITIS, PRURITUS, RELAPSING-REMITTING MULTIPLE SCLEROSIS | unknown | 6 | 0.28961474 | 0.320946597 | 9204.657659 | 0 | 0.002356341 | 42 | 42 | 7 | 0.266738661 | 0.297278912 | 1794.169331 | 0 | 0.001356984 | 25 | 25 | ||
| CLEMASTINE | predicted | Muscarinic acetylcholine receptor M5 | Homo sapiens | 8.19236299 | 4.57708897 | 8.15 | 1 | 1 | 1 | 2 | OPTIC NEURITIS, PRURITUS, RELAPSING-REMITTING MULTIPLE SCLEROSIS | unknown | 6 | 0.276198083 | 0.297860035 | 2256.162608 | 0 | 0.001183478 | 21 | 21 | 7 | 0.266738661 | 0.297278912 | 1794.169331 | 0 | 0.001356984 | 25 | 25 | ||
| CLEMASTINE | predicted | Muscarinic acetylcholine receptor M3 | Homo sapiens | 8.226186632 | 4.678559896 | 7.745 | 1 | 1 | 1 | 2 | OPTIC NEURITIS, PRURITUS, RELAPSING-REMITTING MULTIPLE SCLEROSIS | unknown | 6 | 0.280499676 | 0.304347407 | 3029.87758 | 0 | 0.001343026 | 24 | 24 | 7 | 0.266738661 | 0.297278912 | 1794.169331 | 0 | 0.001356984 | 25 | 25 | ||
| CLEMASTINE | predicted | Alpha-1d adrenergic receptor | Homo sapiens | 8.260010274 | 4.780030823 | 7.655 | 1 | 1 | 1 | 2 | OPTIC NEURITIS, PRURITUS, RELAPSING-REMITTING MULTIPLE SCLEROSIS | unknown | 6 | 0.281046814 | 0.304279931 | 2336.531662 | 0 | 0.001223953 | 22 | 22 | 7 | 0.266738661 | 0.297278912 | 1794.169331 | 0 | 0.001356984 | 25 | 25 | ||
| CLEMASTINE | predicted | Serotonin 2a (5-HT2a) receptor | Homo sapiens | 8.226186632 | 4.678559896 | 7.765 | 1 | 1 | 1 | 2 | OPTIC NEURITIS, PRURITUS, RELAPSING-REMITTING MULTIPLE SCLEROSIS | unknown | 6 | 0.305153547 | 0.341170233 | 14148.52943 | 0 | 0.002040502 | 36 | 36 | 7 | 0.266738661 | 0.297278912 | 1794.169331 | 0 | 0.001356984 | 25 | 25 | ||
| CLEMASTINE | predicted | Histamine H1 receptor | Homo sapiens | 8.19236299 | 4.57708897 | 9.845 | 1 | 1 | 1 | 2 | OPTIC NEURITIS, PRURITUS, RELAPSING-REMITTING MULTIPLE SCLEROSIS | unknown | 6 | 0.280408693 | 0.302438789 | 3868.934814 | 0 | 0.001146468 | 19 | 19 | 7 | 0.266738661 | 0.297278912 | 1794.169331 | 0 | 0.001356984 | 25 | 25 | ||
| PANOBINOSTAT | predicted | Histone deacetylase | Plasmodium falciparum | 7.696529598 | 3.089588793 | 8.74 | 1 | 1 | 1 | 1 | ACUTE GRAFT VS. HOST DISEASE, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHRONIC MYELOGENOUS LEUKEMIA, CUTANEOUS T-CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, GASTRIC CARCINOMA, GLIOBLASTOMA MULTIFORME, HIV INFECTION, HODGKINS LYMPHOMA, LEUKEMIA, LYMPHOMA, MACROGLOBULINEMIA, MELANOMA, MULTIPLE MYELOMA, MYELODYSPLASTIC SYNDROME, NEOPLASM, NON-HODGKINS LYMPHOMA, PROSTATE CARCINOMA, RENAL CELL CARCINOMA, SARCOMA, SICKLE CELL ANEMIA, THYROID CARCINOMA | unknown | 7 | 0.263969466 | 0.297799444 | 8056.565652 | 5 | 0.000819396 | 6 | 6 | 8 | 0.208917351 | 0.224546256 | 1728 | 5 | 0.00042413 | 2 | 2 | ||
| PANOBINOSTAT | predicted | Histone deacetylase | Homo sapiens | 7.669369718 | 5.508109155 | 7.52 | 1 | 0.75 | 0.875 | 4 | ACUTE GRAFT VS. HOST DISEASE, ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CANCER, CENTRAL NERVOUS SYSTEM CANCER, CHRONIC MYELOGENOUS LEUKEMIA, CUTANEOUS T-CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, GASTRIC CARCINOMA, GLIOBLASTOMA MULTIFORME, HIV INFECTION, HODGKINS LYMPHOMA, LEUKEMIA, LYMPHOMA, MACROGLOBULINEMIA, MELANOMA, MULTIPLE MYELOMA, MYELODYSPLASTIC SYNDROME, NEOPLASM, NON-HODGKINS LYMPHOMA, PROSTATE CARCINOMA, RENAL CELL CARCINOMA, SARCOMA, SICKLE CELL ANEMIA, THYROID CARCINOMA | unknown | 7 | 0.263969466 | 0.297799444 | 8056.565652 | 5 | 0.000819396 | 6 | 6 | 8 | 0.208917351 | 0.224546256 | 1728 | 5 | 0.00042413 | 2 | 2 | ||
| NAVITOCLAX | predicted | Bcl2-antagonist of cell death (BAD) | Homo sapiens | 8.272930027 | 4.818790082 | 9.150514998 | 1 | 1 | 1 | 2 | CANCER, CHRONIC LYMPHOCYTIC LEUKEMIA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, SMALL CELL LUNG CARCINOMA | unknown | 8 | 0.167311786 | 0.170781349 | 0 | 4 | 0.000237876 | 1 | 1 | 7 | 0.200906344 | 0.207006527 | 1728.5 | 4 | 0.000544073 | 3 | 3 | ||
| DONEPEZIL HYDROCHLORIDE | predicted | Acetylcholinesterase | Mus musculus | 7.779177584 | 3.337532752 | 8.24 | 1 | 1 | 1 | 1 | ALZHEIMERS DISEASE, AUTISM, CHRONIC KIDNEY DISEASE, COGNITIVE IMPAIRMENT, DEMENTIA, DOWN SYNDROME, MIGRAINE DISORDER | Acetylcholinesterase inhibitor | 6 | 0.272885101 | 0.290775014 | 6150.352346 | 0 | 0.001071529 | 12 | 12 | 7 | 0.214409722 | 0.222245173 | 0 | 0 | 0.000159591 | 1 | 1 | ||
| DONEPEZIL HYDROCHLORIDE | predicted | Acetylcholinesterase | Torpedo californica | 7.572922134 | 2.718766402 | 8.24 | 1 | 1 | 1 | 1 | ALZHEIMERS DISEASE, AUTISM, CHRONIC KIDNEY DISEASE, COGNITIVE IMPAIRMENT, DEMENTIA, DOWN SYNDROME, MIGRAINE DISORDER | Acetylcholinesterase inhibitor | 6 | 0.272885101 | 0.290775014 | 6150.352346 | 0 | 0.001071529 | 12 | 12 | 7 | 0.214409722 | 0.222245173 | 0 | 0 | 0.000159591 | 1 | 1 | ||
| DONEPEZIL HYDROCHLORIDE | predicted | Acetylcholinesterase | Bos taurus | 7.572922134 | 2.718766402 | 8.09 | 1 | 1 | 1 | 1 | ALZHEIMERS DISEASE, AUTISM, CHRONIC KIDNEY DISEASE, COGNITIVE IMPAIRMENT, DEMENTIA, DOWN SYNDROME, MIGRAINE DISORDER | Acetylcholinesterase inhibitor | 6 | 0.272885101 | 0.290775014 | 6150.352346 | 0 | 0.001071529 | 12 | 12 | 7 | 0.214409722 | 0.222245173 | 0 | 0 | 0.000159591 | 1 | 1 | ||
| NILVADIPINE | predicted | Voltage-gated L-type calcium channel | Rattus norvegicus | 7.848322329 | 3.544966987 | 8.98 | 1 | 1 | 1 | 3 | ALZHEIMERS DISEASE, CARDIOVASCULAR DISEASE | unknown | 7 | 0.260627073 | 0.276413561 | 3534.178718 | 0 | 0.000826182 | 9 | 9 | 8 | 0.206768716 | 0.214014432 | 0 | 0 | 0.00016172 | 1 | 1 | ||
| CARFILZOMIB | actual | 7.175223538 | Y | Proteasome subunit beta type-8 | Homo sapiens | 9.058407846 | 3.962572275 | 7.85 | 1 | 1 | 1 | 1 | ACUTE GRAFT VS. HOST DISEASE, ACUTE LYMPHOBLASTIC LEUKEMIA, CANCER, LEUKEMIA, LYMPHOMA, MULTIPLE MYELOMA, NEOPLASM, RENAL CARCINOMA | 26S proteosome inhibitor | 7 | 0.235046221 | 0.246707428 | 28.80497982 | 3 | 0.00028167 | 2 | 2 | 6 | 0.305261299 | 0.329679969 | 7392.83965 | 3 | 0.001170075 | 13 | 13 |
| NINTEDANIB | predicted | Tyrosine-protein kinase LCK | Homo sapiens | 7.543755484 | 2.631266451 | 7.936666667 | 1 | 1 | 1 | 3 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 6 | 0.302272727 | 0.339714671 | 6045.93275 | 35 | 0.000704582 | 16 | 16 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Vascular endothelial growth factor receptor 2 | Mus musculus | 7.6125073 | 2.837521901 | 7.89 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 6 | 0.302802102 | 0.340803933 | 6857.75835 | 35 | 0.00089742 | 20 | 20 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Platelet-derived growth factor receptor beta | Homo sapiens | 7.543755484 | 2.631266451 | 7.903333333 | 1 | 1 | 1 | 3 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.283256881 | 0.322508194 | 516.7195661 | 35 | 0.000513462 | 13 | 13 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Serine/threonine-protein kinase 11 | Homo sapiens | 7.6125073 | 2.837521901 | 7.74 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 6 | 0.294648943 | 0.331145171 | 441.8967398 | 35 | 0.00044388 | 11 | 11 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Tyrosine-protein kinase JAK3 | Homo sapiens | 7.40625185 | 2.218755551 | 8.09 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.271173149 | 0.309087279 | 44.53049134 | 35 | 0.00028069 | 6 | 6 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Tyrosine-protein kinase JAK3 | Homo sapiens | 7.40625185 | 2.218755551 | 8.09 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.271173149 | 0.309087279 | 44.53049134 | 35 | 0.00028069 | 6 | 6 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Tyrosine-protein kinase receptor UFO | Homo sapiens | 7.6125073 | 2.837521901 | 7.92 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 6 | 0.294950529 | 0.331376518 | 486.3247234 | 35 | 0.000448133 | 11 | 11 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Dual specificity protein kinase TTK | Homo sapiens | 7.6125073 | 2.837521901 | 7.66 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.27690583 | 0.314994905 | 89.40718725 | 35 | 0.000345199 | 8 | 8 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Serine/threonine-protein kinase PRP4 homolog | Homo sapiens | 7.40625185 | 2.218755551 | 8.08 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.279773463 | 0.318115343 | 119.5947718 | 35 | 0.000404659 | 10 | 10 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Neurotrophic tyrosine kinase receptor type 2 | Homo sapiens | 7.6125073 | 2.837521901 | 7.72 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.276109869 | 0.313853315 | 76.84935367 | 35 | 0.00028035 | 6 | 6 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Serine/threonine-protein kinase PCTAIRE-1 | Homo sapiens | 7.6125073 | 2.837521901 | 7.68 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.277172171 | 0.315910656 | 365.3534703 | 35 | 0.00041824 | 10 | 10 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | cGMP-dependent protein kinase 1 beta | Homo sapiens | 7.6125073 | 2.837521901 | 7.85 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.288262754 | 0.324287367 | 323.1969736 | 35 | 0.000357101 | 8 | 8 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Mitogen-activated protein kinase kinase kinase 2 | Homo sapiens | 7.40625185 | 2.218755551 | 8.03 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.2852194 | 0.32398992 | 449.5804668 | 35 | 0.000508548 | 13 | 13 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Insulin receptor-related protein | Homo sapiens | 7.6125073 | 2.837521901 | 7.68 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 6 | 0.294548552 | 0.330759591 | 412.4314158 | 35 | 0.000413067 | 10 | 10 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Maternal embryonic leucine zipper kinase | Homo sapiens | 7.40625185 | 2.218755551 | 8.31 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.286258278 | 0.322378749 | 220.6799197 | 35 | 0.000320185 | 7 | 7 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Dual specificity protein kinase CLK4 | Homo sapiens | 7.6125073 | 2.837521901 | 7.74 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.275581766 | 0.313426423 | 874.3090665 | 35 | 0.00039951 | 8 | 8 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Serine/threonine-protein kinase pknB | Mycobacterium tuberculosis | 7.40625185 | 2.218755551 | 8.44 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.279682951 | 0.317729764 | 107.5264429 | 35 | 0.000373845 | 9 | 9 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | Dual specificity mitogen-activated protein kinase kinase 5 | Homo sapiens | 7.40625185 | 2.218755551 | 8.74 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.280136099 | 0.319590184 | 282.7777954 | 35 | 0.000541349 | 14 | 14 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| NINTEDANIB | predicted | G protein-coupled receptor kinase 4 | Homo sapiens | 7.6125073 | 2.837521901 | 7.77 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, BREAST CARCINOMA, CARCINOID TUMOR, CERVICAL ADENOCARCINOMA, GASTRIC ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, IDIOPATHIC PULMONARY FIBROSIS, MESOTHELIOMA, MULTIPLE MYELOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, PROSTATE ADENOCARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, SYSTEMIC SCLERODERMA, THYROID CARCINOMA | unknown | 7 | 0.280226904 | 0.318876862 | 149.656558 | 35 | 0.000437139 | 11 | 11 | 7 | 0.245596591 | 0.275095706 | 580.3026379 | 35 | 0.00155258 | 40 | 40 | ||
| MORPHINE HYDROCHLORIDE | predicted | Mu opioid receptor | Homo sapiens | 7.52187501 | 2.56562503 | 7.420216403 | 1 | 1 | 1 | 1 | OPIATE DEPENDENCE | unknown | 7 | 0.282978723 | 0.306280812 | 10082.87955 | 0 | 0.00121941 | 17 | 17 | 7 | 0.224778991 | 0.236320196 | 7.292984576 | 0 | 0.000267625 | 3 | 3 | ||
| DIGOXIN | actual | 6.871944335 | Y | Nuclear factor NF-kappa-B p105 subunit | Homo sapiens | 8.957314778 | 6.871944335 | 7.91247615 | 1 | 1 | 1 | 2 | ATRIAL FIBRILLATION, BREAST CARCINOMA, CARDIOVASCULAR DISEASE, CONGESTIVE HEART FAILURE, EPILEPSY, HEART FAILURE, HEPATITIS C INFECTION, HIV INFECTION, HYPERTENSION, PROSTATE CARCINOMA, RHEUMATOID ARTHRITIS, TYPE II DIABETES MELLITUS, VERRUCAE | Sodium/potassium-transporting ATPase inhibitor | 6 | 0.289808917 | 0.32014652 | 21962.29414 | 4 | 0.002876854 | 38 | 38 | 6 | 0.333269082 | 0.361229998 | 15884.43882 | 4 | 0.002204251 | 32 | 32 |
| DIGOXIN | actual | 6.871944335 | Y | Nuclear factor NF-kappa-B p105 subunit | Homo sapiens | 8.957314778 | 6.871944335 | 7.91247615 | 1 | 1 | 1 | 2 | ATRIAL FIBRILLATION, BREAST CARCINOMA, CARDIOVASCULAR DISEASE, CONGESTIVE HEART FAILURE, EPILEPSY, HEART FAILURE, HEPATITIS C INFECTION, HIV INFECTION, HYPERTENSION, PROSTATE CARCINOMA, RHEUMATOID ARTHRITIS, TYPE II DIABETES MELLITUS, VERRUCAE | Sodium/potassium-transporting ATPase inhibitor | 6 | 0.289808917 | 0.32014652 | 21962.29414 | 4 | 0.002876854 | 38 | 38 | 6 | 0.333269082 | 0.361229998 | 15884.43882 | 4 | 0.002204251 | 32 | 32 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual specificity protein kinase CLK2 | Homo sapiens | 9.041646246 | 7.124938737 | 7.36 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.274706069 | 0.311151505 | 510.2232819 | 35 | 0.000259324 | 4 | 4 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Nerve growth factor receptor Trk-A | Homo sapiens | 9.041646246 | 7.124938737 | 8.08 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.290100671 | 0.325752568 | 256.9068146 | 35 | 0.000319917 | 7 | 7 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Tyrosine-protein kinase JAK2 | Homo sapiens | 9.041646246 | 7.124938737 | 8.43 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.276286353 | 0.313394751 | 26.97427971 | 35 | 0.00024724 | 5 | 5 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens | 9.041646246 | 7.124938737 | 8.24 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.279682951 | 0.317729764 | 88.58566189 | 35 | 0.000373384 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | G protein-coupled receptor kinase 4 | Homo sapiens | 9.041646246 | 7.124938737 | 7.92 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.280226904 | 0.318876862 | 149.656558 | 35 | 0.000437139 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Cyclin-dependent kinase-like 2 | Homo sapiens | 9.041646246 | 7.124938737 | 7.37 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.285407725 | 0.323835688 | 230.4981303 | 35 | 0.000468944 | 12 | 12 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Adaptor-associated kinase | Homo sapiens | 9.041646246 | 7.124938737 | 8.51 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.276817163 | 0.314609326 | 77.27098461 | 35 | 0.000312639 | 7 | 7 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase Chk1 | Homo sapiens | 9.041646246 | 7.124938737 | 8.55 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.285407725 | 0.320894269 | 232.4463357 | 35 | 0.000272849 | 5 | 5 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual specificty protein kinase CLK1 | Homo sapiens | 9.041646246 | 7.124938737 | 8.02 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.276463064 | 0.314233386 | 96.94989695 | 35 | 0.000314914 | 7 | 7 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual specificity mitogen-activated protein kinase kinase 3 | Homo sapiens | 9.041646246 | 7.124938737 | 8.3 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284749671 | 0.32230301 | 134.4552989 | 35 | 0.000372316 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Eukaryotic translation initiation factor 2-alpha kinase 4 | Homo sapiens | 9.041646246 | 7.124938737 | 8.39 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284749671 | 0.32230301 | 134.4552989 | 35 | 0.000372316 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase PAK 4 | Homo sapiens | 9.041646246 | 7.124938737 | 7.62 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.271003135 | 0.30831612 | 11.95307178 | 35 | 0.000214983 | 4 | 4 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Vascular endothelial growth factor receptor 3 | Homo sapiens | 9.041646246 | 7.124938737 | 7.77 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.291666667 | 0.329145666 | 1284.365223 | 35 | 0.000541215 | 13 | 13 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | BR serine/threonine-protein kinase 2 | Homo sapiens | 9.041646246 | 7.124938737 | 7.8 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.294548552 | 0.330759591 | 390.9319765 | 35 | 0.00041086 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Tyrosine kinase non-receptor protein 2 | Homo sapiens | 9.041646246 | 7.124938737 | 8.18 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.276817163 | 0.314609326 | 71.45080189 | 35 | 0.000312304 | 7 | 7 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | MAP/microtubule affinity-regulating kinase 2 | Homo sapiens | 9.041646246 | 7.124938737 | 7.85 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.274270305 | 0.311771186 | 99.20389171 | 35 | 0.000251924 | 5 | 5 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase PRKX | Homo sapiens | 9.041646246 | 7.124938737 | 7.38 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.270071853 | 0.307207579 | 3.096295107 | 35 | 0.000182503 | 3 | 3 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase PIM3 | Homo sapiens | 9.041646246 | 7.124938737 | 7.74 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.292060811 | 0.327829188 | 288.4572905 | 35 | 0.000349601 | 8 | 8 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | BMP-2-inducible protein kinase | Homo sapiens | 9.041646246 | 7.124938737 | 7.8 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.276728553 | 0.314223746 | 50.89397077 | 35 | 0.000279618 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase 17B | Homo sapiens | 9.041646246 | 7.124938737 | 8.3 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.278781038 | 0.316409155 | 83.62988257 | 35 | 0.000343456 | 8 | 8 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase RIO3 | Homo sapiens | 9.041646246 | 7.124938737 | 8.11 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284749671 | 0.322235534 | 122.7797102 | 35 | 0.000372418 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Maternal embryonic leucine zipper kinase | Homo sapiens | 9.041646246 | 7.124938737 | 7.59 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.286258278 | 0.322378749 | 220.6799197 | 35 | 0.000320185 | 7 | 7 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Tyrosine-protein kinase FER | Homo sapiens | 9.041646246 | 7.124938737 | 7.55 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.28512533 | 0.320286981 | 121.4701833 | 35 | 0.000222611 | 4 | 4 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase D2 | Homo sapiens | 9.041646246 | 7.124938737 | 8.09 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.274706069 | 0.312655265 | 56.45557554 | 35 | 0.000341502 | 8 | 8 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase ULK3 | Homo sapiens | 9.041646246 | 7.124938737 | 8.31 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.295051195 | 0.33152111 | 435.8586458 | 35 | 0.00044334 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase Aurora-C | Homo sapiens | 9.041646246 | 7.124938737 | 8.39 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.29315022 | 0.328619626 | 294.2162272 | 35 | 0.000351399 | 8 | 8 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual-specificity tyrosine-phosphorylation regulated kinase 2 | Homo sapiens | 9.041646246 | 7.124938737 | 7.66 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.294548552 | 0.330759591 | 416.6827054 | 35 | 0.000414428 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Homo sapiens | 9.041646246 | 7.124938737 | 7.54 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.270833333 | 0.309096918 | 40.63906577 | 35 | 0.000281823 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | TRAF2- and NCK-interacting kinase | Homo sapiens | 9.041646246 | 7.124938737 | 8.27 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.277172171 | 0.314956347 | 64.89966469 | 35 | 0.000312128 | 7 | 7 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Cyclin-dependent kinase-like 5 | Homo sapiens | 9.041646246 | 7.124938737 | 8 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284843493 | 0.32268859 | 149.0102443 | 35 | 0.00040313 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | MAP kinase signal-integrating kinase 2 | Homo sapiens | 9.041646246 | 7.124938737 | 8.85 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.293947637 | 0.33022942 | 558.9121793 | 35 | 0.000454716 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Tyrosine-protein kinase receptor FLT3 | Homo sapiens | 9.041646246 | 7.124938737 | 8.479333333 | 1 | 1 | 1 | 15 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.276109869 | 0.316009805 | 1180.098712 | 35 | 0.000588806 | 14 | 14 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Proto-oncogene tyrosine-protein kinase MER | Homo sapiens | 9.041646246 | 7.124938737 | 7.49 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.295151929 | 0.33190669 | 514.5117327 | 35 | 0.000478545 | 12 | 12 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual specificity mitogen-activated protein kinase kinase 4 | Homo sapiens | 9.041646246 | 7.124938737 | 8.42 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284843493 | 0.32268859 | 149.0102443 | 35 | 0.00040313 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase 17A | Homo sapiens | 9.041646246 | 7.124938737 | 8.47 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.270833333 | 0.309096918 | 40.63906577 | 35 | 0.000281823 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Misshapen-like kinase 1 | Homo sapiens | 9.041646246 | 7.124938737 | 8.44 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.295353604 | 0.331819934 | 488.2580229 | 35 | 0.000446843 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase PAK6 | Homo sapiens | 9.041646246 | 7.124938737 | 8 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.288647746 | 0.324031232 | 191.3630946 | 35 | 0.000287428 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual specificity protein kinase CLK4 | Homo sapiens | 9.041646246 | 7.124938737 | 8.52 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.275581766 | 0.313426423 | 874.3090665 | 35 | 0.00039951 | 8 | 8 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual specificity protein kinase TTK | Homo sapiens | 9.041646246 | 7.124938737 | 8.19 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.27690583 | 0.314994905 | 89.40718725 | 35 | 0.000345199 | 8 | 8 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Homo sapiens | 9.041646246 | 7.124938737 | 7.7 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.270748512 | 0.308711339 | 33.60363689 | 35 | 0.000249263 | 5 | 5 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase GAK | Homo sapiens | 9.041646246 | 7.124938737 | 8.14 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.279682951 | 0.317903275 | 135.1755708 | 35 | 0.000409806 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Myosin light chain kinase family member 4 | Homo sapiens | 9.041646246 | 7.124938737 | 7.54 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284843493 | 0.32268859 | 149.0102443 | 35 | 0.00040313 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Mitogen-activated protein kinase kinase kinase 15 | Homo sapiens | 9.041646246 | 7.124938737 | 8.47 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.279592497 | 0.317344185 | 75.90100671 | 35 | 0.000340825 | 8 | 8 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Stem cell growth factor receptor | Homo sapiens | 9.041646246 | 7.124938737 | 7.277777778 | 1 | 1 | 1 | 9 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.283535585 | 0.324522846 | 3010.536614 | 35 | 0.000815755 | 19 | 19 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Microtubule-associated serine/threonine-protein kinase 1 | Homo sapiens | 9.041646246 | 7.124938737 | 7.72 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284843493 | 0.32268859 | 149.0102443 | 35 | 0.00040313 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Protein kinase C nu | Homo sapiens | 9.041646246 | 7.124938737 | 8.05 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.27690583 | 0.313420915 | 614.1437496 | 35 | 0.000290395 | 5 | 5 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Mitogen-activated protein kinase kinase kinase 2 | Homo sapiens | 9.041646246 | 7.124938737 | 8.32 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.2852194 | 0.32398992 | 449.5804668 | 35 | 0.000508548 | 13 | 13 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase TBK1 | Homo sapiens | 9.041646246 | 7.124938737 | 7.74 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.28512533 | 0.320286981 | 121.4701833 | 35 | 0.000222611 | 4 | 4 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase 33 | Homo sapiens | 9.041646246 | 7.124938737 | 7.59 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.294448229 | 0.330374012 | 362.0942014 | 35 | 0.000380046 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Phosphatidylinositol-5-phosphate 4-kinase type-2 beta | Homo sapiens | 9.041646246 | 7.124938737 | 7.74 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284843493 | 0.32268859 | 149.0102443 | 35 | 0.00040313 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | NUAK family SNF1-like kinase 2 | Homo sapiens | 9.041646246 | 7.124938737 | 9 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.283071382 | 0.321737035 | 179.148799 | 35 | 0.000437225 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase SIK2 | Homo sapiens | 9.041646246 | 7.124938737 | 7.82 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.279592497 | 0.317344185 | 75.90100671 | 35 | 0.000340825 | 8 | 8 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Tyrosine-protein kinase JAK2 | Homo sapiens | 9.041646246 | 7.124938737 | 8.43 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.276286353 | 0.313394751 | 26.97427971 | 35 | 0.00024724 | 5 | 5 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Mitogen-activated protein kinase kinase kinase 3 | Homo sapiens | 9.041646246 | 7.124938737 | 8.22 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.280045351 | 0.318105704 | 100.3984651 | 35 | 0.000373304 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Mitogen-activated protein kinase kinase kinase 7 | Homo sapiens | 9.041646246 | 7.124938737 | 8.54 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.296671242 | 0.33283208 | 606.7535666 | 35 | 0.000449467 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Mitogen-activated protein kinase kinase kinase kinase 1 | Homo sapiens | 9.041646246 | 7.124938737 | 7.42 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.285407725 | 0.323835688 | 214.4878618 | 35 | 0.000470042 | 12 | 12 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Mitogen-activated protein kinase kinase kinase kinase 4 | Homo sapiens | 9.041646246 | 7.124938737 | 7.64 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.275493945 | 0.313551736 | 532.8264132 | 35 | 0.00036559 | 8 | 8 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Mitogen-activated protein kinase kinase kinase kinase 2 | Homo sapiens | 9.041646246 | 7.124938737 | 8.33 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.286353097 | 0.322484783 | 231.8027079 | 35 | 0.000320156 | 7 | 7 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Tyrosine-protein kinase JAK3 | Homo sapiens | 9.041646246 | 7.124938737 | 8.64 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.271173149 | 0.309087279 | 44.53049134 | 35 | 0.00028069 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Tyrosine-protein kinase SYK | Homo sapiens | 9.041646246 | 7.124938737 | 8.02 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.27593361 | 0.313018811 | 292.1547847 | 35 | 0.00027233 | 5 | 5 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase Aurora-A | Homo sapiens | 9.041646246 | 7.124938737 | 7.8 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.2902955 | 0.326576056 | 3354.359991 | 35 | 0.000532934 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Inhibitor of nuclear factor kappa B kinase alpha subunit | Homo sapiens | 9.041646246 | 7.124938737 | 8.05 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.271513819 | 0.309482497 | 23.05771105 | 35 | 0.000246749 | 5 | 5 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | BR serine/threonine-protein kinase 1 | Homo sapiens | 9.041646246 | 7.124938737 | 7.6 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.274531597 | 0.311884106 | 29.89580813 | 35 | 0.000278002 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens | 9.041646246 | 7.124938737 | 8.46 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.290198053 | 0.326739927 | 2976.33696 | 35 | 0.000533093 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens | 9.041646246 | 7.124938737 | 8.41 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.277706393 | 0.316170922 | 845.1100231 | 35 | 0.000415694 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Cyclin-dependent kinase 2 | Homo sapiens | 9.041646246 | 7.124938737 | 7.7 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.27057903 | 0.308181167 | 14.84698679 | 35 | 0.000214882 | 4 | 4 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Protein kinase C mu | Homo sapiens | 9.041646246 | 7.124938737 | 7.85 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.294548552 | 0.330759591 | 596.9212822 | 35 | 0.000422655 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual serine/threonine and tyrosine protein kinase | Homo sapiens | 9.041646246 | 7.124938737 | 8.28 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.279682951 | 0.317729764 | 87.3417866 | 35 | 0.000371638 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual specificity mitogen-activated protein kinase kinase 6 | Homo sapiens | 9.041646246 | 7.124938737 | 7.36 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.294548552 | 0.330759591 | 390.9319765 | 35 | 0.00041086 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Tyrosine-protein kinase receptor RET | Homo sapiens | 9.041646246 | 7.124938737 | 7.95 | 1 | 1 | 1 | 5 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.283814839 | 0.324580682 | 2421.142611 | 35 | 0.00074186 | 18 | 18 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Rhodopsin kinase | Homo sapiens | 9.041646246 | 7.124938737 | 7.62 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.279682951 | 0.317729764 | 87.3417866 | 35 | 0.000371638 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | NT-3 growth factor receptor | Homo sapiens | 9.041646246 | 7.124938737 | 7.85 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.276728553 | 0.315212482 | 211.6298007 | 35 | 0.00035213 | 8 | 8 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | c-Jun N-terminal kinase 1 | Homo sapiens | 9.041646246 | 7.124938737 | 7.96 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.28587963 | 0.321896775 | 194.733752 | 35 | 0.000320337 | 7 | 7 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Mitogen-activated protein kinase kinase kinase 10 | Homo sapiens | 9.041646246 | 7.124938737 | 7.82 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.277261065 | 0.315168416 | 53.79253211 | 35 | 0.000309753 | 7 | 7 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase PAK7 | Homo sapiens | 9.041646246 | 7.124938737 | 7.62 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.276109869 | 0.313548982 | 149.8897953 | 35 | 0.000289929 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase LATS1 | Homo sapiens | 9.041646246 | 7.124938737 | 7.52 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284843493 | 0.32268859 | 149.0102443 | 35 | 0.00040313 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Mitogen-activated protein kinase kinase kinase kinase 5 | Homo sapiens | 9.041646246 | 7.124938737 | 7.37 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.282886126 | 0.321206863 | 192.2134847 | 35 | 0.000408997 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Non-receptor tyrosine-protein kinase TNK1 | Homo sapiens | 9.041646246 | 7.124938737 | 8.03 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.2852194 | 0.323064529 | 163.4892935 | 35 | 0.000404796 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Mitogen-activated protein kinase 15 | Homo sapiens | 9.041646246 | 7.124938737 | 8.31 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.295252732 | 0.332118758 | 869.8200284 | 35 | 0.000484692 | 12 | 12 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | CaM kinase II alpha | Homo sapiens | 9.041646246 | 7.124938737 | 8 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.27057903 | 0.308181167 | 14.84698679 | 35 | 0.000214882 | 4 | 4 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | CaM-kinase kinase beta | Homo sapiens | 9.041646246 | 7.124938737 | 7.82 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.286353097 | 0.322484783 | 347.1062788 | 35 | 0.000330079 | 7 | 7 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase PLK4 | Homo sapiens | 9.041646246 | 7.124938737 | 8.82 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.282978723 | 0.321351456 | 383.7674318 | 35 | 0.000415709 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | CaM-kinase kinase alpha | Homo sapiens | 9.041646246 | 7.124938737 | 7.64 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.289711796 | 0.326007326 | 313.3208861 | 35 | 0.0003831 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | CaM kinase II delta | Homo sapiens | 9.041646246 | 7.124938737 | 8.06 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.2852194 | 0.320672561 | 137.9889327 | 35 | 0.000255171 | 5 | 5 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Inhibitor of nuclear factor kappa B kinase beta subunit | Homo sapiens | 9.041646246 | 7.124938737 | 7.92 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.288647746 | 0.324730783 | 494.5994102 | 35 | 0.000366509 | 8 | 8 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Calcium-dependent protein kinase 1 | Plasmodium falciparum (isolate 3D7) | 9.041646246 | 7.124938737 | 8.25 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284468575 | 0.322245173 | 159.1689426 | 35 | 0.000405193 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Interleukin-1 receptor-associated kinase 1 | Homo sapiens | 9.041646246 | 7.124938737 | 8.21 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.2902955 | 0.326335068 | 410.3738579 | 35 | 0.000388406 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Inhibitor of nuclear factor kappa B kinase epsilon subunit | Homo sapiens | 9.041646246 | 7.124938737 | 7.96 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.27057903 | 0.308181167 | 14.84698679 | 35 | 0.000214882 | 4 | 4 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase 16 | Homo sapiens | 9.041646246 | 7.124938737 | 7.72 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.276728553 | 0.314223746 | 50.89397077 | 35 | 0.000279618 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Receptor-interacting serine/threonine-protein kinase 4 | Homo sapiens | 9.041646246 | 7.124938737 | 7.89 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.280136099 | 0.318491283 | 115.2432311 | 35 | 0.000405864 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase 11 | Homo sapiens | 9.041646246 | 7.124938737 | 7.24 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.294648943 | 0.331145171 | 441.8967398 | 35 | 0.00044388 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase 10 | Homo sapiens | 9.041646246 | 7.124938737 | 8.24 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.296569468 | 0.332620012 | 562.8802929 | 35 | 0.000451507 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase RIO1 | Homo sapiens | 9.041646246 | 7.124938737 | 8.05 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.285313531 | 0.323450109 | 180.1133685 | 35 | 0.00043561 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Interleukin-1 receptor-associated kinase 4 | Homo sapiens | 9.041646246 | 7.124938737 | 8.77 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.278960955 | 0.315985017 | 40.05912612 | 35 | 0.000277699 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Mitogen-activated protein kinase kinase kinase 11 | Homo sapiens | 9.041646246 | 7.124938737 | 7.74 | 1 | 1 | 1 | 3 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284937376 | 0.323074169 | 1877.010244 | 35 | 0.000507626 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Bone morphogenetic protein receptor type-1B | Homo sapiens | 9.041646246 | 7.124938737 | 7.24 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.285313531 | 0.323450109 | 180.1133685 | 35 | 0.00043561 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | AMP-activated protein kinase- alpha-1 subunit | Homo sapiens | 9.041646246 | 7.124938737 | 7.6 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.27057903 | 0.308181167 | 14.84698679 | 35 | 0.000214882 | 4 | 4 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Interleukin-1 receptor-associated kinase 3 | Homo sapiens | 9.041646246 | 7.124938737 | 7.8 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.285031322 | 0.323459748 | 213.7973798 | 35 | 0.000469024 | 12 | 12 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | c-Jun N-terminal kinase 3 | Homo sapiens | 9.041646246 | 7.124938737 | 7.92 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.287782956 | 0.324551764 | 328.3510498 | 35 | 0.000418485 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Phosphorylase kinase gamma subunit 2 | Homo sapiens | 9.041646246 | 7.124938737 | 8.77 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.287687188 | 0.323587816 | 237.8285647 | 35 | 0.000319932 | 7 | 7 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Proto-oncogene tyrosine-protein kinase ROS | Homo sapiens | 9.041646246 | 7.124938737 | 7.59 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.272112055 | 0.310147622 | 439.7824862 | 35 | 0.000302779 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Cyclin-dependent kinase 4 | Homo sapiens | 9.041646246 | 7.124938737 | 7.49 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284749671 | 0.32230301 | 134.4552989 | 35 | 0.000372316 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | G protein-coupled receptor kinase 7 | Homo sapiens | 9.041646246 | 7.124938737 | 8.14 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.294448229 | 0.330374012 | 362.0942014 | 35 | 0.000380046 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase PAK 2 | Homo sapiens | 9.041646246 | 7.124938737 | 7.37 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.294648943 | 0.331145171 | 430.6347858 | 35 | 0.000443546 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Myosin light chain kinase- smooth muscle | Homo sapiens | 9.041646246 | 7.124938737 | 7.9 | 1 | 1 | 1 | 3 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.294950529 | 0.331203008 | 436.7124059 | 35 | 0.000412424 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase LATS2 | Homo sapiens | 9.041646246 | 7.124938737 | 9 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284843493 | 0.32268859 | 149.0102443 | 35 | 0.00040313 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase PAK 1 | Homo sapiens | 9.041646246 | 7.124938737 | 7.52 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.270071853 | 0.307207579 | 3.096295107 | 35 | 0.000182503 | 3 | 3 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase ICK | Homo sapiens | 9.041646246 | 7.124938737 | 7.41 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.279682951 | 0.317729764 | 87.3417866 | 35 | 0.000371638 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | SPS1/STE20-related protein kinase YSK4 | Homo sapiens | 9.041646246 | 7.124938737 | 9.28 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.2855963 | 0.324606847 | 534.4683177 | 35 | 0.000543908 | 14 | 14 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase SRPK1 | Homo sapiens | 9.041646246 | 7.124938737 | 8 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.277884924 | 0.315925804 | 86.5935607 | 35 | 0.000311363 | 7 | 7 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Protein kinase N2 | Homo sapiens | 9.041646246 | 7.124938737 | 8.74 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.290393013 | 0.326412184 | 311.7862131 | 35 | 0.000351593 | 8 | 8 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Protein kinase N1 | Homo sapiens | 9.041646246 | 7.124938737 | 8.28 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284749671 | 0.32230301 | 134.4552989 | 35 | 0.000372316 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Tyrosine-protein kinase JAK3 | Homo sapiens | 9.041646246 | 7.124938737 | 8.64 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.271173149 | 0.309087279 | 44.53049134 | 35 | 0.00028069 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Platelet-derived growth factor receptor beta | Homo sapiens | 9.041646246 | 7.124938737 | 7.545 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.283256881 | 0.322508194 | 516.7195661 | 35 | 0.000513462 | 13 | 13 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase MST1 | Homo sapiens | 9.041646246 | 7.124938737 | 8.52 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.289517749 | 0.325236167 | 264.7620101 | 35 | 0.000319726 | 7 | 7 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Phosphorylase kinase gamma subunit 1 | Homo sapiens | 9.041646246 | 7.124938737 | 9.41 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.277350016 | 0.315553995 | 88.18107863 | 35 | 0.000344201 | 8 | 8 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Neurotrophic tyrosine kinase receptor type 2 | Homo sapiens | 9.041646246 | 7.124938737 | 7.85 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.276109869 | 0.313853315 | 76.84935367 | 35 | 0.00028035 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | 3-phosphoinositide dependent protein kinase-1 | Homo sapiens | 9.041646246 | 7.124938737 | 8.47 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.288937166 | 0.325646534 | 856.3985376 | 35 | 0.000440522 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase SRPK3 | Homo sapiens | 9.041646246 | 7.124938737 | 7.89 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284749671 | 0.322235534 | 122.7797102 | 35 | 0.000372418 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Ankyrin repeat and protein kinase domain-containing protein 1 | Homo sapiens | 9.041646246 | 7.124938737 | 7.49 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284843493 | 0.322621113 | 138.7978904 | 35 | 0.000403232 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Phosphatidylinositol-4-phosphate 5-kinase type-1 alpha | Homo sapiens | 9.041646246 | 7.124938737 | 7.44 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284749671 | 0.32230301 | 134.4552989 | 35 | 0.000372316 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Tyrosine-protein kinase ZAP-70 | Homo sapiens | 9.041646246 | 7.124938737 | 7.8 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.286923332 | 0.324838194 | 315.3645967 | 35 | 0.000440173 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase PCTAIRE-1 | Homo sapiens | 9.041646246 | 7.124938737 | 7.57 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.277172171 | 0.315910656 | 365.3534703 | 35 | 0.00041824 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | NUAK family SNF1-like kinase 1 | Homo sapiens | 9.041646246 | 7.124938737 | 8.43 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.294950529 | 0.331203008 | 436.7124059 | 35 | 0.000412424 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase Sgk3 | Homo sapiens | 9.041646246 | 7.124938737 | 8.24 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.279321486 | 0.317286348 | 72.00994757 | 35 | 0.00037182 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase Aurora-B | Homo sapiens | 9.041646246 | 7.124938737 | 7.8 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 6 | 0.295454545 | 0.331665703 | 1435.893954 | 35 | 0.000502287 | 11 | 11 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Serine/threonine-protein kinase MST2 | Homo sapiens | 9.041646246 | 7.124938737 | 8.62 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.287495843 | 0.324576551 | 352.9138976 | 35 | 0.000415791 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | cGMP-dependent protein kinase 2 | Homo sapiens | 9.041646246 | 7.124938737 | 7.6 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.27159912 | 0.309868077 | 30.63374213 | 35 | 0.000279309 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Dual specificity mitogen-activated protein kinase kinase 5 | Homo sapiens | 9.041646246 | 7.124938737 | 8.15 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.280136099 | 0.319590184 | 282.7777954 | 35 | 0.000541349 | 14 | 14 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Myosin light chain kinase | Homo sapiens | 9.041646246 | 7.124938737 | 7.92 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.280045351 | 0.318105704 | 100.3984651 | 35 | 0.000373304 | 9 | 9 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Mitogen-activated protein kinase kinase kinase 9 | Homo sapiens | 9.041646246 | 7.124938737 | 8.46 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.284843493 | 0.322621113 | 138.7978904 | 35 | 0.000403232 | 10 | 10 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Leucine-rich repeat serine/threonine-protein kinase 2 | Homo sapiens | 9.041646246 | 7.124938737 | 8.52 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.27245509 | 0.310591038 | 38.89348917 | 35 | 0.000279229 | 6 | 6 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Receptor-type tyrosine-protein kinase FLT3 | Mus musculus | 5.708312912 | 7.124938737 | 8.82 | 0 | 1 | 0.5 | 1 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.266820988 | 0.303511526 | 0 | 35 | 0.000116836 | 1 | 1 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| LESTAURTINIB | actual | 7.124938737 | Y | Tankyrase-2 | Homo sapiens | 9.041646246 | 7.124938737 | 8.18 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, PSORIASIS | NT-3 growth factor receptor inhibitor, Nerve growth factor receptor Trk-A inhibitor, Neurotrophic tyrosine kinase receptor type 2 inhibitor, Tyrosine-protein kinase JAK2 inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor RET inhibitor | 7 | 0.267316017 | 0.304485114 | 5.537972698 | 35 | 0.000149214 | 2 | 2 | 6 | 0.363846801 | 0.483227299 | 153769.6325 | 35 | 0.015110063 | 388 | 388 |
| MIDOSTAURIN | predicted | Protein kinase N1 | Homo sapiens | 7.457500005 | 2.372500015 | 8.03 | 1 | 1 | 1 | 3 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, LIVER DISEASE | Platelet-derived growth factor receptor inhibitor, Protein kinase C (PKC) inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Vascular endothelial growth factor receptor 2 inhibitor | 7 | 0.284749671 | 0.32230301 | 134.4552989 | 35 | 0.000372316 | 9 | 9 | 7 | 0.264373089 | 0.343983585 | 14122.31028 | 35 | 0.007611746 | 200 | 200 | ||
| MIDOSTAURIN | predicted | SPS1/STE20-related protein kinase YSK4 | Homo sapiens | 7.710421305 | 3.131263916 | 7.82 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, LEUKEMIA, LIVER DISEASE | Platelet-derived growth factor receptor inhibitor, Protein kinase C (PKC) inhibitor, Stem cell growth factor receptor inhibitor, Tyrosine-protein kinase receptor FLT3 inhibitor, Vascular endothelial growth factor receptor 2 inhibitor | 7 | 0.2855963 | 0.324606847 | 534.4683177 | 35 | 0.000543908 | 14 | 14 | 7 | 0.264373089 | 0.343983585 | 14122.31028 | 35 | 0.007611746 | 200 | 200 | ||
| LINSITINIB | predicted | Insulin-like growth factor I receptor | Homo sapiens | 8.061428514 | 4.184285543 | 7.915 | 1 | 1 | 1 | 6 | ADRENOCORTICAL CARCINOMA, HEPATOCELLULAR CARCINOMA, NEOPLASM, OVARIAN CARCINOMA, PROSTATE ADENOCARCINOMA, SMALL CELL LUNG CARCINOMA | Insulin receptor inhibitor, Insulin-like growth factor I receptor inhibitor | 7 | 0.2852194 | 0.320672561 | 967.5190036 | 35 | 0.00030356 | 5 | 5 | 8 | 0.222122302 | 0.238166157 | 0.403225806 | 35 | 0.0001904 | 2 | 2 | ||
| LINSITINIB | predicted | Insulin receptor | Homo sapiens | 8.027054368 | 4.081163105 | 7.74 | 1 | 1 | 1 | 1 | ADRENOCORTICAL CARCINOMA, HEPATOCELLULAR CARCINOMA, NEOPLASM, OVARIAN CARCINOMA, PROSTATE ADENOCARCINOMA, SMALL CELL LUNG CARCINOMA | Insulin receptor inhibitor, Insulin-like growth factor I receptor inhibitor | 7 | 0.285407725 | 0.321443719 | 2745.943338 | 35 | 0.000454148 | 7 | 7 | 8 | 0.222122302 | 0.238166157 | 0.403225806 | 35 | 0.0001904 | 2 | 2 | ||
| SCOPOLAMINE | predicted | Muscarinic acetylcholine receptor M1 | Bos taurus | 7.520833323 | 2.56249997 | 9.39 | 1 | 1 | 1 | 1 | ANXIETY, NAUSEA | Muscarinic acetylcholine receptor M1 antagonist | 6 | 0.288840628 | 0.317466744 | 9434.894236 | 0 | 0.001795345 | 31 | 31 | 7 | 0.226546122 | 0.241010493 | 24.808805 | 0 | 0.000379601 | 6 | 6 | ||
| SCOPOLAMINE | predicted | Muscarinic acetylcholine receptor M4 | Homo sapiens | 7.520833323 | 2.56249997 | 7.736952578 | 1 | 1 | 1 | 5 | ANXIETY, NAUSEA | Muscarinic acetylcholine receptor M1 antagonist | 6 | 0.280136099 | 0.303663004 | 2650.84323 | 0 | 0.001281184 | 23 | 23 | 7 | 0.226546122 | 0.241010493 | 24.808805 | 0 | 0.000379601 | 6 | 6 | ||
| SCOPOLAMINE | predicted | Muscarinic acetylcholine receptor M3 | Homo sapiens | 7.520833323 | 2.56249997 | 8.19 | 1 | 1 | 1 | 1 | ANXIETY, NAUSEA | Muscarinic acetylcholine receptor M1 antagonist | 6 | 0.280499676 | 0.304347407 | 3029.87758 | 0 | 0.001343026 | 24 | 24 | 7 | 0.226546122 | 0.241010493 | 24.808805 | 0 | 0.000379601 | 6 | 6 | ||
| ASIMADOLINE | predicted | Kappa opioid receptor | Homo sapiens | 7.717965377 | 3.15389613 | 9.3 | 1 | 1 | 1 | 1 | IRRITABLE BOWEL SYNDROME | unknown | 7 | 0.28465591 | 0.307871327 | 4741.607676 | 0 | 0.00108945 | 16 | 16 | 8 | 0.221609844 | 0.231410256 | 0 | 0 | 0.000141568 | 1 | 1 | ||
| VANCOMYCIN HYDROCHLORIDE | predicted | Solute carrier organic anion transporter family member 1B1 | Homo sapiens | 8.496589933 | 5.4897698 | 9.007716288 | 1 | 1 | 1 | 1 | CYSTIC FIBROSIS, INFECTION | Peptidoglycan inhibitor | 6 | 0.338223787 | 0.395430885 | 160170.355 | 3 | 0.009667585 | 113 | 113 | 7 | 0.255014749 | 0.275624501 | 126.1916304 | 4 | 0.00023413 | 2 | 2 | ||
| METHADONE HYDROCHLORIDE | actual | 6.781464495 | Y | Opioid receptor | Rattus norvegicus | 8.927154832 | 5.586098371 | 7.29 | 1 | 1 | 1 | 3 | SCOLIOSIS | Mu opioid receptor agonist | 8 | 0.218805366 | 0.228909499 | 18.09984264 | 0 | 0.000271696 | 2 | 2 | 7 | 0.265346839 | 0.283709273 | 1036.856907 | 0 | 0.000261737 | 2 | 2 |
| METHADONE HYDROCHLORIDE | actual | 6.781464495 | Y | Opioid receptor | Rattus norvegicus | 8.927154832 | 5.586098371 | 7.29 | 1 | 1 | 1 | 1 | SCOLIOSIS | Mu opioid receptor agonist | 8 | 0.218805366 | 0.228909499 | 18.09984264 | 0 | 0.000271696 | 2 | 2 | 7 | 0.265346839 | 0.283709273 | 1036.856907 | 0 | 0.000261737 | 2 | 2 |
| LANREOTIDE | predicted | Somatostatin receptor 2 | Homo sapiens | 8.312844996 | 4.938534989 | 9.3 | 1 | 1 | 1 | 1 | CARCINOID TUMOR, COLORECTAL ADENOCARCINOMA, DIARRHEA, GROWTH HORMONE EXCESS, KIDNEY DISEASE, NEOPLASM | unknown | 8 | 0.182730924 | 0.189351814 | 31.27369292 | 37 | 0.000341269 | 2 | 2 | 9 | 0.191472868 | 0.199627273 | 117.6185678 | 37 | 0.000484907 | 3 | 3 | ||
| LANREOTIDE | predicted | Somatostatin receptor 5 | Homo sapiens | 8.312844996 | 4.938534989 | 8.4 | 1 | 1 | 1 | 1 | CARCINOID TUMOR, COLORECTAL ADENOCARCINOMA, DIARRHEA, GROWTH HORMONE EXCESS, KIDNEY DISEASE, NEOPLASM | unknown | 8 | 0.236654804 | 0.251425266 | 2145.579483 | 37 | 0.000392343 | 3 | 3 | 9 | 0.191472868 | 0.199627273 | 117.6185678 | 37 | 0.000484907 | 3 | 3 | ||
| MARAVIROC | predicted | C-C chemokine receptor type 5 | Macaca mulatta | 7.757400694 | 3.272202081 | 9.62 | 1 | 1 | 1 | 1 | ACUTE GRAFT VS. HOST DISEASE, AIDS, AIDS DEMENTIA, HIV INFECTION, HIV-1 INFECTION, HYPERTRIGLYCERIDEMIA, INFECTION, RHEUMATOID ARTHRITIS, VIRAL DISEASE | C-C chemokine receptor type 5 antagonist | 7 | 0.236914223 | 0.248726211 | 3455 | 0 | 0.000537252 | 3 | 3 | 8 | 0.191557722 | 0.197616982 | 0 | 0 | 0.000235913 | 1 | 1 | ||
| INSULIN HUMAN | predicted | Insulin receptor | Rattus norvegicus | 8.469420822 | 5.408262465 | 8.725 | 1 | 1 | 1 | 2 | BIPOLAR DISORDER, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, COLORECTAL ADENOCARCINOMA, DIABETES MELLITUS, GESTATIONAL DIABETES, HYPERGLYCEMIA, HYPOGLYCEMIA, HYPOGONADOTROPHIC HYPOGONADISM, INSULIN RESISTANCE, MYOCARDIAL INFARCTION, NICOTINE DEPENDENCE, NON-ALCOHOLIC FATTY LIVER DISEASE, OBESITY, SCHIZOPHRENIA, SUBARACHNOID HEMORRHAGE, TYPE I DIABETES MELLITUS, TYPE II DIABETES MELLITUS, UNIPOLAR DEPRESSION | Insulin receptor agonist | 7 | 0.285407725 | 0.321443719 | 2745.943338 | 35 | 0.000454148 | 7 | 7 | 8 | 0.222065245 | 0.237780578 | 0 | 35 | 0.000138823 | 1 | 1 | ||
| ROMIDEPSIN | predicted | Histone deacetylase 3/NCoR1 | Homo sapiens | 7.6412555 | 2.923766499 | 9.82 | 1 | 1 | 1 | 1 | ACUTE PROMYELOCYTIC LEUKEMIA, COLORECTAL ADENOCARCINOMA, CUTANEOUS T-CELL LYMPHOMA, HIV INFECTION, LYMPHOMA, MALE BREAST CARCINOMA, MULTIPLE MYELOMA, NEOPLASM, PROSTATE CARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, UNSPECIFIED PERIPHERAL T-CELL LYMPHOMA | Histone deacetylase inhibitor | 8 | 0.233711814 | 0.24635421 | 131.8974355 | 5 | 0.000292733 | 2 | 2 | 8 | 0.214091134 | 0.230214272 | 150.5475026 | 5 | 0.000751211 | 6 | 6 | ||
| ROMIDEPSIN | predicted | Histone deacetylase 3/NCoR1 | Homo sapiens | 7.6412555 | 2.923766499 | 9.82 | 1 | 1 | 1 | 1 | ACUTE PROMYELOCYTIC LEUKEMIA, COLORECTAL ADENOCARCINOMA, CUTANEOUS T-CELL LYMPHOMA, HIV INFECTION, LYMPHOMA, MALE BREAST CARCINOMA, MULTIPLE MYELOMA, NEOPLASM, PROSTATE CARCINOMA, RENAL CELL CARCINOMA, SMALL CELL LUNG CARCINOMA, UNSPECIFIED PERIPHERAL T-CELL LYMPHOMA | Histone deacetylase inhibitor | 8 | 0.233711814 | 0.24635421 | 131.8974355 | 5 | 0.000292733 | 2 | 2 | 8 | 0.214091134 | 0.230214272 | 150.5475026 | 5 | 0.000751211 | 6 | 6 | ||
| OMIPALISIB | predicted | Mammalian target of Rapamycin (mTORC1) | Homo sapiens | 7.858109562 | 3.574328687 | 9.74 | 1 | 1 | 1 | 1 | IDIOPATHIC PULMONARY FIBROSIS, NEOPLASM | PI3-kinase class I inhibitor, Serine/threonine-protein kinase mTOR inhibitor | 8 | 0.217374906 | 0.245949351 | 1736.980676 | 35 | 0.000312811 | 3 | 3 | 9 | 0.178578806 | 0.192545925 | 0 | 35 | 0.000172306 | 1 | 1 | ||
| OMIPALISIB | predicted | Mammalian target of Rapamycin (mTORC1) | Homo sapiens | 7.858109562 | 3.574328687 | 9.74 | 1 | 1 | 1 | 1 | IDIOPATHIC PULMONARY FIBROSIS, NEOPLASM | PI3-kinase class I inhibitor, Serine/threonine-protein kinase mTOR inhibitor | 8 | 0.217374906 | 0.245949351 | 1736.980676 | 35 | 0.000312811 | 3 | 3 | 9 | 0.178578806 | 0.192545925 | 0 | 35 | 0.000172306 | 1 | 1 | ||
| FIPAMEZOLE | predicted | Alpha-2a adrenergic receptor | Homo sapiens | 7.680842059 | 3.042526176 | 8.14 | 1 | 1 | 1 | 1 | PARKINSON'S DISEASE | unknown | 6 | 0.287304752 | 0.316396761 | 9934.046794 | 0 | 0.002098773 | 36 | 36 | 7 | 0.225718016 | 0.238763117 | 2.197540481 | 0 | 0.000226315 | 3 | 3 | ||
| FIPAMEZOLE | predicted | Alpha-2c adrenergic receptor | Homo sapiens | 7.333333333 | 2 | 7.86 | 1 | 1 | 1 | 1 | PARKINSON'S DISEASE | unknown | 6 | 0.279321486 | 0.302544824 | 2596.316271 | 0 | 0.001323976 | 24 | 24 | 7 | 0.225718016 | 0.238763117 | 2.197540481 | 0 | 0.000226315 | 3 | 3 | ||
| TIVOZANIB | predicted | Vascular endothelial growth factor receptor 3 | Homo sapiens | 7.768455051 | 3.305365152 | 9.065 | 1 | 1 | 1 | 2 | COLORECTAL ADENOCARCINOMA, GLIOBLASTOMA MULTIFORME, HEPATOCELLULAR CARCINOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, RENAL CELL CARCINOMA, SARCOMA | Vascular endothelial growth factor receptor inhibitor | 7 | 0.291666667 | 0.329145666 | 1284.365223 | 35 | 0.000541215 | 13 | 13 | 8 | 0.227022059 | 0.243664794 | 9.200235002 | 35 | 0.000218485 | 3 | 3 | ||
| ALISPORIVIR | predicted | Cyclophilin A | Homo sapiens | 8.033875064 | 4.101625193 | 7.812017039 | 1 | 1 | 1 | 4 | CHRONIC HEPATITIS C INFECTION, CHRONIC KIDNEY DISEASE, HEPATITIS C INFECTION, LIVER DISEASE | unknown | 8 | 0.229920213 | 0.240721997 | 5.359920888 | 3 | 0.000250149 | 2 | 2 | 7 | 0.258832335 | 0.281306288 | 1207.452082 | 3 | 0.000516385 | 5 | 5 | ||
| ALISPORIVIR | predicted | Cyclophilin B | Homo sapiens | 8.043525604 | 4.130576812 | 9 | 1 | 1 | 1 | 1 | CHRONIC HEPATITIS C INFECTION, CHRONIC KIDNEY DISEASE, HEPATITIS C INFECTION, LIVER DISEASE | unknown | 8 | 0.229920213 | 0.240721997 | 5.359920888 | 3 | 0.000250149 | 2 | 2 | 7 | 0.258832335 | 0.281306288 | 1207.452082 | 3 | 0.000516385 | 5 | 5 | ||
| ALECTINIB | predicted | ALK tyrosine kinase receptor | Homo sapiens | 7.544275114 | 2.632825343 | 8.72 | 1 | 1 | 1 | 1 | LIVER DISEASE, NON-SMALL CELL LUNG CARCINOMA | unknown | 7 | 0.271428571 | 0.309646369 | 368.2221356 | 35 | 0.000322417 | 6 | 6 | 7 | 0.233207445 | 0.25015974 | 5.036206023 | 35 | 0.000203932 | 3 | 3 | ||
| Relugolix | predicted | Gonadotropin-releasing hormone receptor | Rattus norvegicus | 7.762694614 | 3.288083843 | 9.49 | 1 | 1 | 1 | 2 | ENDOMETRIOSIS, PROSTATE CARCINOMA, UTERINE FIBROID | Gonadotropin-releasing hormone receptor antagonist | 8 | 0.226249673 | 0.24017117 | 6906 | 17 | 0.001040428 | 5 | 5 | 9 | 0.18452508 | 0.191721061 | 0 | 17 | 0.000260568 | 1 | 1 | ||
| SELEPRESSIN | predicted | Vasopressin V1a receptor | Homo sapiens | 7.586115636 | 2.758346907 | 8.62 | 1 | 1 | 1 | 2 | SEPTIC SHOCK | Vasopressin V1a receptor agonist | 7 | 0.245736214 | 0.257741882 | 3265.002883 | 7 | 0.000704922 | 6 | 6 | 8 | 0.201327434 | 0.207902999 | 11.81304087 | 7 | 0.000297781 | 2 | 2 | ||
| SELEPRESSIN | predicted | Vasopressin V1a receptor | Rattus norvegicus | 7.586115636 | 2.758346907 | 9.26 | 1 | 1 | 1 | 2 | SEPTIC SHOCK | Vasopressin V1a receptor agonist | 7 | 0.245736214 | 0.257741882 | 3265.002883 | 7 | 0.000704922 | 6 | 6 | 8 | 0.201327434 | 0.207902999 | 11.81304087 | 7 | 0.000297781 | 2 | 2 | ||
| SOMATOSTATIN | predicted | Mu opioid receptor | Rattus norvegicus | 8.703132137 | 6.109396411 | 8.22 | 1 | 1 | 1 | 1 | CIRRHOSIS OF LIVER, GASTRIC CARCINOMA, KIDNEY DISEASE, PROSTATE ADENOCARCINOMA | unknown | 7 | 0.282978723 | 0.306280812 | 10082.87955 | 0 | 0.00121941 | 17 | 17 | 7 | 0.223500517 | 0.236165964 | 8637.526673 | 37 | 0.001130778 | 8 | 8 | ||
| SOMATOSTATIN | predicted | Somatostatin receptor 2 | Mus musculus | 8.496589933 | 5.4897698 | 9.55 | 1 | 1 | 1 | 1 | CIRRHOSIS OF LIVER, GASTRIC CARCINOMA, KIDNEY DISEASE, PROSTATE ADENOCARCINOMA | unknown | 8 | 0.182730924 | 0.189351814 | 31.27369292 | 37 | 0.000341269 | 2 | 2 | 7 | 0.223500517 | 0.236165964 | 8637.526673 | 37 | 0.001130778 | 8 | 8 | ||
| SOMATOSTATIN | predicted | Somatostatin receptor 3 | Mus musculus | 8.496589933 | 5.4897698 | 10.1 | 1 | 1 | 1 | 1 | CIRRHOSIS OF LIVER, GASTRIC CARCINOMA, KIDNEY DISEASE, PROSTATE ADENOCARCINOMA | unknown | 8 | 0.182730924 | 0.189351814 | 31.27369292 | 37 | 0.000341269 | 2 | 2 | 7 | 0.223500517 | 0.236165964 | 8637.526673 | 37 | 0.001130778 | 8 | 8 | ||
| SOMATOSTATIN | predicted | Somatostatin receptor 5 | Rattus norvegicus | 8.496589933 | 5.4897698 | 9.07 | 1 | 1 | 1 | 1 | CIRRHOSIS OF LIVER, GASTRIC CARCINOMA, KIDNEY DISEASE, PROSTATE ADENOCARCINOMA | unknown | 8 | 0.236654804 | 0.251425266 | 2145.579483 | 37 | 0.000392343 | 3 | 3 | 7 | 0.223500517 | 0.236165964 | 8637.526673 | 37 | 0.001130778 | 8 | 8 | ||
| SOMATOSTATIN | predicted | Somatostatin receptor 2 | Homo sapiens | 8.493171705 | 5.479515114 | 9.919683078 | 1 | 1 | 1 | 13 | CIRRHOSIS OF LIVER, GASTRIC CARCINOMA, KIDNEY DISEASE, PROSTATE ADENOCARCINOMA | unknown | 8 | 0.182730924 | 0.189351814 | 31.27369292 | 37 | 0.000341269 | 2 | 2 | 7 | 0.223500517 | 0.236165964 | 8637.526673 | 37 | 0.001130778 | 8 | 8 | ||
| SOMATOSTATIN | predicted | Somatostatin receptor 3 | Homo sapiens | 8.496690975 | 5.490072926 | 8.818333333 | 1 | 1 | 1 | 12 | CIRRHOSIS OF LIVER, GASTRIC CARCINOMA, KIDNEY DISEASE, PROSTATE ADENOCARCINOMA | unknown | 8 | 0.182730924 | 0.189351814 | 31.27369292 | 37 | 0.000341269 | 2 | 2 | 7 | 0.223500517 | 0.236165964 | 8637.526673 | 37 | 0.001130778 | 8 | 8 | ||
| SOMATOSTATIN | predicted | Somatostatin receptor 5 | Homo sapiens | 8.518040495 | 5.554121486 | 9.122210487 | 1 | 1 | 1 | 18 | CIRRHOSIS OF LIVER, GASTRIC CARCINOMA, KIDNEY DISEASE, PROSTATE ADENOCARCINOMA | unknown | 8 | 0.236654804 | 0.251425266 | 2145.579483 | 37 | 0.000392343 | 3 | 3 | 7 | 0.223500517 | 0.236165964 | 8637.526673 | 37 | 0.001130778 | 8 | 8 | ||
| IBRUTINIB | predicted | Tyrosine-protein kinase BMX | Homo sapiens | 7.663451608 | 2.990354825 | 9.1 | 1 | 1 | 1 | 1 | ACUTE GRAFT VS. HOST DISEASE, ACUTE MYELOID LEUKEMIA, CARCINOID TUMOR, CHRONIC LYMPHOCYTIC LEUKEMIA, HODGKINS LYMPHOMA, LEUKEMIA, LIVER DISEASE, LUNG CARCINOMA, LYMPHOID LEUKEMIA, LYMPHOMA, MACROGLOBULINEMIA, MANTLE CELL LYMPHOMA, MULTIPLE MYELOMA, NEOPLASM, NEOPLASM OF MATURE B-CELLS, NON-HODGKINS LYMPHOMA, PROSTATE CARCINOMA, T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Tyrosine-protein kinase BTK inhibitor | 6 | 0.288744155 | 0.324416811 | 381.6415807 | 35 | 0.00033432 | 7 | 7 | 7 | 0.247353362 | 0.264281583 | 39.08774635 | 35 | 0.000285948 | 5 | 5 | ||
| IVACAFTOR | predicted | Cystic fibrosis transmembrane conductance regulator | Homo sapiens | 7.577754356 | 2.733263067 | 7.592 | 1 | 1 | 1 | 5 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CYSTIC FIBROSIS | Cystic fibrosis transmembrane conductance regulator positive modulator | 1 | 1 | 1 | 1 | 40 | 0.000814229 | 2 | 2 | 2 | 0.666666667 | 0.75 | 0 | 40 | 0.000429939 | 1 | 1 | ||
| EVACETRAPIB | predicted | Cholesteryl ester transfer protein | Homo sapiens | 7.557904357 | 2.67371307 | 7.59 | 1 | 1 | 1 | 1 | CARDIOVASCULAR DISEASE, DISORDER OF LIPID METABOLISM, HYPERCHOLESTEROLEMIA | unknown | 1 | 1 | 1 | 0 | 39 | 0.000558036 | 1 | 1 | 1 | 1 | 1 | 0 | 39 | 0.000558036 | 1 | 1 | ||
| CARIPRAZINE HYDROCHLORIDE | predicted | Dopamine D3 receptor | Rattus norvegicus | 7.794900717 | 3.384702152 | 8.8 | 1 | 1 | 1 | 1 | BIPOLAR DISORDER, SCHIZOPHRENIA | Dopamine D2 receptor modulator, Dopamine D3 receptor modulator | 6 | 0.28961474 | 0.320946597 | 9204.657659 | 0 | 0.002356341 | 42 | 42 | 7 | 0.229128015 | 0.24431959 | 8.075080837 | 0 | 0.000232951 | 3 | 3 | ||
| CARIPRAZINE HYDROCHLORIDE | predicted | Dopamine D2 receptor | Rattus norvegicus | 7.845844525 | 3.537533574 | 7.8 | 1 | 1 | 1 | 1 | BIPOLAR DISORDER, SCHIZOPHRENIA | Dopamine D2 receptor modulator, Dopamine D3 receptor modulator | 6 | 0.2855963 | 0.314121843 | 9635.285337 | 0 | 0.002095645 | 35 | 35 | 7 | 0.229128015 | 0.24431959 | 8.075080837 | 0 | 0.000232951 | 3 | 3 | ||
| CARIPRAZINE HYDROCHLORIDE | predicted | Dopamine D3 receptor | Homo sapiens | 7.794900717 | 3.384702152 | 10.05 | 1 | 1 | 1 | 1 | BIPOLAR DISORDER, SCHIZOPHRENIA | Dopamine D2 receptor modulator, Dopamine D3 receptor modulator | 6 | 0.28961474 | 0.320946597 | 9204.657659 | 0 | 0.002356341 | 42 | 42 | 7 | 0.229128015 | 0.24431959 | 8.075080837 | 0 | 0.000232951 | 3 | 3 | ||
| CARIPRAZINE HYDROCHLORIDE | predicted | Dopamine D2 receptor | Homo sapiens | 7.794900717 | 3.384702152 | 8.665 | 1 | 1 | 1 | 2 | BIPOLAR DISORDER, SCHIZOPHRENIA | Dopamine D2 receptor modulator, Dopamine D3 receptor modulator | 6 | 0.2855963 | 0.314121843 | 9635.285337 | 0 | 0.002095645 | 35 | 35 | 7 | 0.229128015 | 0.24431959 | 8.075080837 | 0 | 0.000232951 | 3 | 3 | ||
| CARIPRAZINE | predicted | Serotonin 2a (5-HT2a) receptor | Homo sapiens | 8.092823065 | 4.278469196 | 7.66 | 1 | 1 | 1 | 1 | BIPOLAR DISORDER, PSYCHOSIS, SCHIZOPHRENIA, UNIPOLAR DEPRESSION | unknown | 6 | 0.305153547 | 0.341170233 | 14148.52943 | 0 | 0.002040502 | 36 | 36 | 7 | 0.242632613 | 0.26004985 | 12.62605456 | 0 | 0.000230235 | 3 | 3 | ||
| BREMELANOTIDE | predicted | Melanocortin receptor 5 | Homo sapiens | 8.185237798 | 4.555713393 | 7.77 | 1 | 1 | 1 | 1 | SEXUAL DYSFUNCTION | Melanocortin receptor 1 agonist, Melanocortin receptor 3 agonist, Melanocortin receptor 4 agonist | 7 | 0.255466903 | 0.270263571 | 1109.932089 | 0 | 0.000309373 | 3 | 3 | 8 | 0.211524345 | 0.219652841 | 1729.654373 | 0 | 0.000423786 | 3 | 3 | ||
| BREMELANOTIDE | predicted | Melanocortin receptor 4 | Homo sapiens | 7.896563971 | 3.689691914 | 9.65 | 1 | 1 | 1 | 2 | SEXUAL DYSFUNCTION | Melanocortin receptor 1 agonist, Melanocortin receptor 3 agonist, Melanocortin receptor 4 agonist | 7 | 0.268062016 | 0.284331708 | 4202.48789 | 0 | 0.000559377 | 6 | 6 | 8 | 0.211524345 | 0.219652841 | 1729.654373 | 0 | 0.000423786 | 3 | 3 | ||
| COSYNTROPIN | predicted | Melanocortin receptor 4 | Homo sapiens | 8.52278396 | 5.568351881 | 9.19 | 1 | 1 | 1 | 1 | ADRENAL GLAND DISEASE | Melanocortin receptor 2 agonist | 7 | 0.268062016 | 0.284331708 | 4202.48789 | 0 | 0.000559377 | 6 | 6 | 8 | 0.211420885 | 0.218881682 | 0 | 0 | 0.000162935 | 1 | 1 | ||
| GANETESPIB | predicted | Heat shock protein HSP 90-alpha | Homo sapiens | 7.535422195 | 2.606266584 | 8.3 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, COLORECTAL ADENOCARCINOMA, GASTROINTESTINAL STROMAL TUMOR, HEPATOCELLULAR CARCINOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, SMALL CELL LUNG CARCINOMA | unknown | 7 | 0.266245765 | 0.284776502 | 2327.470302 | 4 | 0.000615011 | 7 | 7 | 8 | 0.210340633 | 0.219143325 | 38.92691675 | 4 | 0.000276864 | 2 | 2 | ||
| GANETESPIB | predicted | Heat shock protein HSP 90-beta | Homo sapiens | 7.535422195 | 2.606266584 | 8.3 | 1 | 1 | 1 | 1 | BREAST CARCINOMA, COLORECTAL ADENOCARCINOMA, GASTROINTESTINAL STROMAL TUMOR, HEPATOCELLULAR CARCINOMA, MALIGNANT PLEURAL MESOTHELIOMA, MELANOMA, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, SMALL CELL LUNG CARCINOMA | unknown | 8 | 0.232580038 | 0.243478201 | 182.9090368 | 4 | 0.000278847 | 2 | 2 | 8 | 0.210340633 | 0.219143325 | 38.92691675 | 4 | 0.000276864 | 2 | 2 | ||
| CERLAPIRDINE | predicted | Serotonin 6 (5-HT6) receptor | Homo sapiens | 8.03337132 | 4.100113961 | 8.89 | 1 | 1 | 1 | 1 | ALZHEIMERS DISEASE | Serotonin 6 (5-HT6) receptor antagonist | 6 | 0.306234502 | 0.3399171 | 12310.50404 | 0 | 0.001709791 | 28 | 28 | 7 | 0.234472471 | 0.247945413 | 0 | 0 | 0.000135595 | 1 | 1 | ||
| ORVEPITANT | predicted | Substance-P receptor | Meriones unguiculatus | 7.543755487 | 2.631266462 | 10.5 | 1 | 1 | 1 | 1 | POST-TRAUMATIC STRESS DISORDER, UNIPOLAR DEPRESSION | Neurokinin 1 receptor antagonist | 2 | 0.666666667 | 0.75 | 0 | 41 | 0.000429939 | 1 | 1 | 1 | 1 | 1 | 1 | 41 | 0.000814229 | 2 | 2 | ||
| COBIMETINIB | predicted | Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens | 7.467711133 | 2.403133398 | 8.715 | 1 | 1 | 1 | 2 | ACUTE MYELOID LEUKEMIA, NEOPLASM | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor, Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | 6 | 0.290198053 | 0.326739927 | 2976.33696 | 35 | 0.000533093 | 10 | 10 | 7 | 0.224954463 | 0.240664849 | 0 | 35 | 0.00012899 | 1 | 1 | ||
| IDALOPIRDINE | predicted | Serotonin 6 (5-HT6) receptor | Homo sapiens | 8.024335905 | 4.073007714 | 9.08 | 1 | 1 | 1 | 3 | ALZHEIMERS DISEASE | Serotonin 6 (5-HT6) receptor antagonist | 6 | 0.306234502 | 0.3399171 | 12310.50404 | 0 | 0.001709791 | 28 | 28 | 7 | 0.234472471 | 0.247945413 | 0 | 0 | 0.000135595 | 1 | 1 | ||
| GILTERITINIB | predicted | Tyrosine-protein kinase receptor FLT3 | Homo sapiens | 7.721027784 | 3.163083351 | 9.39 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, LIVER DISEASE, NEOPLASM | Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor UFO inhibitor | 7 | 0.276109869 | 0.316009805 | 1180.098712 | 35 | 0.000588806 | 14 | 14 | 8 | 0.222809278 | 0.240958853 | 1.086947243 | 35 | 0.000197294 | 3 | 3 | ||
| GILTERITINIB | predicted | Tyrosine-protein kinase receptor RET | Homo sapiens | 7.556255464 | 2.668766391 | 8.47 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, LIVER DISEASE, NEOPLASM | Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor UFO inhibitor | 7 | 0.283814839 | 0.324580682 | 2421.142611 | 35 | 0.00074186 | 18 | 18 | 8 | 0.222809278 | 0.240958853 | 1.086947243 | 35 | 0.000197294 | 3 | 3 | ||
| GILTERITINIB | predicted | Proto-oncogene tyrosine-protein kinase ROS | Homo sapiens | 7.556255464 | 2.668766391 | 8.72 | 1 | 1 | 1 | 1 | ACUTE MYELOID LEUKEMIA, LIVER DISEASE, NEOPLASM | Tyrosine-protein kinase receptor FLT3 inhibitor, Tyrosine-protein kinase receptor UFO inhibitor | 7 | 0.272112055 | 0.310147622 | 439.7824862 | 35 | 0.000302779 | 6 | 6 | 8 | 0.222809278 | 0.240958853 | 1.086947243 | 35 | 0.000197294 | 3 | 3 | ||
| TIOTROPIUM BROMIDE | predicted | Muscarinic acetylcholine receptor M2 | Rattus norvegicus | 7.512499989 | 2.537499967 | 9.82 | 1 | 1 | 1 | 1 | ASTHMA, CHRONIC BRONCHITIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CYSTIC FIBROSIS, EMPHYSEMA, OBSTRUCTIVE LUNG DISEASE | Muscarinic acetylcholine receptor M3 antagonist | 6 | 0.279141104 | 0.301821862 | 2744.829815 | 0 | 0.001203924 | 21 | 21 | 7 | 0.225541351 | 0.239178991 | 8.211800515 | 0 | 0.000324407 | 5 | 5 | ||
| DOCETAXEL HYDRATE | actual | 8.472693473 | Y | Growth hormone-releasing hormone receptor | Homo sapiens | 9.490897824 | 8.472693473 | 9.85 | 1 | 1 | 1 | 1 | BLADDER CARCINOMA, BREAST CARCINOMA, BREAST NEOPLASM, CANCER, CARCINOMA, ESOPHAGEAL CARCINOMA, GASTRIC ADENOCARCINOMA, GASTRIC CARCINOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LEUKEMIA, LUNG CARCINOMA, NASOPHARYNGEAL NEOPLASM, NEOPLASM, NON-SMALL CELL LUNG CARCINOMA, OVARIAN CARCINOMA, PANCREATIC CARCINOMA, PROSTATE ADENOCARCINOMA, PROSTATE CARCINOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL LUNG CARCINOMA, STOMACH NEOPLASM, UPPER AERODIGESTIVE TRACT NEOPLASM | Tubulin inhibitor | 8 | 0.200859665 | 0.209152689 | 0 | 3 | 0.000171695 | 1 | 1 | 7 | 0.25130814 | 0.268042359 | 1781.071512 | 3 | 0.00041399 | 4 | 4 |
Using graphs to monitor target relevance and drugs specificity.
Data can be re-shaped in a graph mode so that we can explore the relationships with molecules and targets. By calculating centrality measures we can better understand the importance of protein nodes and the promiscuity of drug nodes. The graph below shows all drug-target identified relations. It is interesting to see how the graph clearly identifies a non specific promiscuous kinase inhibitors cluster with big drug nodes (lestaurtinib, selumetinib, enzastaurin and others) connecting with many protein targets.
All relevant drug-target relations sized by degree.
Now we can query the graph by centrality cut-off centrality (left), exclude targets containing only actual records (middle) or select only targets that have only predicted records (right).
Selection of higher degree nodes.
In this graph, protein nodes lacking of predicted values have been removed.
Selection of targets interacting only with drugs with predicted activity.
Relationships can also be clustered to detect populations. The graph below shows the four main modules detected by modularity classification.
- Module 35 corresponds to kinases targets related to promiscuous kinase inhibitors.
- Module 5 is enriched in nuclear receptors.
- Module 0 is basically made up by classic GPCR targets and their drugs.
- Module 3 has a strong component of transporters.
P53 drug-targets graph segmentation.
Each cluster can be analyzed separately with an individualized layout.
Module 35: Kinases and promiscuous kinase inhibitors.
Module 4: Nuclear receptors enriched fraction.
Module 0: GPCR drugs and targets.
Module 3: transporters.
Now we can use degree or any other centrality measure to select potent targets with many interactions with drugs with few interactions. The two charts below show targets interacting with more than 6 molecules (up to 147), but each of these molecules having less than 5 positive records of positive interaction. There is one chart for each, actual or predicted P53 scores.
Drugs with good actual P53 potency and centrality measures for target and molecule.
Drugs with good predicted P53 potency and centrality measures for target and molecule.
And we can use a treemap to check how the drugs and their actual or predicted P53 potency fit in the respective clinical pipelines…
Drugs for repurposing from actual P53 scores.
Drugs for repurposing from predicted P53 scores.
Drug-target interactions filtered by centrality measures.
| molName | proteinNameC | organismC | kindOfValue | p53ActivityScoreActual | p53ActiveActual | avgPredIndex | AvgPrediction80RFRegression | AvgChemblActivityScoreC | countRatioRpart | countRatioRF | countRatioAvgRpartRF | CountChemblActivityScoreC | degreeProtein | degreeMolName |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALECTINIB | ALK tyrosine kinase receptor | Homo sapiens | predicted | 7.544275114 | 2.632825343 | 8.72 | 1 | 1 | 1 | 1 | 6 | 3 | ||
| BREMELANOTIDE | Melanocortin receptor 4 | Homo sapiens | predicted | 7.896563971 | 3.689691914 | 9.65 | 1 | 1 | 1 | 2 | 6 | 3 | ||
| COSYNTROPIN | Melanocortin receptor 4 | Homo sapiens | predicted | 8.52278396 | 5.568351881 | 9.19 | 1 | 1 | 1 | 1 | 6 | 1 | ||
| DOCETAXEL HYDRATE | Tubulin | Bos taurus | actual | 8.472693473 | Y | 9.490897824 | 8.472693473 | 5.951771244 | 1 | 1 | 1 | 9 | 6 | 4 |
| GILTERITINIB | Proto-oncogene tyrosine-protein kinase ROS | Homo sapiens | predicted | 7.556255464 | 2.668766391 | 8.72 | 1 | 1 | 1 | 1 | 6 | 3 | ||
| PANOBINOSTAT | Histone deacetylase | Plasmodium falciparum | predicted | 7.696529598 | 3.089588793 | 8.74 | 1 | 1 | 1 | 1 | 6 | 2 | ||
| SELEPRESSIN | Vasopressin V1a receptor | Homo sapiens | predicted | 7.586115636 | 2.758346907 | 8.62 | 1 | 1 | 1 | 2 | 6 | 2 | ||
| SELEPRESSIN | Vasopressin V1a receptor | Rattus norvegicus | predicted | 7.586115636 | 2.758346907 | 9.26 | 1 | 1 | 1 | 2 | 6 | 2 | ||
| TOLVAPTAN | Vasopressin V2 receptor | Homo sapiens | predicted | 7.543755487 | 2.631266462 | 9.37 | 1 | 1 | 1 | 1 | 6 | 1 | ||
| VASOPRESSIN | Vasopressin V2 receptor | Sus scrofa | predicted | 8.312844996 | 4.938534989 | 8.48 | 1 | 1 | 1 | 1 | 6 | 4 | ||
| VASOPRESSIN | Vasopressin V2 receptor | Rattus norvegicus | predicted | 8.035324313 | 4.105972939 | 9.221616674 | 1 | 1 | 1 | 3 | 6 | 4 | ||
| VASOPRESSIN | Vasopressin V2 receptor | Bos taurus | predicted | 8.207012307 | 4.621036921 | 8.82 | 1 | 1 | 1 | 1 | 6 | 4 | ||
| VASOPRESSIN | Vasopressin V1a receptor | Rattus norvegicus | predicted | 8.000986714 | 4.002960143 | 9.508 | 1 | 1 | 1 | 5 | 6 | 4 | ||
| VASOPRESSIN | Vasopressin V2 receptor | Homo sapiens | predicted | 7.99762736 | 3.99288208 | 9.328622445 | 1 | 1 | 1 | 9 | 6 | 4 | ||
| VASOPRESSIN | Vasopressin V1a receptor | Homo sapiens | predicted | 7.864291535 | 4.307160319 | 8.657857143 | 1 | 0.928571429 | 0.964285714 | 14 | 6 | 4 | ||
| GANETESPIB | Heat shock protein HSP 90-alpha | Homo sapiens | predicted | 7.535422195 | 2.606266584 | 8.3 | 1 | 1 | 1 | 1 | 7 | 2 | ||
| INSULIN HUMAN | Insulin receptor | Rattus norvegicus | predicted | 8.469420822 | 5.408262465 | 8.725 | 1 | 1 | 1 | 2 | 7 | 1 | ||
| LASOFOXIFENE | Estrogen receptor beta | Homo sapiens | predicted | 8.239586668 | 4.718760003 | 8.2475 | 1 | 1 | 1 | 4 | 7 | 3 | ||
| TORSEMIDE | TAR DNA-binding protein 43 | Homo sapiens | actual | 5.244666445 | Y | 5.081555482 | 3.622333222 | 6.250031916 | 0 | 1 | 0.5 | 1 | 8 | 4 |
| IRBESARTAN | Angiotensin II receptor | Homo sapiens | predicted | 7.880839757 | 3.642519272 | 8.52 | 1 | 1 | 1 | 2 | 9 | 3 | ||
| LOSARTAN POTASSIUM | Angiotensin II receptor | Homo sapiens | predicted | 8.128041094 | 4.384123281 | 8.52 | 1 | 1 | 1 | 2 | 9 | 2 | ||
| NILVADIPINE | Voltage-gated L-type calcium channel | Rattus norvegicus | predicted | 7.848322329 | 3.544966987 | 8.98 | 1 | 1 | 1 | 3 | 9 | 1 | ||
| TASOSARTAN | Angiotensin II receptor | Homo sapiens | predicted | 7.618339973 | 2.855019918 | 8.4 | 1 | 1 | 1 | 2 | 9 | 2 | ||
| COBIMETINIB | Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens | predicted | 7.467711133 | 2.403133398 | 8.715 | 1 | 1 | 1 | 2 | 10 | 1 | ||
| DONEPEZIL HYDROCHLORIDE | Acetylcholinesterase | Torpedo californica | predicted | 7.572922134 | 2.718766402 | 8.24 | 1 | 1 | 1 | 1 | 12 | 1 | ||
| NORETHINDRONE | Estrogen receptor | Rattus norvegicus | predicted | 7.793755474 | 3.381266422 | 9.2 | 1 | 1 | 1 | 1 | 12 | 4 | ||
| TIVOZANIB | Vascular endothelial growth factor receptor 3 | Homo sapiens | predicted | 7.768455051 | 3.305365152 | 9.065 | 1 | 1 | 1 | 2 | 13 | 3 | ||
| GILTERITINIB | Tyrosine-protein kinase receptor FLT3 | Homo sapiens | predicted | 7.721027784 | 3.163083351 | 9.39 | 1 | 1 | 1 | 1 | 14 | 3 | ||
| DEXMEDETOMIDINE | Adrenergic receptor alpha-2 | Rattus norvegicus | predicted | 7.543755487 | 2.631266462 | 10.82 | 1 | 1 | 1 | 3 | 15 | 4 | ||
| DOCETAXEL HYDRATE | Neurokinin 2 receptor | Homo sapiens | actual | 8.472693473 | Y | 9.490897824 | 8.472693473 | 6.045 | 1 | 1 | 1 | 2 | 15 | 4 |
| ASIMADOLINE | Kappa opioid receptor | Homo sapiens | predicted | 7.717965377 | 3.15389613 | 9.3 | 1 | 1 | 1 | 1 | 16 | 1 | ||
| ALFENTANIL HYDROCHLORIDE | Mu opioid receptor | Homo sapiens | actual | 6.622147581 | Y | 2.207382527 | 4.31107379 | 6.11 | 0 | 0 | 0 | 1 | 17 | 1 |
| ROPINIROLE | Dopamine D4 receptor | Homo sapiens | predicted | 7.333333333 | 2 | 8.11 | 1 | 1 | 1 | 1 | 17 | 4 | ||
| GILTERITINIB | Tyrosine-protein kinase receptor RET | Homo sapiens | predicted | 7.556255464 | 2.668766391 | 8.47 | 1 | 1 | 1 | 1 | 18 | 3 | ||
| ROSIGLITAZONE MALEATE | Peroxisome proliferator-activated receptor gamma | Homo sapiens | actual | 5.61640004 | Y | 8.538800013 | 4.875065606 | 6.953333333 | 1 | 1 | 1 | 3 | 18 | 3 |
| TORSEMIDE | DNA-(apurinic or apyrimidinic site) lyase | Homo sapiens | actual | 5.244666445 | Y | 5.081555482 | 4.793499862 | 8.102372909 | 0 | 1 | 0.5 | 1 | 18 | 4 |
| TRIFLUPERIDOL | Sigma opioid receptor | Homo sapiens | predicted | 7.762511039 | 3.287533116 | 9.08 | 1 | 1 | 1 | 1 | 18 | 3 | ||
| TRIFLUPERIDOL | Sigma opioid receptor | Rattus norvegicus | predicted | 7.762511039 | 3.287533116 | 9.1 | 1 | 1 | 1 | 1 | 18 | 3 | ||
| DEXMEDETOMIDINE | Adrenergic receptor alpha-1 | Rattus norvegicus | predicted | 7.750010938 | 3.250032813 | 8.3 | 1 | 1 | 1 | 3 | 20 | 4 | ||
| NORETHINDRONE | Progesterone receptor | Bos taurus | predicted | 8.132258151 | 4.396774452 | 8.47 | 1 | 1 | 1 | 2 | 21 | 4 | ||
| TARANABANT | Cytochrome P450 2D6 | Homo sapiens | predicted | 7.791048642 | 3.373145927 | 9.23 | 1 | 1 | 1 | 1 | 22 | 4 | ||
| DECITABINE | ATPase family AAA domain-containing protein 5 | Homo sapiens | actual | 6.625068446 | Y | 5.541689482 | 5.216464815 | 6.236422276 | 0 | 1 | 0.5 | 1 | 26 | 2 |
| CERLAPIRDINE | Serotonin 6 (5-HT6) receptor | Homo sapiens | predicted | 8.03337132 | 4.100113961 | 8.89 | 1 | 1 | 1 | 1 | 28 | 1 | ||
| IDALOPIRDINE | Serotonin 6 (5-HT6) receptor | Homo sapiens | predicted | 8.024335905 | 4.073007714 | 9.08 | 1 | 1 | 1 | 3 | 28 | 1 | ||
| TARANABANT | Cytochrome P450 2C9 | Homo sapiens | predicted | 7.791048642 | 3.373145927 | 9.03 | 1 | 1 | 1 | 1 | 28 | 4 | ||
| CINCHOPHEN | Glucocorticoid receptor | Homo sapiens | actual | 5.863755198 | Y | 8.621251733 | 3.931877599 | 7.850780887 | 1 | 1 | 1 | 1 | 30 | 3 |
| CARIPRAZINE HYDROCHLORIDE | Dopamine D2 receptor | Homo sapiens | predicted | 7.794900717 | 3.384702152 | 8.665 | 1 | 1 | 1 | 2 | 35 | 3 | ||
| CLOTHIAPINE | Dopamine D2 receptor | Homo sapiens | predicted | 7.333333333 | 2 | 9.31 | 1 | 1 | 1 | 1 | 35 | 3 | ||
| ECOPIPAM | Dopamine D2 receptor | Homo sapiens | actual | 5.925073903 | Y | 8.641691301 | 5.925073903 | 6.01 | 1 | 1 | 1 | 2 | 35 | 4 |
| ECOPIPAM | Dopamine D2 receptor | Rattus norvegicus | actual | 5.925073903 | Y | 8.641691301 | 5.333994084 | 6.29 | 1 | 1 | 1 | 1 | 35 | 4 |
| CABERGOLINE | Serotonin 2b (5-HT2b) receptor | Homo sapiens | actual | 5.525070214 | Y | 6.841690071 | 3.519012717 | 8.37 | 1 | 0.5 | 0.75 | 2 | 38 | 1 |
| HYDROFLUMETHIAZIDE | Nuclear factor NF-kappa-B p105 subunit | Homo sapiens | actual | 5.644663438 | Y | 8.548221146 | 5.399338268 | 7.271646218 | 1 | 1 | 1 | 1 | 38 | 4 |
| HYDROFLUMETHIAZIDE | Nuclear factor NF-kappa-B p105 subunit | Homo sapiens | actual | 5.644663438 | Y | 8.548221146 | 5.399338268 | 7.271646218 | 1 | 1 | 1 | 1 | 38 | 4 |
| ECOPIPAM | Dopamine D1 receptor | Rattus norvegicus | actual | 5.925073903 | Y | 8.641691301 | 5.156303352 | 8.72 | 1 | 1 | 1 | 1 | 39 | 4 |
| ECOPIPAM | Dopamine D1 receptor | Homo sapiens | actual | 5.925073903 | Y | 8.641691301 | 5.834448372 | 8.82 | 1 | 1 | 1 | 4 | 39 | 4 |
| CARIPRAZINE HYDROCHLORIDE | Dopamine D3 receptor | Rattus norvegicus | predicted | 7.794900717 | 3.384702152 | 8.8 | 1 | 1 | 1 | 1 | 42 | 3 | ||
| CARIPRAZINE HYDROCHLORIDE | Dopamine D3 receptor | Homo sapiens | predicted | 7.794900717 | 3.384702152 | 10.05 | 1 | 1 | 1 | 1 | 42 | 3 | ||
| VINORELBIN DITARTRATE | Proto-oncogene c-JUN | Homo sapiens | actual | 6.97510404 | Y | 8.991701347 | 7.051750965 | 6.971428747 | 1 | 1 | 1 | 1 | 45 | 3 |
| HYDROFLUMETHIAZIDE | Prelamin-A/C | Homo sapiens | actual | 5.644663438 | Y | 5.214887813 | 4.505943059 | 6 | 0 | 1 | 0.5 | 1 | 46 | 4 |
| VINCAMINE | Solute carrier organic anion transporter family member 1B3 | Homo sapiens | actual | 5.494407437 | Y | 5.164802479 | 3.662606159 | 5.902575883 | 0 | 1 | 0.5 | 1 | 59 | 3 |
| CINCHOPHEN | Peroxisome proliferator-activated receptor delta | Homo sapiens | actual | 5.863755198 | Y | 8.621251733 | 4.689847029 | 6.177182204 | 1 | 1 | 1 | 2 | 68 | 3 |
| MYCOPHENOLATE MOFETIL | Peroxisome proliferator-activated receptor delta | Homo sapiens | actual | 6.97510404 | Y | 8.991701347 | 5.632572828 | 6.125112489 | 1 | 1 | 1 | 1 | 68 | 3 |
| DECITABINE | Geminin | Homo sapiens | actual | 6.625068446 | Y | 5.541689482 | 5.216464815 | 6.636200055 | 0 | 1 | 0.5 | 1 | 75 | 2 |
| PHENSUXIMIDE | Geminin | Homo sapiens | actual | 6.225045311 | Y | 2.075015104 | 3.32032666 | 6.886056648 | 0 | 0 | 0 | 1 | 75 | |
| CLOFARABINE | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | actual | 7.075204004 | Y | 9.025068001 | 5.806403003 | 5.775104529 | 1 | 1 | 1 | 1 | 82 | 1 |
| MYCOPHENOLATE MOFETIL | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | actual | 6.97510404 | Y | 8.991701347 | 6.810512037 | 5.97510404 | 1 | 1 | 1 | 1 | 82 | 3 |
| VINORELBIN DITARTRATE | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | actual | 6.97510404 | Y | 5.658368013 | 3.24377601 | 6.525055665 | 1 | 0 | 0.5 | 1 | 82 | 3 |
| VANCOMYCIN HYDROCHLORIDE | Solute carrier organic anion transporter family member 1B1 | Homo sapiens | predicted | 8.496589933 | 5.4897698 | 9.007716288 | 1 | 1 | 1 | 1 | 113 | 2 | ||
| ACIPIMOX | Androgen Receptor | Homo sapiens | actual | 5.125066148 | Y | 8.375022049 | 4.718571182 | 6.175093529 | 1 | 1 | 1 | 1 | 147 | 3 |
| GEMCITABINE HYDROCHLORIDE | Androgen Receptor | Homo sapiens | actual | 6.97510404 | Y | 5.658368013 | 4.951714093 | 6.221342368 | 1 | 0 | 0.5 | 1 | 147 | 1 |
| LORAZEPAM | Androgen Receptor | Homo sapiens | predicted | 7.579166617 | 2.73749985 | 8.568636236 | 1 | 1 | 1 | 1 | 147 | 1 | ||
| MYCOPHENOLATE MOFETIL | Androgen Receptor | Homo sapiens | actual | 6.97510404 | Y | 8.991701347 | 6.882589334 | 6.171340103 | 1 | 1 | 1 | 1 | 147 | 3 |
| VINORELBIN DITARTRATE | Androgen Receptor | Homo sapiens | actual | 6.97510404 | Y | 8.991701347 | 7.051750965 | 5.696343248 | 1 | 1 | 1 | 2 | 147 | 3 |